var title_f39_45_40656="Triamcinolone: Pediatric drug information";
var content_f39_45_40656=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"16\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Triamcinolone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12645390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/56/16260?source=see_link\">",
"       Triamcinolone (nasal): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/36/16963?source=see_link\">",
"       Triamcinolone (ophthalmic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/11/27831?source=see_link\">",
"       Triamcinolone (systemic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/10/14500?source=see_link\">",
"       Triamcinolone (topical): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12858 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-75239E8C8F-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_45_40656=[""].join("\n");
var outline_f39_45_40656=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/56/16260?source=related_link\">",
"      Triamcinolone (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/36/16963?source=related_link\">",
"      Triamcinolone (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/11/27831?source=related_link\">",
"      Triamcinolone (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/10/14500?source=related_link\">",
"      Triamcinolone (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_45_40657="Positioning for puncture of the glenohumeral joint";
var content_f39_45_40657=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F79773&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F79773&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Positioning for ultrasound-guided puncture of the glenohumeral joint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient and needle positioning for puncture of the glenohumeral joint.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Introductory Guide to Musculoskeletal Ultrasound for the Rheumatologist, Second Edition. ISBN 978-90-313-9206-3; Bohn Stafleu van Loghum, Houten 2012. Copyright &copy; 2012.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_45_40657=[""].join("\n");
var outline_f39_45_40657=null;
var title_f39_45_40658="Patient information: Head injury in children and adolescents (The Basics)";
var content_f39_45_40658=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15527\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/17/34078\">",
"         Bicycle helmet fit",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?8/47/8947\">",
"         Patient information: Closed head injury (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?22/12/22722\">",
"         Patient information: Concussion (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?3/31/3570\">",
"         Patient information: Headache (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?33/52/34626\">",
"         Patient information: Mouth and dental injuries in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/56/28546\">",
"         Patient information: Seizures (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?33/24/34178\">",
"         Patient information: Skull and facial fractures (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?13/44/14020\">",
"         Patient information: Head injury in children and adolescents (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?33/27/34229\">",
"         Patient information: Seizures in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Head injury in children and adolescents (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/head-injury-in-children-and-adolescents-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H195939378\">",
"      <span class=\"h1\">",
"       What causes head injuries in children and adolescents?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common causes of head injuries in young people are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Falls",
"       </li>",
"       <li>",
"        Car accidents",
"       </li>",
"       <li>",
"        Bicycle accidents",
"       </li>",
"       <li>",
"        Sports",
"       </li>",
"       <li>",
"        Beatings or other kinds of physical abuse",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Children recover from most bumps on the head without problems. But children who hit their head really hard can have serious problems. For example, some children with head injuries have a mild form of brain injury called a &ldquo;concussion.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H195939385\">",
"      <span class=\"h1\">",
"       When should I call a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should call a doctor or nurse right away if your child hurt his or her head and:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fell from a height taller than 5 feet",
"       </li>",
"       <li>",
"        Is younger than 6 months old",
"       </li>",
"       <li>",
"        Throws up more than once",
"       </li>",
"       <li>",
"        Has a seizure or passes out",
"       </li>",
"       <li>",
"        Has a headache that is really bad or gets worse over time",
"       </li>",
"       <li>",
"        Has trouble walking, talking, or seeing, seems confused, or is acting in ways that worry you",
"       </li>",
"       <li>",
"        Is still dizzy after a while",
"       </li>",
"       <li>",
"        Has blood or watery fluid coming out of the nose or ears",
"       </li>",
"       <li>",
"        Has a cut that keeps bleeding after you put pressure on it for 10 minutes",
"       </li>",
"       <li>",
"        Is weak or numb in any body part",
"       </li>",
"       <li>",
"        Is very cranky or can&rsquo;t stop crying",
"       </li>",
"       <li>",
"        Has trouble waking up",
"       </li>",
"       <li>",
"        Was hit really hard or with something moving very fast",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H195939392\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to help my child after a head injury?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If the injury was not serious, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have your child lie down, do something quiet, or nap",
"       </li>",
"       <li>",
"        Have your child drink clear liquids if he or she has thrown up",
"       </li>",
"       <li>",
"        Press on the injury with a clean cloth or gauze, if there is bleeding. Hold the pressure for 10 minutes.",
"       </li>",
"       <li>",
"        Put ice or a cold pack on any lumps or swollen areas. Hold it there for 20 minutes.",
"       </li>",
"       <li>",
"        Give your child pain medicine, such as",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        &nbsp;(sold as Tylenol&reg;) or",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sold as Advil&reg; or Motrin&reg;)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Watch your child closely after a head injury. If the injury gets worse or your child starts acting strangely, call the child&rsquo;s doctor right away. You can also go straight to the hospital.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H195939399\">",
"      <span class=\"h1\">",
"       Are there tests my child should have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse will decide which tests your child should have based on his or her age, symptoms, and individual situation. Most children with head injuries do not need an imaging test, such as an X-ray or MRI. Still, if the doctor or nurse suspects serious injury, he or she might order a special kind of X-ray called a CT scan (also called a &ldquo;CAT scan&rdquo;). CT scans create detailed pictures or the brain and skull. They can show internal bleeding or bone fractures.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H195939406\">",
"      <span class=\"h1\">",
"       How are head injuries treated in children and adolescents?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on how serious the injury is and what symptoms the child has. Often, the doctor will just want to wait and watch the child.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H195939413\">",
"      <span class=\"h1\">",
"       Can my child go back to normal activities after a head injury?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on how serious the injury is. If your child has a concussion, he or she should not play sports until a doctor says it&rsquo;s OK. If your child has had 2 head injuries in a row, check with your child&rsquo;s doctor before letting him or her go back to normal activities.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H195939420\">",
"      <span class=\"h1\">",
"       Can head injuries in children and adolescents be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Here are some safety tips that can reduce your child&rsquo;s chances of getting a head injury. Make sure he or she:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Always wears a helmet when sitting in a bicycle seat or when being towed behind a bicycle in a trailer. The helmet should fit well (",
"        <a class=\"graphic graphic_figure graphicRef59465 \" href=\"mobipreview.htm?33/17/34078\">",
"         figure 1",
"        </a>",
"        ). If the helmet has been in a crash, you should throw it away.",
"       </li>",
"       <li>",
"        Is watched closely while biking until he or she is old enough to ride a bicycle alone",
"       </li>",
"       <li>",
"        Doesn&rsquo;t bike in the street unless he or she can control a bicycle. The child should also be able to follow traffic rules.",
"       </li>",
"       <li>",
"        Always sits in a car seat or booster seat until he or she is 4 feet, 9 inches tall. Make sure the seat is secured and set up the right way.",
"       </li>",
"       <li>",
"        Cannot fall down stairs or out of windows higher than the first floor. Gates and guards can protect young children.",
"       </li>",
"       <li>",
"        Knows how to cross streets by looking both ways for cars. Young children should never cross streets alone.",
"       </li>",
"       <li>",
"        Wears safety gear while skateboarding, skiing, or doing other sports. Gear includes helmets, mouth guards, and eyewear (glasses or goggles).",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H195939427\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/52/34626?source=see_link\">",
"       Patient information: Mouth and dental injuries in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/47/8947?source=see_link\">",
"       Patient information: Closed head injury (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/31/3570?source=see_link\">",
"       Patient information: Headache (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/56/28546?source=see_link\">",
"       Patient information: Seizures (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/12/22722?source=see_link\">",
"       Patient information: Concussion (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/24/34178?source=see_link\">",
"       Patient information: Skull and facial fractures (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/44/14020?source=see_link\">",
"       Patient information: Head injury in children and adolescents (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/27/34229?source=see_link\">",
"       Patient information: Seizures in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?39/45/40658?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15527 Version 5.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-298F256B3B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_45_40658=[""].join("\n");
var outline_f39_45_40658=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H195939378\">",
"      What causes head injuries in children and adolescents?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H195939385\">",
"      When should I call a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H195939392\">",
"      Is there anything I can do on my own to help my child after a head injury?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H195939399\">",
"      Are there tests my child should have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H195939406\">",
"      How are head injuries treated in children and adolescents?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H195939413\">",
"      Can my child go back to normal activities after a head injury?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H195939420\">",
"      Can head injuries in children and adolescents be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H195939427\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15527\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/17/34078\">",
"      Bicycle helmet fit",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/47/8947?source=related_link\">",
"      Patient information: Closed head injury (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/12/22722?source=related_link\">",
"      Patient information: Concussion (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/44/14020?source=related_link\">",
"      Patient information: Head injury in children and adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/31/3570?source=related_link\">",
"      Patient information: Headache (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/52/34626?source=related_link\">",
"      Patient information: Mouth and dental injuries in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/56/28546?source=related_link\">",
"      Patient information: Seizures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/27/34229?source=related_link\">",
"      Patient information: Seizures in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/24/34178?source=related_link\">",
"      Patient information: Skull and facial fractures (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_45_40659="Vitamin E: Patient drug information";
var content_f39_45_40659=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Vitamin E: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/28/19910?source=see_link\">",
"     see \"Vitamin E: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/12/33988?source=see_link\">",
"     see \"Vitamin E: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F234560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alph-E [OTC];",
"     </li>",
"     <li>",
"      Alph-E-Mixed [OTC];",
"     </li>",
"     <li>",
"      Aqua Gem-E&trade; [OTC];",
"     </li>",
"     <li>",
"      Aquasol E&reg; [OTC];",
"     </li>",
"     <li>",
"      d-Alpha Gems&trade; [OTC];",
"     </li>",
"     <li>",
"      E-Gems&reg; Elite [OTC];",
"     </li>",
"     <li>",
"      E-Gems&reg; Plus [OTC];",
"     </li>",
"     <li>",
"      E-Gems&reg; [OTC];",
"     </li>",
"     <li>",
"      E-Gem&reg; Lip Care [OTC];",
"     </li>",
"     <li>",
"      E-Gem&reg; [OTC];",
"     </li>",
"     <li>",
"      Ester-E&trade; [OTC];",
"     </li>",
"     <li>",
"      Gamma E-Gems&reg; [OTC];",
"     </li>",
"     <li>",
"      Gamma-E PLUS [OTC];",
"     </li>",
"     <li>",
"      High Gamma Vitamin E Complete&trade; [OTC];",
"     </li>",
"     <li>",
"      Key-E&reg; Kaps [OTC];",
"     </li>",
"     <li>",
"      Key-E&reg; Powder [OTC];",
"     </li>",
"     <li>",
"      Key-E&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692172",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vitamins are needed for growth and good health.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vitamin E is thought to protect the body from the harmful effects of a chemical reaction known as oxidation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12154 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-1FB45B5B38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_45_40659=[""].join("\n");
var outline_f39_45_40659=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234560\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018152\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018151\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018156\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018157\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018159\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018154\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018155\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018160\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018161\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?19/28/19910?source=related_link\">",
"      Vitamin E: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/12/33988?source=related_link\">",
"      Vitamin E: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_45_40660="Intralesional injection";
var content_f39_45_40660=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intralesional injection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/45/40660/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/45/40660/contributors\">",
"     Barbara M Mathes, MD, FACP, FAAD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/45/40660/contributors\">",
"     Patrick C Alguire, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/45/40660/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/45/40660/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/45/40660/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/45/40660/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/45/40660/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intralesional injection, the direct delivery of medication percutaneously into skin lesions, has been an important part of dermatologic therapy since first introduced in 1961 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/45/40660/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Intralesional injections are effective for a wide range of indications, are easily performed, and are relatively safe.",
"   </p>",
"   <p>",
"    The rationale for intralesional therapy is simple: to deliver a medication directly into a specific skin lesion to treat local tissues with minimal systemic effects. The skin also serves as a reservoir, allowing medication deposited in the dermis to be delivered over a period of time, resulting in prolonged therapy while avoiding or minimizing the adverse effects of systemic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INTRALESIONAL DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The drugs primarily used for intralesional injections are corticosteroids, but in recent years",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    , 5-fluorouracil,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    , and interferons also have been dispensed in this manner [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/45/40660/abstract/3\">",
"     3",
"    </a>",
"    ]. This review is limited to the use of intralesional corticosteroids.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     Triamcinolone",
"    </a>",
"    acetonide (Kenalog, TAC-3) and triamcinolone diacetate (Aristocort) are the most widely used intralesional corticosteroids, although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (Decadron) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    (Celestone) are used by some physicians. Triamcinolone agents are available as micronized suspensions. Characteristics associated with micronized suspensions that make them desirable as intralesional corticosteroids are the small size of the corticosteroid particles, the persistence of small crystal size for extended periods of time, and that the process of gently shaking resuspends the drug evenly in solution. Small corticosteroid crystals are more efficiently delivered to the treatment site, thereby decreasing the total administered dose of the drug and reducing the risk of systemic side effects and skin atrophy. In addition, because micronized crystals of corticosteroid are in a depot form, the active ingredients are stored in the tissues and released over a period of weeks, making this type of corticosteroid delivery system well suited for the treatment of chronic inflammatory dermatoses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/45/40660/abstract/3\">",
"     3",
"    </a>",
"    ]. Examples of chronic inflammatory dermatoses that are particularly amenable to this type of extended action include psoriasis, lichen simplex chronicus, cutaneous lupus erythematosus, and prurigo nodularis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS AND CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for intralesional corticosteroid therapy are acute and chronic inflammatory processes, hyperplastic and hypertrophic skin disorders, and conditions that typically have a favorable response to systemic and topical corticosteroids. In addition to antiinflammatory properties, the atrophogenic side effect of corticosteroids also can be used advantageously when treating hypertrophic types of lesions, including keloids, lichen simplex chronicus, hypertrophic lupus, and psoriasis.",
"   </p>",
"   <p>",
"    Intralesional injections are not advised when the possibility of infection is present, either as the etiology of the lesion or as a secondary sequela. Intralesional corticosteroids do have some degree of systemic absorption and, although it is rare to have systemic effects, large amounts of corticosteroids, frequent injections, and even small amounts of corticosteroids in diabetic patients produce unwanted systemic effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EQUIPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most intralesional therapy is administered via needle, although a few physicians prefer jet injection devices (eg, Dermojet). Typically 30- or 27-gauge needles are used, although 25-gauge needles are acceptable. The needles are placed on 1 or 3 mL Luer-Lok syringes to prevent the needle separating from the syringe under the pressure of injection. One milliliter syringes are most frequently used because the quantity of medication delivered is usually in the tenths or even hundredths of a milliliter, and the smaller syringe allows for greater quantitative accuracy.",
"   </p>",
"   <p>",
"    A larger bore needle (21 or 22 gauge) is used to draw up the solution and subsequently to dilute the corticosteroid with saline or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    , but then it is removed and replaced with the small injecting needle. Thirty-gauge needles are the most desirable and widely used by dermatologists because they produce less discomfort when penetrating the skin, and prevent rapid injection, which is associated with increased pain. Smaller gauge needles also allow greater precision in injecting the desired quantity of drug.",
"   </p>",
"   <p>",
"    Corticosteroids cause a burning sensation for up to three to five minutes after injection; the higher the concentration of corticosteroid, the greater the discomfort of injection. Thus, most corticosteroids are diluted prior to injection to minimize patient discomfort. Saline is an excellent diluent for all corticosteroids, but some physicians prefer to dilute with the local anesthetic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    . A study comparing saline and unbuffered lidocaine as diluents, however, found no significant difference in discomfort between the two [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/45/40660/abstract/4\">",
"     4",
"    </a>",
"    ]. It is possible that the anesthetic effect of lidocaine was offset by its acidity, which in itself causes burning upon injection; lidocaine buffered with bicarbonate does diminish the pain of injection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/45/40660/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other standard equipment for injection include nonsterile gloves, an alcohol swab, 4x4 gauze, and protective eye wear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MIXING THE SOLUTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unless a clinician injects multiple patients with the same concentration of corticosteroid daily, it is impractical to prepare large quantities of prediluted drug. Rather, most physicians prefer to mix the solution at the time of injection in the syringe to be used on the patient. The final concentration should be just sufficient to treat the lesion and low enough to avoid local or systemic side effects. Kenalog and Aristocort are available in 10",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    and 40",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    multidose vials; TAC-3 is available in 3",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    concentrations, ideal for injecting cystic lesions.",
"   </p>",
"   <p>",
"    To dilute a single dose of corticosteroid, it is necessary to gently shake the bottle to resuspend the particles. Saline or 0.5 percent or 1 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    without epinephrine may be used as the diluent, especially when using high corticosteroid concentrations or injecting more than 1 mL into a single site. Do not dilute with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    and other long-acting anesthetics, because they will precipitate the corticosteroid in the syringe.",
"   </p>",
"   <p>",
"    To obtain a 2",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    concentration, draw up 0.4 mL of saline for each 0.1 mL of 10",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    of Kenalog; to obtain a 20",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    dilution, draw up 0.5 mL of 1 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    for each 0.5 mL of 40",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    Kenalog. Immediately before injecting a lesion, gently shake or roll the syringe to ensure even suspension of the drug in the diluent, and consequently, even delivery into the tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INJECTION TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most pathology in inflammatory skin lesions is in the dermis, and it is in this layer of skin that corticosteroids should be deposited. The clinician should first prepare the skin with alcohol, then insert the needle at a 45 degree to 90 degree angle into the lesion to the level of middermis, then slowly inject the drug (",
"    <a class=\"graphic graphic_picture graphicRef75695 \" href=\"mobipreview.htm?17/34/17953\">",
"     picture 1",
"    </a>",
"    ). When deposited correctly into the middermis, the skin rises slightly and blanches (",
"    <a class=\"graphic graphic_picture graphicRef69986 \" href=\"mobipreview.htm?11/15/11508\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Enough material is injected to just slightly raise the skin surface; often this is only tenths of a milliliter. For large lesions, the needle should be withdrawn partially and redirected to cover additional areas, or the needle can be removed and reinserted in another site. Caution is needed to avoid injecting into subcutaneous tissue; this is easy to recognize because the injected solution flows easily into subcutaneous fat, while resistance is felt when correctly injecting into dermis. Correct injection technique depends upon knowledge of skin anatomy and particularly an awareness of the different thicknesses of epidermis and dermis in different body sites, at various ages, and in specific diseases.",
"   </p>",
"   <p>",
"    When injecting inflamed acne cysts or cysts and sinuses of hidradenitis suppurativa, the tissue immediately surrounding the cyst but still well within the zone of inflammation is the target area. Protective eye wear is strongly advised, especially when dealing with cystic lesions, to prevent material discharged from the injection or the cyst from splashing into the eye.",
"   </p>",
"   <p>",
"    Keloids and hypertrophic scars are directly injected with corticosteroids; however, thick and longstanding keloids are often so tough that they must be softened by pretreatment for 5 to 20 seconds with liquid nitrogen. Alternatively, an injection can be performed immediately peripheral to the affected tissue, directing the needle toward the keloid. Keloids often need multiple treatments three to four weeks apart until there is adequate flattening of the lesion (",
"    <a class=\"graphic graphic_picture graphicRef73191 \" href=\"mobipreview.htm?8/48/8963\">",
"     picture 3",
"    </a>",
"    ). It is not unusual to use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    in strengths of up to 40",
"    <span class=\"nowrap\">",
"     mg/mL;",
"    </span>",
"    however, most dermatologists recommend beginning treatment with triamcinolone, 10",
"    <span class=\"nowrap\">",
"     mg/mL,",
"    </span>",
"    and increasing the strength as needed to avoid excessive and sometimes permanent atrophy.",
"   </p>",
"   <p>",
"    Having completed the injection, gauze is held lightly over the site to stop any bleeding. Occasionally an adhesive bandage is placed if bleeding continues.",
"   </p>",
"   <p>",
"    Data on intralesional corticosteroid therapy for many of the disorders treated with this modality are limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/45/40660/abstract/6\">",
"     6",
"    </a>",
"    ], and there is quite a bit of variation among the experts regarding matching the concentration and volume of corticosteroid injected to the type of lesion being treated (",
"    <a class=\"graphic graphic_table graphicRef66500 \" href=\"mobipreview.htm?34/20/35147\">",
"     table 1",
"    </a>",
"    ). In general, acute inflammatory lesions (eg, acne cysts) and lesions in thin skinned areas such as the face and central chest necessitate lower corticosteroid concentrations and smaller drug quantities than more chronic conditions (eg, psoriasis, lichen simplex chronicus, keloids) and lesions in thick-skinned areas like the scalp and back.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS, COMPLICATIONS, AND PITFALLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common side effects of intralesional corticosteroid injections are local. These include atrophy, hypopigmentation, and rarely, sterile abscess formation. Atrophy and pigment changes usually resolve over several weeks but occasionally persist longer and are sometimes permanent (",
"    <a class=\"graphic graphic_picture graphicRef50142 \" href=\"mobipreview.htm?29/3/29746\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Micronized crystals of corticosteroid remain in skin for weeks and even months, so some physicians suggest injecting sterile saline into persistently atrophic sites in an attempt to activate the drug and clear it from the skin more quickly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/45/40660/abstract/3\">",
"     3",
"    </a>",
"    ]. However, there are no clinical studies that support this practice.",
"   </p>",
"   <p>",
"    Darkly pigmented skin is most susceptible to hypopigmentation and depigmentation; caution should be used when injecting these patients and the patients should be advised of this potential complication.",
"   </p>",
"   <p>",
"    A sterile abscess may require drainage, and this is usually accomplished by stabbing the abscess with a number 11 blade. Systemic antibiotics usually are not necessary if the abscess has been drained completely.",
"   </p>",
"   <p>",
"    Complications related to intralesional injections typically can be avoided by using the lowest concentration and smallest quantity of drug needed to achieve the desired results. It is preferable to inject corticosteroids in small amounts and low concentrations and have to repeat the injection in three to four weeks than to overestimate the corticosteroid dose and suffer a complication. Patients should be advised that the first treatment may not be completely effective and more than one injection may be necessary.",
"   </p>",
"   <p>",
"    In addition to using too much of or too concentrated a corticosteroid, another pitfall is incorrect placement of the corticosteroid into the skin. When deposited in the subcutaneous layer, the atrophic effect may be exaggerated and the therapeutic antiinflammatory effect minimized. Likewise, injecting too high in the skin, in the upper dermis and epidermis, may cause sloughing of the skin.",
"   </p>",
"   <p>",
"    Systemic side effects may occur. Repeated frequent injections producing a high cumulative dose of a corticosteroid (more than 40 mg per month) may result in menstrual irregularities and have the potential for adrenal suppression, although clinical evidence of this is lacking. More problematic is the diabetic patient in whom glucose concentrations are likely to rise and be less responsive to insulin or other hypoglycemic agents. Diabetes is not an absolute contraindication to intralesional corticosteroid therapy; in fact, judicious use of intralesional injections can result in lower blood glucose levels as compared to repeated applications of potent topical corticosteroid. Regardless, caution should be used and appropriate monitoring performed when treating diabetic patients with corticosteroids of any type.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/39/9842?source=see_link\">",
"       \"Patient information: Keloids (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intralesional injection is a technique used to administer medication directly into the skin. The antiinflammatory and atrophogenic effects of injected corticosteroids are useful for the treatment of a variety of skin disorders. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications and contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of a one millimeter syringe, rather than a larger syringe, allows for better control of the quantity injected. A small diameter needle, such as a 30 gauge needle, will decrease patient discomfort. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Equipment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"       Triamcinolone",
"      </a>",
"      is the most frequently used medication for intralesional corticosteroid injections, and is available as a micronized suspension. Dilution with normal saline or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      may be required to achieve the desired dose. The syringe should be shaken or rolled immediately prior to injection to ensure even suspension of the drug during delivery. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Mixing the solution'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The dermis is typically targeted during intralesional corticosteroid injections. The concentration of corticosteroid and the injection technique vary according to lesion type and site. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Injection techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Potential side effects of intralesional corticosteroid injection include cutaneous atrophy, hypopigmentation, and abscess formation. The lowest dose required to achieve the desired effect should be utilized to minimize this risk. Systemic side effects may occur in patients receiving frequent high doses of corticosteroids. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Side effects, complications, and pitfalls'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Article modified with permission from Atlas of Office Procedures 1999; 2:129.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40660/abstract/2\">",
"      HOLLANDER A. Intralesional injections of triamcinolone acetonide; a therapy for dermatoses. Antibiotic Med Clin Ther 1961; 8:78.",
"     </a>",
"    </li>",
"    <li>",
"     Madden S, Ho VC. Dermatologic therapy. In: Dermatology, 3rd ed, Moschella S, Hurley HH (Eds), WB Saunders, Philadelphia 1992. p.2200.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40660/abstract/4\">",
"      Lugo-Janer G, Padial M, S&aacute;nchez JL. Less painful alternatives for local anesthesia. J Dermatol Surg Oncol 1993; 19:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40660/abstract/5\">",
"      Stewart JH, Chinn SE, Cole GW, Klein JA. Neutralized lidocaine with epinephrine for local anesthesia--II. J Dermatol Surg Oncol 1990; 16:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40660/abstract/6\">",
"      Richards RN. Update on intralesional steroid: focus on dermatoses. J Cutan Med Surg 2010; 14:19.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5568 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-641A5F4110-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_45_40660=[""].join("\n");
var outline_f39_45_40660=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INTRALESIONAL DRUGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS AND CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EQUIPMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MIXING THE SOLUTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INJECTION TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SIDE EFFECTS, COMPLICATIONS, AND PITFALLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/5568\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5568|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/34/17953\" title=\"picture 1\">",
"      Intradermal cyst injection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/15/11508\" title=\"picture 2\">",
"      Skin appearance post injection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/48/8963\" title=\"picture 3\">",
"      Keloid injection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/3/29746\" title=\"picture 4\">",
"      Steroid atrophy post injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5568|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/20/35147\" title=\"table 1\">",
"      Intralesional steroid dose",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/39/9842?source=related_link\">",
"      Patient information: Keloids (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_45_40661="Jejunal leiomyoma Light";
var content_f39_45_40661=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Jejunal leiomyoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 437px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Medium power view of a jejunal leiomyoma shows sheets of short, spindled, and round cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_45_40661=[""].join("\n");
var outline_f39_45_40661=null;
var title_f39_45_40662="TLR signaling";
var content_f39_45_40662=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F57602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F57602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 615px\">",
"   <div class=\"ttl\">",
"    Toll like receptors: Organization and signaling pathways",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 595px; height: 489px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    TLR signaling in conventional dendritic cells, macrophages and plasmatoid dendritic cells. TLR2 (TLR2 in association with TLR1 or TLR6), TLR4, TLR5 and TLR11 are localized on the cell surface for ligand recognition. TLR3, TLR7, and TLR9 are localized in the endosome, which is transported to the endosome via the ER-localized transporter protein UNC-93B for ligand recognition in the lumen of endosome. All TLRs, except TLR3, recruit MyD88, while TLR1, TLR2, TLR4 and TLR6 recruit the additional adaptor TIRAP, which links the TIR domain with MyD88. TLR3 and TLR4 recruit TRIF. TLR4 requires the additional linker adaptor TRAM, which links the TIR domain of TLR4 with TRIF. Dendritic cells or macrophages stimulated with TLR1, TLR2, TLR5, TLR6, and TLR11 ligands initiate the MyD88-dependent pathway whereas TLR3 ligands initiate the TRIF-dependent pathway. TLR4 activates both MyD88-dependent and TRIF-dependent pathways. In the MyD88-dependent pathway, MyD88 recruits the IRAK family of proteins and TRAF6. In turn, TRAF6 activates TAK1. The activated TAK1 activates the IKK complex, which activates NF&kappa;B subunits. The activated TAK1 also activates the MAPK pathway. In the TRIF-dependent pathway, TRIF interacts with RIP1 and TRAF6. Activated TRAF6 and RIP1 activate NF&kappa;B and MAPKs. TRIF also interacts with TRAF3 and activates TBK1/IKKi, which activate IRF3 and IRF7. Plasmacytoid dendritic cells stimulated with TLR7 and TLR9 ligands activate NF&kappa;B and MAPKs via the MyD88-dependent pathway. To induce type I interferons, MyD88 associates with the IRAK family of proteins. IRAK1 and IKK&alpha; activate IRF7. IRAK1 also interacts with TRAF3 and activates IRF7. The activated NF&kappa;B subunits and IRFs are translocated to the nucleus. NF&kappa;B and MAPKs initiate the transcription of inflammatory cytokine genes whereas IRFs initiate the transcription of type I interferons.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. Biochem Biophys Res Commun 2009; 388:621. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_45_40662=[""].join("\n");
var outline_f39_45_40662=null;
var title_f39_45_40663="Mediastinal lymphoma";
var content_f39_45_40663=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F53317&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F53317&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mediastinal diffuse large B cell lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 313px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEATkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD0KSebw9bWMmledc2y3ouD5H7otbnpEo5z644rP06XUtY1fUpNevbPVPD/ANuMLjqsTZ5w38IX0561S0HUpNQ8QS2d4Q1tZxm3v5JGOxbheBICRznJx9K6HUPB3h2b4ZzeC9A1FpXtJhMcsS7yhtxDHvnmrbtoz3JPkkvPr2KPh3xDc2ni/wAe6m80lt4J0S1WCK0KcNKB/rY/UHB577hWHq2sprfgrwV4h0O6ubeCbU0tb9rYbZWUZwrDuFIGRVrQ/wDhKfEDatpGo20lpDLLK9sLqMeXapG48pUGfmUpuHOO1dn4Wt7C4jvtN8q3t7PzRdvGsYTypM9cfwsWwaHJRdzFU7Rcr6dTiY9M1/TYPGGq634lfUdKuLiSKJbKQSvD8/zOo42FVypXnjPNXbK1vLGRrmxUzvBaotvvbJkDR5jb64IPtUmnaPpF38UfEuh6qlrDYXUMNx9lEpYzznDGbGOOevqa2fDBmn8Ua3efaDcW1sRDHKwxnHyllX0HSictDai3BSa7fnbQnjttVu/BWjp4gs7ttVl3ecscnMbqSynHckAY+tcNql/r2oXl3c+EpCiWLB73S7+PZ5cyj5CTzkkgfXpXaWPihPG+gTTaTcXkc+k3E8E4WII0ziNtrRnPTpg+tc/4Mu9Q1r4XXf8AYsN6uqicG5uNSh8ya9UPyOSOeMfhSjdbmUKjXxd/u1IofiD4jvPA9zqGqQ6Jc6lf3SW+naVbszlwMCWKU44c84+orMfStNsIdN1rxbptvomkSy+Rp2gCDz7hnY4ZdwIwM5P413fgnQrHwDdX9zc6xdtptzGswhuTujjk+8zoBnnnbn/ZxXLQQaLpngjWdM0PVb+8kvpTNA97HlrUkkl48nj296akl8JNGM5O1JO19/62Jtevr+5+IzCCItpunxKN7H7oI4QfTv8AWsyXUrjSdZjuchJkm3zELuAB6AD1qz9rm0lQ0m0s9ucLN87ucc9cbmNZVmH8VaGI9AuWh1i5d3Wby87iMZGD0AoX4HswioRs9rHSfEe2XX9V8Paz5ki21ncKL61Q535+7x788+1avh3U4TqOvWtjPPPqFndPbR2Vx0t/NG5QnqAENY0UqNpt9JLPJfXFygaWADbslXgYHZferLWt2ui3/iKwvEj1m0iEwguE+RJBwwc/xNyBSe3Kzz3BJJXsv60/roZPinwpceINHmP/AAlcepWxhA/sqWPylibILENnJ57Yrt/DGvaVo3gi8g0i7hDaZalZITx5dwV+Vcf7R6Cs7w5dw+MfCQ17x40GmQJutTBKBEYpgcGVWJyCefl5pLK9tfDqweH5ILDVNWv232627Ey3cCglJZBjCnAAyT3qXfZmNWcakeST1T8vz6/8E4/w1NNdeCJdA1yZrrxRquXvrO3+V5lkOVBf+BlB5OD0IrZ8IaLpOkrdeHfC2rWi3tjLGb8XT7zE+0AfMQN4A+UcCofB9xa6zr/iK10yE6T4g1SPzQL2PzkXZ8jImcDI5OR1xmuR1fRpPEunJqOsXuqeH7zSnktr1kXLXSISFkK5BxgAZGcVq1rqC0lZbnd3up6XZaRPHrn9rWEdvPKjTMvlyRR4J8wgZBR24UZ53Crl7JFqHg23bSTMYryL/Qb22j23MLsNilkzxg85zWFK/izUJdJfwlb2OqeFbqFI5V1A5heNANw553Eg4bFQ6vqb6d8QNbuNOtrnTU0zSlsDPL8tm7udytjuE3jH+72qOVbdSlVk3ytnUafo9m2j2KeJNSiOvoBHNNxEZ2B4dvwwPqDVy70jXtLSzh0hbG4KTCQ3AlCytH1O49x+FeffEmyi8e6todjbySP4g06yZ5rtoB9hmfZuRWckY+bkEA4zSR+C9SGu6ndWXiW1g22Kw3d5JcGWXSQwxIgT+It0DZGKORWu2TGvOKs3ddnqdf4N0a8ufGmq3Gq67bzNHbiKz061f93Fkn95IO7ehqLx9qIv/EraZqF/JJZRosiRgYCyj1Heuc06e/03VbyKwg1C3uZwqxTzQ5+2xL918g9c5P41R8QR32n2ksly5utTClwrrhnbtU297c9HD4Xlq88nutPJj9WvtG0vVRYJ4gaa2cArIYSPK9j7cV1nh7WtT1bQnfwxrEGraaCFk+ySfv4s9nUgbSfrXFaDqkeuGG8eKMPJH5ZVPlCuOtQTaeW8SQabY3EVhqWquGs2iixvuo+jzY+8gUv+JFNroa4mMox5pNNLV3X/AAx3Hhazv28YXt9GbyysbNI0gLjzSzbSX3JxtUYIJz6V0mv+KpoptPur6xkl8PXsLwvcwjkZO3kdsgnA9M1gWt7IusaiReLPcw4i3hdgvZApVzgZwCxB/CoJvFtvqFpH4SlkgW+tEBuFV/mBBHT3GahptnFOlKpUTmrr8k0Z9lYm213QvC3hfTdPl8ByXDyXB5aUzBiVYk9CCF/Ks7x8ZPEev3elWs+/Tkjlg1O4iOJQqsW59V3gH68V03hi+uofGa2i27i1eGRVvVXK+cEJVgvdsDp3rm4b5ptY03URo8eo+Ir0SWuoyQ/uBawhyomePoGZecZ71cLp3RHs/ZS5d1/X+RHZ31xZ6f4S0XT9emtdRtxJet5i/Jc2y5B3v2wASBj2rqbjWJ4PFGp6LbQ3clxFbLd2eq3nz2soYBiuOyjPB7niodOjsY7XULO/je58yOWBig+dbbBBVT2yOc++ai03SXufEGjaJ4Uu5W8PaZp6yy2tz8/m5kYqvmHByDgbcdB70m7iq3hLXREPgu3uU1XWU02L+z/t8Ki+0KV8QRTMcG4hc9FIwcY611aaVqeieHpl8NWyTeIJALXddL8jKTzIf7yqDnHeuIv9OtPEdx4i8Ki+kuby3dne7kuC9yoK8QkkDCg8D2roPBGueIG0XSdA0iS2kNjGIrnU9Rf58ZIG1f4m7Yz2FEk90YyhKVO8dF1uzP17U08LWt3pGt3n9qXd7DGiz+Xtjikyd2B26jA9q1tKuI5/C8Xhu/xc3kcfmwRSj5Z4f4oz7YxVPRtA0fxZY6idahu7+8t79J5ZGl8nJB6g/wB0Y6Vx+u69rl8bm78JtDZpAA106xBhDHGcYYA/Ipz2znFNR5vU6Zvek1qra+dvy/M6m20mLXL60TTrmXR4rUmKUCTc5tTyYV46jaPpXM2jyeLNf1yS4tU0PSrdTJbavK/lzxEMNkjnuMbhj/aq9qHi6w067hvNWu5YtWtnWG/Gnp8vmAfMq+hORgD3pdY8LWPiO6SPVtSudNOsIttaWER3RMikEGX+7I/ce1aK8dzKdpar/hv8zqriKwtINYtLMC9tJbZbwSyN8hkYjDhvTBPNYH2Y/wDQXs/+/p/wrR8S3+nN8Q9B8F6ZbOEWyW1uF2fJDGoBUfXC10/2DQP+eX/kes72Nqdf2cE3e7OTsdOh8a29hc2t5dppktx9olQ/u2RBnO76ccV2ej6jplhoVmLOaKQXk7vJLIcEKx5cH06Vxdnero/hXVrq/uIopZvMt7SCR/L+0yn3HTNVfh1ZGax07TRK100E0kU0k8SsunonPlsrfKwPGM03G6v0FWgndTlov8jpfD+q3sMepf2voBsYRqgsbffMZDcqckSj+6TgfnVPWPEOl+FtVuZNY8xRJIVKIpaSWTBKwnbngnHze1Qf8Jbputz6vptgt9bXwu0aGSRPKG5f4lAPIIzikTVPs3i5rfTLm0j1C7zJIl7GZHz1BDEYA/GlyPqiIxdpJ72/yOesNUvb61tvGOuWcGi6jpM1xb3MaRBTfROjbEJ6nYSoII5IzXQRSa5olx4Rk8O6ajCe2R7q5uioVkkcMydcpgEtnHOMVz3xP1nUbm5tzPoTHUrN42iuVfNvdSswTa69DgEkZ9K2PEvgKLWvEyaneapq9veMLfzljcfZo1i2lwRu+78pHTA681bstWZu8Y8tt7/8Aj1TSdZ1Lw94n0Pwxpt3plhJOs0GsSXQ3H/SA8gAJBAHzEH0rV1SfWrjX5YLjVIDpElqttpc/wApWWTywJDuBydx3DPb8Kx51XxX4j8eQ6J4gtNRlv8ATWt0sdhDq6DK4GNpQgBd2c5NSapa+G9Jj8AWsUV6l1DayW1pBbpuhgldD5hlZsY+Yt0yaXkRBqNRO39aHPeIbPUrLULSa2l1m1liESXVvFL9x1fOEbOWUjHtzW/c2+rpoEt5HBBZalcXCMl7fESRKc/cKnue9UtNsNUvbvXLmCJde1dnWPTle5Kwqv3Xye23GcdxXQeP/Ddx4q1jRdLF5CZLBleQQTbhE7ALll9iOKd7tJndOpGD9n16/wDAOe8SzHW7zRb3WtPjj1C1xJGsEhMUc4PJUkDI4B5xVqfR7q70y3s9HefT5brUraC5vIJ9j2sJLZ2EdS3cewqGwitr+21Kw1K+VHVTbLIx25JONynqD9K2PCvga5vvDL6XfXi2UljfRNeTK/IMWSrIenO7k1N0isVGEKLpvTYk1CIWHxC1We5ht30S2s3muYmYAlG24L49x39a2YdZku/H2oaLo2nyvIulRzebJ/x5vnGAD754OO1c3rvhvwXrvjzXZ4NSvhfxWwfVLNZjFaXgOMM75xjjp3qzp+keI28d+G4YriXSrKxt2uYxC5NvNGcb4Cvftj0xQ7NHnNucbp6pdTY1zQWcab4Y1TRTrvh8l57i+vJCzxzYJBT0I5AHpXka3WqaVZ6xqcmtMvh+RhpxubQDzn3HasIGfl2+vbFelfFvW9XurXwzf6DqHkaO12326W3mwm0HGxzn0J/GuQ1Pwto9hcT6rdXlpbaMt0L6KG9Xy4WiwVOQoPmcsMcZ6VVN2V2VSUlC9lr+aOj/ALJvJPEfg0WGqfYZNNtZLCOK5I3XPyn95Gc5YjHNUbTQNb0u3k1HxuJNe1MXD2sF1AQ0kFiwJdgevc59K6a11Lwpd6noF8LEa1rUlq02nSxIuyOJTs4LEbeuDxVvU20y38Q6Xca3fppGoMxCWMc5IuN38OB2JPNRzSvYldHbRHM+NtPt7/wxYWGnXz6b9h2vps8N2WuZY93zgr1ztyRUvimK71mxgum0UaozPshtNQvWtneLyghHyg53kE4bHLVcm8M6CnxCuPEN1p08WpOgH7iY/fGECoOApIA9Koawbe913WriKSYyaayxtaN+8kneVQoXJ/hBI+hoTvsbwgmrPS/6kWp+HbDxVrNpoXivUdZ0mZoUvbXSUUQwW8IGwwq6kh+UPXB56Vo6Zc6L4F1IadrttY3F5rsTma6tYwHljQYjQgfe4z8xI5q3rEf9mW1lp2seIXa61K3IshcIC0UyjJ2kZxtGPyrO07wNqGl+GIYINV0u71k7ba6uLtM7rIsTJGhIzuYN1pXTWuxg4RjHV3LEHiQaf4Utr7w3BdI+piRdPNzGZVhSPqpPUFskDtxWPpUus+IfB2m6r4kSZdeYyLFGI8JLGx+UnPcYPX1q74esPET+I7vU4dVay05cw21gHRIlAGFDqSMY5IIBPNa41LXrO917U/Essdt4LtYDHax3EKmR3PAfnrz+dDstI/15G/M6c+br/Wn9bnD2Wi3ZSTyLAiU/OsA4bjrjNaWgmWPUfMec2lzDnAYYk3EdB9a6jRvCusajpOoaZ4i1rdfbi9tfwwhJIgcEL7jpxUfiTQb+CCz1TUttw9qottQmKBftCA8Sr6Gpcle1ztWNVR+zl1I/h3ZSXmvT4hV4LY4eU8YJ9PeuT8c6n4A8K/FSa913w1fRaharE0d1byZS5L4G909s9e+K6S+fT0tFjguriw0u5vU+xPFNtZ5UB+8R/AxwOfWs3TluPEmpa3ceOvClmbVCpnvIZRlsEFYNzbchTtHB5xTivtM4sRedRyeisaHijEmvzXGnzxQXEMK3kYiYlmhJAVzxwcEHHpVO7uZ9UuhYw/Z7fUNTnSOW5EW17mArztfs+f0rU1y8t57vSNM121ls/EGqLJJbJYqGiht0ztEjZx90A/Wsfwb4k0bXNSaK0j1x7bRnYxSzRL5bTkEbVYEkHPOMfWlZpaGtOrF0/e1a/pa9dR+pta+HvsNjqrPLe3F+LCKaRsgx9NpIzg4pfGseoar4wsNP0LSv7M1hZEnnnSYr5iRt8uexXCisfwwDYXNn4fudOmv7m5uZ7m5upV3eTNIzBSpPBIBH5Vt+LtTvBqDLb3FvFrPliNBw52L8pLr2zg1drPQiCnOavuF9Y6fp2uaxc6LZl9dvJ8T3AcOWXYPu91G7PasXToIYbe1iu4ZHvYLzzLLa+Ck03yOdvRtoUEZ6Vp+FL+3h8bXOrNp0Sa1e2yWc0g+SPg8uB2GMflV+5tLDSNT+1y3cNxbxSNCGTBKeaMGQY7r6GpTtobxi4L2Ul2fe5p31qs/hzxNDp+ntfSJYtEdNVtj3foxI6EnPT0ryXw4mqDVbPw74ds10q68V7ptXubaIM1lGOPKQ9FK855716Lruj+J9S0++XwrqcejaxcJCibiI3khUkllxyvWrSvqPhbVLu00WbSGup4lMgnCwgz4+d09c8ZH0qoO2iOGabco3vszL8J6VpsNzcXWrWbX1/pc0ive24EZNyvHmMmRzzwfrXJrYavpPiK11LS1muV+072+1SeYhOceZjuwBOPTNdvd29/qF5rmrJ/Zz2jAW73iOCsn97A6gqcc+9UoYX023SG4DG5iO2MEfO6t1wKak0ztpRi4t97af15mp4i1/w5omvR6o8M5muz9iedVJaZ2BUOT228/nWD/wpiy/6GbWf/Ahqm1O8a08P6kfs++8d0SFrkeYUI7gHoa5b+2fGP8A0FL3/wABE/xqoRlb3XYylQbdk9ibUpY9ShNjrGmNe27yI7WDlly4P31bqM+1bPh5rfXNa8beE7BL3+ytZDTrdFJENvNwSjtjhQcDj1q3DqNo9tbnxHLKusWEJ/fRYEcYf7hWTo2dp4JyK0PEuqQ+NvD8Ohz32p6LNvWSWWxHltPhTlSRjCtnP4Urvsa4pe1XNCH9fqYuk6Lqdtp15L4lMMB04W8VmGuPNkndEIJVskkZ6E0aRYWXiXWVuRJdQ+IrSKS4gQSnyrwjko6evv8AjVfVPD97NF4buovLt9H07B3Ocs6ICqgt1wM9T1p1nDcWOt2uqWKs6xOJFk7Meh59DmhtnRCip05JvXp2TXQmt9S1u9tdP1LUdOt9Hij8yeS0u33okgysaqOWduQxyOADW5DEfFXgyJ9Uugmq6uskN0dPk++qMVDqrYKrxyAOtGmQ28seq6TrwuWXUb/zrK6eEM9vJJyyhuo5JAI7GsOyGn6V4lgzb38h8PQ3UVvNa/PKcswkV0PJHLFTjk4o323OCUZK3NuvxX/DnQeGLq00XUtc0Hw/4YljuPD+mh7C/wBuWviV+6X7je3TOOvSoNX1fVrnwzYweKLG1sNSedbg2dthmQAAl3xwozke9RabYXUXw+tbHQNZuruG6uxcNcxTHzG+bzHtjziNimRxj5qg+F87Xr+I7fWdIayiuHZIZJ3Z5IlHSNnb7578E0mrXZFGMVJ1JajtCvbXwNFqsum2TX0P2bzIkXI3Nku3OOTzT/AqaV4c0i+1vTormLUNaxLFZXRDyWxyc7mzknvk84xVTUvGv/CKWWbxlkYxyNbRrCHBEYJbJxwNoHWs3xDr6+NNK8O/8IsktlfajcyQXE7wfIqKisxYgcEhsKfamkzoqqDnefzt1+RY8OW9o+867YyvdzybyV+9Dg8GtzS00q70jxR4SmvZEsorPzr6QSF5jHyS49z0I9qteDNJ+3zSHVJWey0y32ySA7XmIzjJ/OuSGp2rXV3qem6FNp0OpFra6iuJdtyY1xtIOeAee+eKS1dkaYhqrJw62RrfDjTIfG/hebTNd0eW18JWxT7CeYzexqT5ZduGYjB46c1NeRa9Pc3s+ja/bXuuR36zxWozstLXDAoV7HkZA9Oag8Q62mv/AA4vrvX1vdE0qCSFrSbTHYykoSFKK3GDk5q0uj6jrI8Wat4Mt7a1l1R9q3qyMC5UjerK33D6464p3d22efrGo3PQr+E30T+0rrwnDpk89oZHaWW4jJha8PzN8hG0ISD09q0/Ga3Wq6p4etZfDaanpjn7Jcq0ZVIsqTuRf4QMdcVZ8Oahfw6jZ6f/AGjp4ZX8u5mlDEXUjKfljJHy4PI6Diue+HmoeINP1jW9DudTN7qRnlhtGuXYPgkthweeAOCOMdKXVtGk4SjJ+h0GoeGjaCx0VbeBrdbKTzZYVJuYbdW3iOPI+bcVAOecmuP8EXVr448Srd6tpIsNH8PxNMj3MeblSWOxXbkjHB2jir76/rw8NpF4e23msW8s8VxemRpPssQDFhuPJJYAD0zWd4R082PgWPUrnWf7D0/UrlTq1wXe4keVsKi7mywOSBgcCmlZO4mpKLu7L+tfu2O41y5TVdcu2e+W30m3mhkkuY4t2ZGRdoHHBOQa594V1VJdV0qKT7Et0H/tLeA0wU4OQD0DA8V0fhCAWnhbVbPTpIX1ItJII7klt2zO1u5YnArn7LT3ufhvp9u1zZ+FXtppb3VbUMZW2ZY7gOWCk8ke5rOPkbKp7KoodFZf8H5mldasuo+JdOFlFFKg/dQzXdsryc/fMeex9q534saHPea4L21uri9v9MQYsI5/IhkQc/MQQUbnrWw58P6h4k8PjRH1e7uruA3EOtWsTG3gjQndGoPyqX2lc4yM1zPhnVtM8Xax4q1DwvpF0viGSSJrqz1KUlbi3DbS0a5wTkE+lOK5XdGTrUudKCt+Bt+KvD3hjXtYN/faZLPf3UEJuFa9kjjtZGGFXC9SSOtLDoMeueHbnS9QudSufDp1JCry3fnSJt+7sYk5i69emOla19oMo8Ky2t1OtpfFE+03AO/aVJKhiM4xnn8KSC7ksb17Cxt7S10m+tFQ3fHlpJzyqjr9cY5pXdtGaJKStHU0kv8ARtD8RWo0a9m1q81oKsFo135iLGg+Z1ycDGRx1qfw9rkusaxqGmtrOj6hbrK5msohvkih/hTBHPue1cDrVtpOmeM9N1WZ44TArXttZWcADOkQxIqgDChiynJwTirHhu60jSo5fHWj6DbWmq6pNtuYbq48iaKJj82FJCjnB460ON1c5ZU2vNm1q+mQaN4p8tvs0WieT89lJDv3BucLxhcHHPFcZ8QtKjuPB+kn7Jrd1pV5rscNxaCQsI1AYK64J+X68fjXXancNrmvXDaJqEd5Y26eRfQyk7hJg/Ln/PSlg1DWNJ8EmKyu/J1GwkFysLLuWaMAjynPZec5HcChX0TOmpCTpJp66XHeBvCa2HiTU7K51CKTTpd8Vqpumd3w+doB+6FAIwO/NYfhxfDWmaxr0eleJ7qS08PG51C409l8lQ+WUq78E8nAIrBtNUSw13QrvTdMlvNf16ZlkuIpmeG3VjuLQ4OCyHhs+hFdDe2LXvxJXT7h7PUwsiW2uWun2ihpM/MklwxAwhG0kA8NVNO+plOT1tLTz/Q1vDnjrX77T92o+H9M022toRPK+9mAMg3Q7OPm+8pP41QhWSDUp9b0rT7G51bUGNit5cALFAgTzJJ5M9cZOB/s1d1uSa80i7tbWSD+z4b1mikxxGkQ6Y7qAuBj0rlvBfieLXvtNpq8aw2eoJKl1ps8ewXEZUp50T4ygI4IJB9qlK+qR0xpKFNpL3n/AF+P/ANXxBFFp0nh/T7e6Op3scRJv3CgXRZyQQBxgE4HsBTk8OWfhDXLHzdMmvdT1S8WaS1SZVto5GwA8hYjjj7ozWLrdiugxQ3l20cGkWe22g8tjKIgfuKDyT25rS8RxHX/AA5BJN9paRnZ49hV2YsoUbMngjGQTjBNNK7XY1qRlGlGMH0176+ZFpWna9c+PPENxf3FtdxlWjTVFmKszJyYY4T93AIBIGBwc1b1XQtK8Rz2ct+0eqafYTkSRCQieOcY3oWHXtnnHSotQmt7K70jX9agns9TkthpL3bDKxSyZXdjo24YBbk8cVX8DSXmg2evx+I2t7PUruWS2gmeHbAbiTHlAbR1bBy3sOat33RyxclB8z2Hax4ZTwfrdrofhgJ9muL1p9R82cTYjI/d7g5zk85Cg9BWh8GNU013vdJng1S/8QaC0khe45kuFYjkE8DGOBnFVB4Kh1jXtG1PxLqDWXifTW+zyBuYLrZ0YP3IB5zVoL/wiOoak/h/VYtR1fUmk8m8nTmNsj5AANrhRnH1pOSa5SXTco+zWr79/wDh/n953Xii2sYWS4ltnMF1EZ7hGXLIFxyMc555xXN/8J14Q/59rv8A78Tf/E1keFf7b02/vtR8UatcXEE7oqvwQrlSdqAfwn26Yqx/bV7/AM/X/j5pKPLpuXTw8pLlbvYwo7Swa/v/AA7rLC4i43aeC2yEdizjow9AeKtaf4LmglS9WS8tRPKbS2W4uCyTKx+VxzngAjn1rp/CWgeH7yxsoNBnkju2lM13JdAu9zn7xLdz09qzdRvr3Q/H9npV1p51PS7fzLmS9lkI+ylvupGoOCV9wTzVc/RHTKvzPl6+n9dTR1+zs5Li68P6tBeXdlaWgja2sw++6ZsHbkfdGQOSRWr4V1Wzgi0/w5rfh7+xEitJJIbZpfPEcKEY3OM84569azDZ3CaabvWLie1tri2lmu3SQpNdAj7gfOEKkjHSud+F9zLrHh2C5s7G5ZdOLWEd3ezBnmgb72ecFgcVNk43OWrDmfkla9+psXOtGW00zxTY+c/hw32Nrj95GFJTcf8AZOM+tZfxYR4vEd/JcasdM0LWLWOaLVbW2YvE6Efu3eMZ2kDdya2rbTIINEl037b/AKL5c4uY4AfIUR5KN83IOFGcdT0qt8OtVuzrFn4eaL7dp97a+dJG65jELLkMc8jIIGD6078r5kacvtKfPHeN/K8f8/zN2zFvZ3diunxomjR2Ss19CoWCeRxgyHHBY5znrXEeL72/u73RtC8MKNPsEkk8y71J2GZME7kOeRjke/FdLqar4U0jW9I8G6eHuki82z0q6MjLIgbdLtUnqPmIA9sVz3itLnxPpfg7S/FmhTjWLkSyvBbFkjhjVCy7j2bpwKcN7s56Xu/1+J1uladodvbST22p6Xs1GJrFTeYZJZ9uCUDc8k8rSfDC689dV07VTDZz20hyBEqBkXqRgYx/SvPoReX2mpp/iHw7ZqItSC6bcSsY1hZwqDHIyTgde9Tx+NNPsfHmq2l7bLqFjYWsdpeTQpIJBOWIC7O6HozY6Ck4X0LnBpS5nvt30Oy1q5O/WrjQbhC0sKvZKv3Zxkh8r36dawPFMms+J0bTrDRUt/s2lx6ybxkYv9tGdsJJ4KnHK1q64LnT7ptR0+G1e+MObKB8rEGx8sb4xgVc1aHxFrWhSWmgXMdt4ohaA34EmLaMPu3MmeTgDjNTHQKrsov01/A5eKHV/GF14f8ADWrRXDaKy/bG1O2j2BZkGfLIHyhBk9eeafPqE8GmxWiPdw6TeanK8otFLEsTli56hOOMcetdbJql1beHb3+zb7dZaRbbXuBs/wBPnYYyVX7ozn61yXgueXwnaXkkuo22pQpEqM82QEkcHMT44X2J61V7mlBPllUtr0/ro3dDLrTItdi1AXE8aaZOoGm3tsSDMQOMnorrjHFRanPBpQsNSnuZptStLP7L5ygNLcOy4RQepfn8s0y91WNtKtLHybfS7CzBFta27FljGeWYnncaueH1i0xItbWyOsCCRZ7ZI2BKttK7iencgd8kUO51W5YXqK7XQ2PA3gq98EfD+/vNWvZbi6uIfNNoqAYZiCAccl+1UvEjTTWHh3RBcWWj6HfTxO5mhEs95OSGKBFBCANgFjg8VduGuta8V2niLV1ud9nsMWltMY4rEEg+Y4BBdseuRzVHV28P6FrFzef2brsely34vjqMTxyo9w52bUDZYAlug6Ule+u550pSk71PXy20Kd5rMt94h1u2gtm0PVtOulENuw3GUKo+ZXXoWxnBOCD607xnD/bdhoPie3g+y6ncy/ZdTdAdhVOQrj/awBjvmtDxXrHhXwl4rso9UtL3WdZmuY5S5lCva7wFUsoILAZHUGsfW9SvbrXIdR8PW0erWOrXT2z/AGcsuGQfd8v1Ujdvx+NVHe60NlUU1FW26/LVenXUt6db63r8unLpFzc6dZ6bK8cckAMVvuPIUxrhSMnuKk8Qz6ql9eat4dGiWV+Y4bC1vmyGmUOTIAnRRkntXT+Pobuz0fRrTw3Z27zRHM0F1cmGFFI5Z9pDFs5wBWBsh1fRY7TxfqVnNq1pcve2ktlAYoFQKB5LZHPQ8nk5qVK+plGPPZxjob/hyew1PwTq2kzrNb3t8sv2oFWO2RlALZPboRmsrw9aWOnafp2lyCB20xVigLzCR7ggndlScgdMA0zXTPfSR3ukalFaxKq8SMC0o7lwKkn0PRry90PxDc2sdtqzM7NLHKQJtgG5mGeg9ueajTqacip+89L/AIaHLXWp3Fx4wuY/C+gpF4hedzq0uoyNtsrfI2lVJwVYZOF9BXQeJfDlhqNqgs9EtfETCZJmsJL/AGSwkA/vA5bpk8KxwRVfWfFMHjjUXk8LF00+Wx8+4vorfMhaM8xOCMjGRx37VS8NXmiXR1O51DQZ9P1LUL2JQLGfzDelQ2JAMnaqjOVGBz0q3fRkXfs79Hv6FnwNDb3uu+IbW08tZUSM6lq7MED3OOYEQfKxU5BYDGe/Nad34V1MiZklaWSa3aNomJCyBuigjp7msXS7W3uPG9kmlW8AuHmuGgSGYNFDpwcb7iQZ/wBY52fKfm5PFdL4L8QarrevanFo8lv/AGbbzzFW6usRVvL2qeeu3NTO+6CFWpGMrO9tyha2z+Hh4fM9hZae9lbvawPYyF44S33sdi277xPPWsyxGoKuu393qMQ1TT2H2yO1jEImhkHDtIMb8g5AJOO1cto6X2q/D+5TU7i00b+yNXku31FLkFLqQFhNE0bEsHILHAAHFelx3MGv+HL6TSLeP+zjZCeKOTaryj7uH78DkduBTkmjSE4Kzt117b/M4nU7fT7jwZpmnfabuLU/Elw0Omx2rDfbwqTukYE8rlSSevPFaunWFlrXhbTrRNSsNT02zjl06a5KmKe5kXPK7sEYJxn29Ky/Fdsy/C2wvrOBov7OtZ7Wa8AH2m1L7iACOSrbguR61h+Fo7WPXvC80NpfXV7btFpi2TR7BAjqHlnlGP7sh+Y/jVpXiFRz9pKV9E3/AMD8Dr9T0Z7CM2Fp8yvD5aQufMXYF4kB5DEHjj0qr4V0i5tLa509bme01NLCZYJdod9wBbIU8Z5GKW81i6tLnTLjRbKO5s21V7K0wxMVvAhBZ2bPRiWAye1db45u7RtY07VEWW2vYswXUAGHjDD5XHZue/Ss23szo9rKpD2fdPXzOIm1zStb8H6qPE63tlbabqMTTSQBpQAuNjhWyQpbdnb0rS8Q3Oj3uoTz3dnc6ojSpcXxtbgmCzkhGYXVSc5bceOnFaN5puiv45stSGsxWmpXln5Uum3IBguLc5DSY6bj/SmeChcC08Q+HtP0G10qFp0FpfRzif7USTy5yRkY6dBmrbW5wOV/6+8sX9/Bdafaak0O6JL/AO1yW87f63zOm0dQOOapap9mleG113T2tELm9tDZEb7fkcv/AHRzzVjxdaSQ65pdnfRK11aJHueMYWXJ647AYqe1m0aP4meILfz7h9U1BommtpuPOh2N8sOf4ehJ74FQu6OqU1CEdL3u/wDhjSutLtdYu7kQ3LxWNmI7q3k28SMwJI2jnkZ6U3+0/DX/AECtV/8AACT/AOJrnNR1nXo7/wAPpoVs873UpgP2dNwRYiFWQg/wkEnNew+Z4j/542P/AH0aVtDmxHNTa1/G23yPPfC97B4x0NPEFvcLBDZzvFbBkEckRGOcLgHPoRXH+Ndcu7e5021s5FtdYvb+Rpri4UsjjcMLjtxnmtTw0L23ifS9C0yCOMqs0jB8s4H8bdgfwre1Q6dq9tFffY474wwuEkA8xYpsjcWK9x/WrulLY7VB0pWf4dCv4i8W6f4a03VtLuLKfUWliF4PtcirFK8hB8hWPAwM4+lLd6xp3hmPQ9QmtJbaDVmhjs7K3ZWihkkTBSQjgjksCOuKxNfdh4XmtrjSE1meF4ZbS3uFIXzR8u89yAGPfmtK18O6nH41v9Vjjtrq+k06C0sNrhoYptgzN5f8ITBGT1/Gj3banLUpuDev/BKXxGlsrPSPEejzSSlr+/ttPiaLOQ5i6kLztz1xWp8KbZfC7Xh8T3ptL+EJpUc0zKsVztHy+VnkkYxjmoNFhtI4ksNRu1vLtC901zcxENLNGCJJj6L97Aqh4i8SaH4j1Pw9plza/wBt2TFp47nyXRYpuRG6YOSenXIxQk2uVBWUmnCPVK/4fnYqMunxWwu/Dd1qt5rXh+8uLmBNSfy59QmZGLphgCUVScADnFWtBvr7w/4Agv4rS6/t7xTqYMcV4XItHfAZlDfMFHJwf5Vp22g6e2qabrGoXhn8R6Or28NoylI5JnYt5nPLHY2DzxiiXxLp+ieHNK1DxFfSahai7aOzkMZ8y4nLnMe08qFPG49hTv0SMeSO9tEU/C2o3mt3N7K7s0VrciCSxYLJPJsOWmQY6g5IwKj8WNaWbT614S1KOMwn/iZPdWwJuYz1jQhR8454PPSspbq2+G954w1C5k1otM62q3vkqyW5m+YSxfL8wTeM9c7a7G48PR6nrV+32kGyMYl8wKA07iNWLhenzZ6460SsnzdDopVYzk+Z2SX9IoeHLXVPEEK3un2iuJWIMt1kCEgDB29zz3rcljl062i8M2k5e8uo3ae5VcyO452qegA/2vWsrTriRfHVzfW11d2PhHQdEWe3wpEU8rlw7sf4iAvSsf4S+HLe+1PUvGGn/a49Ct0kOircSNmYkHzJ3DHPJAA7VD7sipiPaN32Wy8+hosYbzSoPDPh6zEV1fKLm5klYFl25zuxxn6Vzl3YR23hTXLHUdLvLa61QQy3rQD9/dFT8iqrZCgDcSQBXT/Bww3Y8Ray8BjuZRiPJ4XOc4PbJArF8GeGL3/hBbCXUDLe6hY6hcmBZS7SKWIHBz86Bcjv1pprW5tWtSn7G2it/wCBNb/oM1O0WTTZdYsJNP1RkkdYUhlXZLEp5Zu3p+dXbSxXW/FlnoN3bSQ6fc2sOoQiBzH5TGI7w23AIBPT1qvt03Q7PWbWJbTR/Dvhtra8V7dS8zCRSZY+SfvNt65Faf8Awka2Pi7R9bFvNLY3dkLoBIi0sVu+AqKg5Jyy5+hp69BKtOSceqT/AOAZ/ivwzHqV+fCFncxWWmaTbfbDqMN95t/5+eA8eSTHzzuBxV6DWb/xDdaPqPhLxDa3unaVaC01W0aEfvJc4M6AjGQ3zenFXfHl5YaLNc6l4Y0eGK91NDJqGqzkRIEVSpVy/ftgYwcZrlfBQ0bwt8NLnxPBaxp9skLkxTCRIlU4ALr8u7uAevSktY3e5ywp3SlLfsZfhbQNOl1i4/4SnXpBfWjS6jIlxD5l2URywZnUbfLIAO0888V03wSWS48Vai2m3Frb6VBI0sNkqEgRyDcXRz1ySe/HTtWZ4p8OP4o07SvEK2l7davcQGO8ubT9x9qt3O1EcMOoBU8Y4FdrbWY8DfD1hNaRQzRxCxs4mYMwDH+Jl6/eJqpz0t1ZolKS5Fu9P6/4Jx3xVnjm1XUbqzvTFbTkbJXJOZRwPLX3IxzxkVNqmhXmk6TajW9Kkvre+eKzl8qYAQq/33lI+7wR0xW/pcUtlDpej2NjaTzSYnn+2rl5znIKA8qAehrJ0XTHtb/VrXwzHPrN3eS7tVjnv1eGA54UejVN9DrVVx/dxfurTfp+hqappy+ELOXTILMT6BBZedb3RYNlcncjt1GODuz3qv8ADTUAdAuZb9V1mewuHuVkQDakbD7sfqOPxrNN7rFnrb6FeaQuo+HPKezuYnciZS4+dNuctGRtww9+aPBejx31tHY6/Fb29iGNqttpjtFEirykbkkseSec1OltSOV+zcZK67/8DzRV8K6ZNqPh68t/DHhvUfCt3p96NSjgmciO+U5BTeewGOpxzV3xZ4ptfDdz4NvvtiSR2zSfaIrOJTHcyOONr4zx04POauTnVbnwvqtt4iX+zrKRBDp8VrI5mjAPK7iTuB44HNUtfW7svCN/a+XLrqahLFDYaPbWyxSabCAcnJBI5xljVLfU5mrLbT/gFn4VaZd+GINf8QXVlNa2OrQm7ImCvIjH7qoVGNp3dPYVyXgfV9X0zy7u6jjhvoZXZfLXBaJmyQ46V2Piia5TQbDSMRGe1tI5L/7NKzJCccKvPT3rX8DeGLHX/CFpNdOEiE7u8i/fcKSCCfSplPds7aLhQourV+07GX8Rv+Ff+IvDpm1iY2WyeO6cwR8GYkD5gByWzgn3qLRZ7uTWLG1vbay0zw7qltLYzGZjDNGwY7FXccHOAAB2NabSNp/2uXTbbTYLFmZ4xcBWaRI+N6q3UZA5rnJrrR/GUdtbavbSzWNxcC5jdX2m3mDcsvcKe496IvS3QweGbi1T29TP8I6jZeGvDHirTrvVZksPPNjcPOnm/ZZnbZGUYghlClSc5wav/DCx8QReLVuL5rgaJp8Y0wSXcHlPfFxxIpIBYfMMc9ABVpdXn22eg67Z2Nx4g1iaQWsMUQ+a0jZtrufuk/LnpnFT3GrAeELjxJcXHiKyi0m+jUWLKJJJdrqMINvAY8Z7CrbevmYybd5NrXR/kYei+KNM0/U4LBdPSzsJrt7H7PPKMRGNy+SB0LFuh5oNtqcEuqz3+tRasrS+VG7AK8Ssf3efbOR+FX/FNvBqCeItXOipNfWKx6vY2nlneZGA5ZRySMDNU7dE1F7/AMLyaW15r1tZtfXKoTHHBcBBJCGbvy30oVmtDqVVQal1SX46mh4gl0CPRNO1zXkna3sJdkj21jI7RgjBLNjG0e3FY9pbxwaT4X0rU9fsLvRdVuVurK4ti0ElzKGOd3IKgAqCOM5rZ8KeML3RtZk0TWdHludDu7MXBmRd0KMchlORgk4xitXV7rwxLZafDo+gKJ9MG/T5Zo9q25znKg9aSbWhjOnVc7JXj/X5FbxwZ9T8Uz3Ct+7ijUoEcDdGv8X455FQwXV7q3iaHVZ0tnay0x4Yrjy8TAsQCAemD60unyy3GqxyDyWZVbzPPOBNu+8f5cCuesrt7SK/WSdDbC9kiiMbfN5BYFcj04oS0OxUk1Gk1qlodL4/16z0bTtF8Dafd32n6tdW8ZSe2hz5qDqgYDIPfPtWF/Z83/Q+eI/zT/CtnxHeaxrvifQ5tEube0tIljjuTIEEiqecruGcHGOPWvUvNt/+gU//AH7T/Cjm5Ujgu6Pxat+Z57p7CS2ltEtUuYYnJiu4X4z/ABQ7xxnpwauppNlqdhpAt4rjT44LjzrvT4Dxcseqt65OCT7VLqln/Zl7pdhpFvJp5vLh7ma2tRi3mc43byc8njkYxiud8Xalq1ol75OtPpDuVLRzMIvsxHBVZSMNuyMcdqErvQ1UnWV3p8zrH0+a41gnU7dbHLAWjE4UoOAnscVnfEDXr34caPFPZ28d7PqOpQ2NvDcAlUjcEuMrg8YxVDw1LB/YF3pt9qOsG61FZFWy1Vw0nnLn54WAHyMeRT/BkU+seE57LWZZJhHGYbmCU5lhXH+sQ9irYpWs7vYykpVINN2S/rT+vmVPEeppp3h2WWwik+1jUDBF9iw0sERkw+4EH931z/Ort3p08fiGCw8HWOjR2E9vLDeXjNiZHeNtskIzjaCRkAdqq+CND36tDELi2ktthNxP5m6WREGMsOxbAJ+tQy3uqeKrPSrLQZbW01B9Qf7VFbjLR2SSEKxP8IIA+uarXoaYiEVJ2f8AwP6sZOmaTq7p4MsLLUZodK02SSLUJNSHlTzkyNmVc8lSTtX2xXdePba41mW3i8P3aXWlxrJaalp0aoPldSBIrEHa65zx6Vk+I/EUh8SeIrrS7ZNS+w6etvaQjDEy+Zh2x3KjJx7Va8Fi38PfD20M9lfrdarvlu4du1wWJXfz93jkCk76Se5g1K0X1XT11f8AXc4y/uNbtLGbTI9I1e4hvFj0rS7eSPzGEaNukndsYC4buO3Wu9tLfSdKbw3pWj3ZOq21uJXD5LPbgnfu9wc4FcpY+BrJLKw0u01XUl0OC/fUpRcXObh2Cj5NuMsvHbGOSc1uTWGm6fNf6npaXM39pSPM07uGWHYo+UcfKDj7tEmpaGkYyctX936nPN4f8RaPDe+IGikstUbzHXTIJRJbpEhycZyPnBHB6YrpvDGr6jqXh3x1c3F7HPZxyMtnDGgVbdAnKDFWrLXJNU1DT2kngcTBEkYtlY0yenoT3zU+mJbDwl4iSw8p3trmUNbxjBjkGPlkHr3pSk2tUKUeW0Z73X5mD8NTHD4Z1mGZQYfIJJDhRJvBymezDHB965zQ/Eml/DnwZpyXk1+1xfXcj2MF788sLEhZNzDAIyRjiks7q+tLeLRLfSjew3JjuXVW2syjO0q38J68nPStPwX9vl8T69NqOvaRq1h5E5tYnkQtZycFQUIyMdCfXFUlo2zoxkUqspNeZV8RaW3g/S9dm0p4LnV9VhjcJcg+Ysa4DbVPBJJGOK1bHW7m28faTNq3lRwR6QklxHt+aJwm7GPXAPAqhoyNrOi+EvEnj2aKO8sHuUkAO6SUqwZGLDjbhSCMdSK43Qo9Z8SeOtX8SmVoUuN1xY7jkJEfuhh67MjHvTsmrMdFOpeT3ad/yOz0jTPE+p6Nr95NqVjPDrLtNp9replBBKd3zLwVbYcheuRWFea7cz+DNJ8PPZTaILu+Wy0dktv3VyEYI7TIeVOQSM9ua1pdT0T/AIR1dXvYNRuNOtZlU2Mim1xJwoO05JAB655rR8EatHLe3Wh6dBNDpdpIb6yv52ErB2+Z0wR8uAWA/Ci73sYzTjZxd/loakMs1vHqlvrmr22rxaXcQ2tlbRfLJHOqq7eYVIGPbHC1zurXWveKpG1DUYmtba1lPkxkbowcff8A9oe9bWo6Bbar4rtZb7VLHTH1CRjbW8UR33biPh3bOC47jH3eKz7/AEPVbXSbew8Qzi3u7V2YTwkrBL8xKsnocYBU5qNDTCThTenxfl6f8A1odc1C4s72I6hDF5dqzR30iAfY0C8zE9do5IHtXN2vh2HxZ4ZvZtF8TPOutPDO8zxG3UXETEGQgYLB8AYB7VjW80VrNFb3LmNtRiMpWeXy0kXcVccj7u0ZI966K+0nQGfw/b6bq2lxTwWbrpttbuRGFYnc7LnJOc85qrcuwqtJcycDbSwktj4Z0+38S2z6xpaYvmvYyJbi3XlpQM5XGTy2RxWZ49ktvDv+mSSrd2F863EdzD85Qse23jbx1rO0TTtPhgN3DqlpqmuaOBZ3EgyjeRkloACTuB3H61X8R2Ok6LPqN68l5pmi2cKHTZbdswrvzlWjIJ4I9e9SlqFG9Kd73X9fcejWtsniSTT9R2C3kgj8qaKb5htGMSJ/U+9ct8Q9JlvfiRos8HiK10VZQNsQBZ79MguuAfYY/GqNxrtzpPhS2sri4uLW6tZUnstQWP8AdvA3J3DvH0yPpS/Eb7Lq2h2fiK4SLUdUihdbTTmyu+bIXMWOQo3ZPXPHpSimpbmc6MoPmXw62/M6e98IWl5qV/4j8GakkuoRuyyWpbfbSuPvRsP/AK/FYs17rg8FXkWvCLRNJkZ4liggY3EzMS22NQc4GDn1Ga2/C+nXvhP4f6FpFsEl120UGa3tDjLsp+/nO7Bxn1xXJ6sbmz0yC/8AibqMks1lJIbW8jgKOsr8FEhz8yhSRn6URjdhCtUcbSs0tm99P600MzQ7rUdLGk6fcXjeIdKvbeWfatsQ9iuDhou5AOMrzyMV0Wm6QNP+wS6zqFhOGsnea8VfJBDf6slSeHOQMeprmdEhu4vD+tTxazrHhjTkuLeLS5dUg2yRAlSXRTztfpjturpPGa2VzYzabeafGtvLJtni5PmseRI+OoLfMMYq5PoVTnOpN8nW5z+uWU2t3tzoMSmG+XTB5GpRZRrRfMzsYnkbienXmtHwnd+KdC0nT9L0XTbXXtCslD3lxfyZmaTcSxXptwOm4HpVzVBFe6dPpMkU2nW7wW14t/5g+zO8EigRBsZBKoOCTmp7zxLJFq4uZDayH7RmKNVKxyQmMDDj1DZNJttWKjD2za5df8jS15NP1CxudSu1lW9KnMcBKugYYCn8OfxqCyjutQhex0o3lxPdLmXzCsccaADBlbG5j6YIrOl0rVfEWsWMum6rHFBbLI81uDsVy+Rkk/e4wMe1dxpmjxWGg6rpX28fabyF0+0pyVLLgflWbskVVmqMLbtbLsc5PdSafFLDHf2eoOjC1uQqfLbOvO1fz5qlo7P4hltbTS7X5J5C81+o3RxIOqg9M1lR6TcaJ4L07wxNNC+owzNuu0Ur5pY/fOSc8dTXommeIPCPhnSotKsb2CG0sov3gjUlFH8TMfxpvTYJ1JQpqUYtyf8AV9DyzxDrNjPDeJoz3M8dmHG+5t2i8zbjcVPcc8VS029j8QjR7FbTyXvIGmWTgYI5C/kDzXQXi+DLCC9TwtaTwC+nWe4ZwQnGcBQe3J4FP8O6foWmy6qLy5mOraHbpMspG2ONZgdqZ7n2rRNW2No1pU6UXNWlcseF9WtbSzlWa1F3dagohgzyzAcYHpitH/hDZf8AoCah/wCBZrmvhqi23i+0gvwJDAk8yA8bJEB+X271k/8AC7L7/oHav/3+H+FPkbfumWKnKlVapddXqztLrXdZutL04+MY7jSdS0i6jmaPSo/Mj1Qc/JE2fujjd6cVzHxLu7DxR4jmsPFjR6P/AGfaw39rOr7ZJVJ+6w/iycf7tdfpdxFpVmukXOtrcfYCGv7qRdwD4OII19T9eMd6g0N7zxzY2Euu+HEs7mCTbaxSJiWOHrv3H+ElRxTTUdTjjTUdtu5DqOt2MHiU694j0xZPsUK3MLJMGeJSQAqLj5sA57dK0tdeaz1zw/qfhq1uri11FZHaQx5iRcZJk9Aeua5yz/sjxf4tvJI9NSHXS00cn2liRBEmVclOnf5Tmui+E9ro8/hFNJ0O01CLTYJprUG8JcSqxJZu3Bx+FTJWV7Gs26LT8tV5WEs9S0a7u2uNFe0sbue3YNeL89vM2MNG3I6c/jXMW7r4Us7jT/Cem2un6nfqkMl3KSZZS7AfKewBbIrY1Hwqul3LaZoenR2VhaEpbxQncQX5LnPqeanngn0HSJdX8TXUt9Z6VA6xXL4MokfjIx/dzwfapT7HR+7UYzdm+z1/4f5kfjXR9D07T7G3e9hh8RRRAGcybQCvLTSL1KgggtWv4ZurzUvAGlNqt+l7M0rBrm3cSLdRbiCUIHPoPesvxTJ4WaTTfEkmn3F/rFxaDTXu4vm+zpNFjzJV6Hh/xrn9Ds9Y8PX1j4etRNbadoAYNMrb5ryBwXV417/Ox4zxVct42OOLnOzl01LEt5Mura740iY2/wBmtJLa5sw29UJBVJP9kgAZWpfGeoanp/wt0C91B7fTdW1Hi4c/LGrn7pK+4xxWndRXay6XHezW2iSNdG8ltVmGdQgXDO0oxyNvUfhVbX7eHxD4uXRtTuItQazlMsXncIIwA4bb3xu6+1O+xtTalUT2S/y/zOYvXsNGvbLwVY6RFf6lO0OpXyux/eS9RHn+EcZ/Gu10+I6d4s8Q+KrB0Xw1run7pU3fMt4gIwV/vHNUZrrRNKPjXxtp9rqGsalbsHkiZNqKwACoo5+UY5PpVMyjWNFso9F065i1fxIU1zUId5cQNjAAzjAODxQ5EOKr1Yxas+r/ABf/AADC+Hetz3MDXGlwNFb2Pm3Kalcvhd6kf6Nt988fStPWLLTbHS/EXiGxsrKVpkU+RawlJFSRh5x8vJy2QvOat6VpPgzSLoNq93d6Trty8kDQIpjV3TG59vIbqPm4zUsFzpVvJfaeb2K+iMAl06/tz1YdYyPWk3bVI7JTjXk2m7+n9X7/AHmD8TNkGlaV4M8FxMlrfEXl85bLDcRiM+mScke1aeh2EemX2k6b4ebS5FjuNmr3tyTIYJl4WOFMjODwTmrmly2WrXFlFZlRJLI0bCOTY4CqdzBscEYrL8Jz2mj63pcPh3SNRvbC61CWWfUbttw8pQ26RT25xz3oT0sZ1/3dP2evd+f/AAP66C+Opb/V9RlHiC607+xrK9jWaYwkbpRwFQZ5btW54y8Z3dlqFmvhvQH1q3eBpp9ybVtoowQ3PqQCcVy03iXSviTqkWkeFdR/sy6hvnu3s54P3V4sb7jKGzw2B+VWbzWW07x5rc1pqN1fWt9af2hJHax/LbBDjaD/ALWNpHbJquW9r7mHNGVuljN8IaZ4d1Z72+8NabrVxcWUT3un297dbraWd8guBgYwTt69q9L0G4v9Z+Gema14tt2a6tEme7toY8GXbuAUDPGCB+VcwUudf+Dd5qltJB4Vtr597KBzEqyfwnj72OR7k10GjTSWvgTTPDEGp3GvT3kWft+3YJIWY7lB/vAZH05rObur+ZjyXmlDTX7u5x2oanrWqapY6nrF3DpejwlX0+1sEDTyRtgPDP7ED261c1PU/D+mvDqH9gPNP5bwlY12sC3QIPb0960bHU9PsPEcnga6vbbTZuZEazh3/uwvAklJ4bg8YqDxFBFo9/AkFnbuQnmWt4km3fyc+ZHg4+uaOtmd1FUr2gnd/wBf1a5W8arBD4E0/wAW/wBixWMt/MiapNAu7ELceayjuMdexqLVE0K3tmjvpdZuob20FpDFEwnttj/duG4GGHPNbHw3gkitbrRZZxNpEjN59jdN5oET/eCvxx17Vn6n4fgTXo/DFpb3NhptrEyWN/ajIVeC8Ej/AN7pt9MmhS6djJxUKjhLbfT8CDVl07UL25Wzv31RTbLGY5PljOByFX+EHjv2rJ07TLy48BS6XfalNpkls3nW81ud22En54Sf4c8HPtWx4insdSu5dLWH+wdPS4iXT7m3h3SXOM/O3Tcp9OMVs3yW+kQalp83mNfxuscZTgyx9nb096V2kkdScakPZ2fT+v8AM4/V/CsviO/WVGutXjt4bddMEGofZ9yBSJQflOGHHB61n+H/AA7otvq3iJLvRNeu7OwiH2KLUbjdJLMGDBEGBxkZ/AV6a1xp9lotvMpjaTyyqpE2GDereuKrC9TUdOtv+EitHiuDu8q7UbUulHAJPZh601UZzOg3eVvI5HUNS0fUyngpoLmLxTqMkOoTHUbc+W7thzA3Py4QkA+oFdpfPaaverO1qYLe3RrRY2b5i8eeD7fLtBpuoXVtd3+hw2V5GLp/3L315GPOVVGcF++SB+dcLrgn8K+HdRvNNhtIoNS1Z455Luc/OSpXfG2OG3cfShe9oEYyh78nr/np/XkdRo17Ya/p2h6pEqWOnTXLq8N02GSSNiAQO4yuc1n6J4n1fR9WvbzV4LJrCEXE728cHmGaJAxWZZc4BJG3GO1aXxBu73TbLQdO0bTW1vxBqFiLZ7aTmPyduXZz/u5Gfxqe9tDo/h+/lsY4Y9OihSPTNO8nzhby7QXwuQTHuznn1pafeZe0c1yy2t+p5xo3iqe/8B6jN4GstR1K7ub11v4Lh/Nmt4nHAhYAYXJOTjiu58MWy+HPDOnTW/2prR0+e4kfzAshJypbvjp0rkdS1LxjZi5h8K2xsbSTywiaXEIY2LAbivXBDZJ9q7aaefw9fSR6rqV5fajfpDA1gkIle5kUbmdRkAgAgZ46GtJLS3cqKlSVpdTN1S5sV8NaZqbNFHL9re1lmZ8s0nGxQO2c1XuLC7fS31bVgtx4XS0nae0UDEjnb/rO5zjj8aj1DQrL/hJ9Q0+2sIkvLu6Q+ZcceWQAVAHRTycmrGqpHpv/ABJ9TnxBJE1rLaCX9zPuxlsf3uKlW6HdUjz0+VddV6E3jW60+/1zSrawtWS51GxjuzEBjJb7oA9sVueM9EW78CwWN1qMEM03l3NzfsmFzEQQrn05Nc94UudE17xRN/Zgun1OzEdq19criKCGIN+7Q/xNzyeO1b/iJ4dU+Gt9qNxPNZ6JBF5qMq7XlYkYkB7DPGO+aW0lY5KkvchF9P8APT+vIiv7Py/F+keKtMkgksNQi3ecq4USbCCcdsk1xXl+JP72m/8AguP/AMVXV/21qP8AwrzTLLWreGC8a+MMSwrgPb5Pluo9cYrY/sbXP+gtd/8AfY/wq4vl0M5c0oxlOy6arojmLe38L6R4tv8ARFTWrK+E/wDat3OctbLKnRFP907vxrp7u7/suw1HUZ4bjVfExZLmTTbZ8yW8L8LuTuAO1c94V8WvpfhTTJtc1JPEV1qt5jTxGCzyOQcb++xSP1rQ023eDw/f6/4ojtvD/iHVYit3byTbzvziNv8AYU9wM9qJLXUz5lF8ier7a/1/wxHPJotoL6TRNJ1C81GK5jN3bxtsN1vU7kkJ4WNO689qjs9Y8T6FY6vcalZ2dn9qv4rfTTCweKK0WNiWQjqF2gdutZnisiy8MN4U1/V/seuX9vuk1gQ5tZmLr+73jJLHnggVs6do6WU2l6F4dsIZbPSosrGxKxy3Mg3NuPZep9qHZIqnBTevwrVv+vMr+IJ116xudSka/u4PJhKCzYwTMWmRA6ntw2fpms/xFc2mlyeJVvbzUItKtrqK21GK0tvtEjp5I27mJHU4YsM811j+IFudfnto4liv20maCaGD5l82M4/dHvjBFZ3hu3vdP+Hmiadr+oX66rqP2jyJmTE0e7cQW68hT3Pakm1uVUbTVtE9DnNIvNP1bQ/+EZ1+2ujb+JUE1i8cXkSLBDyGkYE/3M+/Suh03T5by0uW0O8RrtbX+zLW/nkIAT+Nsf3tpOD60eDTbXuk3ul6Zdxa5FajEl7K22WI42uAMdMZPuayvAdzqksOq2E1pcR6NaN5Flvt/KkDq3mFi3UqVOMU3d3Htf1/r/hjSfwxcfb9BN+qW89ik1hp82oXPz3ULpiTeMHJOWwD7VJ4itDbahrd1qNxYaTZRxtbWmoCLDxR7AD5hB+YZzXOfEvwxrPiWHUdWt7prnS7meG4j00jbJ5qgLtT0ztxW/rEFzfaN4Qv/sslneIJLm802JN8UjbQu2U9sBRx65o87kRUrq27/Mz7y7vbCS90DwdcXNhfW09tcT3+0Fbm3m4EoB91PFLr7lvDqubq+j1rXdTjtY7hk2vIwPC4z8kZ55rrI7O08aaTqNzrCLZQ7B597aHypPLTJ2bhzx2PvXPXGtaN468Manqdu95Y2umn7a9xPGftMYXhSF9DtOOc0lK41JwbhLfq/wBC7ZPo/iDXtVvrnWLS5uNLVlubfy9xidh86xscYU7evtXM2uk6bN4Yl8R+HV86ylkt7HR7ZI9kkYUMHjPqScHd3AqG61W21K30gaPokdrfeKLp0cXa+TJPaxY/eSD/AGtx59q6Txmu7TLXQ/CzPDploP8Aj5X5EjJ4yG7kAnn3oehpQjJyi4v/ACsv+CYPgG3uofFL+fbbTp1xKs2eI1JyhRexLbsj6VNqd9pHhPTr7QPCllbya3PMqPYak5eRT1wOOU2g4HSuq8D2hXw/HpclvBb6ZDfusT9XuIYQ2ZHPdmODmqWj+J9B8ceJ9RmttI+yarp9qqxardQhBMTjEQY98/pmlzau5OIq80rtaLT/AC/UzNX16z0LxtoSz+F7eK4/sp/tGowDZsiZSzJBGBy4PG7I7im+DPDlnrV7/bPhHUrrTNH1ALHdf2lbgz3IUcQ5J4U4ycda0bfWr+DTry58XabDb+IbKOSMXCwjz1gY5Kwt6Y/Tmua0q8/4T+1ht9Q1WOXT9IuYrm1nT5LVSAPLTzThpJRwWG3rnmn00M/Zyhu0r7efnsbvxJ0fVdSlvdLm09Y9K0xoZ7R7lvJtJiwVWiRhk5CkkfL1FLeata6Pa7biyLxW0arbRqhZ4c8Fgvc9s596tyXcuq/ESy0g3V9fG0ie9kuVkzGsgU7Yiv8AACcYPfOKo65qesRsmuq7tY6Ohme3sWLy3MzuVMEqnHQc7hnAPTiktbJlxfslrq/uKWv3NxY+G7RtNsIx4gvP9Ij0+6GyW4gByWHXnqcZre8OJfBrjWZNlrosflxxXUyeY0iN99iDjAU5H4VBoetWUFre2evak2va0N08Wj7B5lgSu/yy/U5DAZrpY/ENt45+E93faJojXoeNoP7KnfyiZFPMZb075pSutLEVMTP5P7vkcjHqc9zq/iO0/s/+yLCx2hNRmTCzL1Lg989h3rpdFudJ8QaXp2o6NcyLE6fa5Cw8uQsvCl4vQ8965q21b+xdE8Qa5rE+pX2LmOzXSLlcWkLcZit8n5lGeTgZ4qHWotM8O6Rrh0mO9k8QaxamWFJblnkdBgvHFx8hQMMfWhxBSlJK/T/gGvJo+qajrGrXtikivZRLHCTdkZlz94JtwMD3qv46iW18X3EPmyGQwRsXY7tz46sO4q3E+saT8KZdW0WBV1i1kMoS5PnywxnG6N2PVxXJ+C9Tj1j4m2llrEj/AGmdnliaU7hchB3Prz09qmzevY68K7c9WW0U1+Rv2i3/ANrup/sD3l/HaqY2tF2qjf39voeeKojw9rd7ejWp0vWjABSzjA+zqQOSYs85PJqOz1bVPE2pOseozaF4j0S/uLdIwu83sCt/EGIBGQBjoM1dh8K6lrOrN4i8TX1/oTaZHH5clrc+XDOHwcHH3ShwpAzk07W1uJ4lpXsl99x11Y20tsk0yiE3RWP7R9l8tVfrhTk454qWW9t9U1DRPBeoaGl7AweWSZ3+SKVJDt+XoTgbs5q39oF94c1i+0vXIbvT7SdjfrJEdgZeSRkfnjrWQ82la1p+k3/hmSV3utxYL8u/sSvoM8Z9KXqVeNZcrf8AwNOpv+IdG8Sal440a70yUnRp4p7O8jjIQWo2Mqy785LdMDHXFVHvdM0+fytQubzUNSit3hiZeQzDKqGHqcAk+9V28HW32/zPEWr6haajZqJrW0hm/duMcMozl+eDkDmsd9I1DXdMfXvCV1FrVzbviWxmJtnVg2TuQA5b09aLJqxjSVOLbc7r5r8S5qDLctP4Yhs3gimIEt6H2uCVB3QnuVJ+YcZArm7K2a98BWuh6h4pubPXLK6dpRJFtvJ7UHhDydoPJHPNdVosb6V4Qvlura6t7FrlJ7UX0vmPFM2A0YPXBOcD3rQ8V6Dpsegv4teZI9Wt4hc3N3b4AvCB/qJB/EcAAZq1JLQzqRUZ+93M5NN1vU/DcuveIfstreLmRGtyXaUAAIMYHPGfxqlfaNBPfWlo+paVf60SJEs8YnyOS3viq8eueL7+6GpaTqVylrqREdxYyWy40rA4MbZ+4c/eA/Crvgmzs9e8S2Gs2dytzrNpZS2cV0ymOGWWP7soXuDuOfpT5bK7NoV6sY3dtL/gW0hjnezh0S2e0vvsk3mbFDiKXj94wz065Fc94p1LTLnwbD4YW9kW41KKOSS7VNkMU8TqD8vYSZOPpVzRNLuvD0t8k89rF4g1MytqstvIZI0kJyHTgbAfQZxVeHT7zwv4JvtU8Swx6pIkouZbK2Jd4IXYYLvjLY6gYoVluE7SSlN20JvGum3LWUK6a4kl0zVFHmF927fljH/wEL0rrP8AhYEXpN/3yaz4YLnVNA1GPQh9usbq4Gr2equ4SSQvksu3qSudv41S/tTXf+gXJ/35oubUYxrU0pK9vPuZrarN4Z0rRNZh8LxL45vrgwW+n7Sxjtnz84AG2NvlXjNTeINZ1Ky0bw/F4gtdH1rxfd3LRObuIIYoAQV3RrndV/Ur/wARXvjPRrfQlgtV0wJdXFrNMWNxDID+8lPXPynB5xk9K043tIJHuLTTNMn1mOIx2+qM4kkhT1Z36kepNNvucMaMlK71+a/HyKJvZNA1fXdQewRfDNoVu2MiiW4vr+XGFjz91Uywqlomp69qHhNbrw9JFa6o+p3K6hc3QytuMsSz56fLkDGeTW21tba9pot9lzBfaSYpDcSSAi9LDdJ5WCclSANw9fekvW01NK8XT31vdx6cIUuLlEIV5ZduBtIPRs96V18y4W5ZLfX/AIH6lWym8PeF9Pm1a2vC1rpdpKjzDdJJbvP8yuAB/GSCPrmuYbxI2kaCNHs9XuLvXruW0ulW9neTyllVPmJYfKWZwdvTmtxote8QeE9IfwBDZ6TLKge9mlt0aCfam1IpGYZYovHQjI61Z8e6fqYvPCsMOiaZL5hh/t+/lREB2IABnqFBG4Y9AKadnqZqcuf3l/X3jvDVw+hDWP7E0O2h16Eh9RlZzskQNlwinhcjLYHc5q1r6T6R4ovdVGv6sLG809rmG1J85IQE3F41J4K+neqvxCvpTPrNlpumtIuqxRyJeM22OMRYyrt1Xeq8H/aq7pStc+DLHxDb2xTWtNtDax2s8haIhm4JIyWUZ/HFTf7TNZ00oqaW/wCq/R6E1vqVoln/AMJhbyTXMtxEgaF5CIJSoyrqvbJ6+hzW6bDUoj4gvbvULVbW8svMtrOED5HC5L56ntj8a4nVLK48cX9r4c0eKbS7bRbwG9MYMKhHjUnaB1BYt8vpVOG70y88Q39+iu9xBG+m2twshaOJEHzJt6AnP60OP9fkKFJzdk9V+W6/rsdJ4Zubi7+GEsBt2truWQxvCCGbJPAOf71cboPibWNI8dabpeq6bDomlXdsz3lu+2VjI4wqk9zxnHbNdTrksOjSaZazQST2jArNcxzGMohAw646sDnGax9Rsra+nXxBYeGGk8RW0gis4Lm7dYpiej5H3n9c8dOace7WjHNpyfZ3ZuT+GtK8LeDLQeMdVk1a5SR1s7+/XEscrgeXCGBOF+U8dOtUNP1KGy8Lp4m8dSTPprMltb6dFFuV3GdvyjqOKPiJqV5qfgbQ9H8R6eqXd83nyTqFaOHyyMA+jHdxj0NZPji9SfX7Hw5HfXlzrNjKnlaXYRlZNmQQQxwAFGSWzUxjtcVJuFCzdrt69ku3qa2q6zF4b0TVNc8SQagHvdsEOn2CDfAjg7ZAM8ZrlfGUYu/Atz4St9Vu77VLKG31MreuIXKkDbEGzjzMNk89jXSeKrP4ia547mt7Q2Fn4XUANfFY3E6LwRkZYuewxgGs3SPB+kaz4qvbS8Mt7LDt2Wd5EJpomyCrsTlcBQRgnoaqNo63Ii1JOXb7joNOOleLptI1C4muYr/SbAwm0FwWiYNHtcSH+Irk8+1R266B4V8PaDZ+ItIW9tYLvfYLborxwqxIM5ycD7xOetQzRQafrt1D4Q8OWdzcXAaDUjDfbLdLU5DsvPyNk5OBWVfW3hy70zwzoHh5rvU/D8QuJlZp2DSGOU5Rn/uDB46YFK19XsVyXl7GKsnr+BPaWtlqnjrxVoEVpfWl3erFdyalZyOruI2UxxlsAAMoU5z3rO8PeMdQ05NSi8bRXen6tNcqLa1t7UgtApx5odc7jwQc9QK1da8b3PiKGxt0tL3SNBmkNvJJZOPOnwNoKvkYRfUHqMV0UcGr2mh6JY+Edbg/smzZ/tc2qkPcToSThGOSDyQDx29Kd9kwnSqUmnKPqcnNpOkaJ8V/E+u3WqWlv58ESWcYyJ/OdRwRj5lIIye2aveJft//AAhN/c+EVt77SbnyTElsowkqsfN3KcdRjpVvWr2yu9Etrrxh4Xjn1W2laO3ksLhmlReqgyD58nP05qvq+gaRN4VtbTTrvW9Jj052ukgjfzJNzAEhuf3n4/jSutGxR59P6/4JYn1WV/A+m6747VFa+kjSDR7iJV8lwcDy+ckng5OKvPJdQavYAGSS4i8uMTRR79rPnJOevAH5Vzninw9B4guvDLalrkWqxaOqPf292/lyKpOWm9uMAj/ZrrvDesX9/oUtrp1/pc3iDEv2KdFItyVxktgdACKmW2g0nCne1yDw4l9rHjPxpoDw28XhRokMRjkxIZT95xjqG7g9MCvP9I8rRfibp9pfRiO6s7s/v3jB8tOhwe2c1rfDIW2k/FbxGmozTwSz6iEtEYlFuXcHLRj+JPl57dKp/Eu3mvPiRLeadtMNu/l3UTkgu3YjscY7+tD0lbyOrAaSnS3jJfjsanx+8S6D4evUtLu4Fve6jbSiWS0s0knZCw2Yckbfw61Nc6aupeF/C/g7U/NfRLvTH1G5uzP5MqlCrKCAec9xWT8UtI0HxJpXhTX/ABZdtaWGnSTWt5HGh8xh1VAf4fu8E4rOjs9C+JGh6drnmX9tpNmY9M06AT/v7crhSzMT824DNVG3Kl2OBRmv3Uls/wAjofh/f6Ha+EPENlaajq9/a3i/aEi1CMqkIdf9XG2TkfN3xVLQNOvoYraLQZbCKC4i+z2hLlmhKrudXXGD0OOueK3PGNuNL1m/0ueV4tMi0hbLT7YD5ZpXZSzkjncOV9s03wHGdDvdK0m+sTbQo6tBlwZEOzDEsCc854POKTe7R10ElRcorf8AHQs3baEmlWfivW9RKXtpAbK/vdhBWEsVC7R90liOlZGk6hBqUF1rGma60FppkiRxanZ7mW4U4wkqOF3sM9gRjvWtrt5aaX4mk0mK1YwatOkr2t9CktvcpvCt1zjufWuWuEvb+y1GGbT7u0tNA1J33LAsEc8TqF8qIA8bV+bcPrRFdTKCldW2f6m/Z6RF4e0PWdM1G4vNUnvLtdQ82ZwS7HBXaueF9x0qTxEsv2jUNJ0LSrC5vbq2Z0J/eRtcbBu81cY3Y24rm9R06xS/8Ka14ZutTm09LmLTruIsZ57FXfOWYndtO4jNacmpJ4R0i0u7HUbO6u7e7b+0HtWZ0EAYnDbgDuI4x7U7X2BJL3VpLt5l2+sdf06xTVdc1DTZ5NL00WxtNOhAj85yQM8AMF4IU9CT61B4butShs7a/meOEyysmmQ7AFhGOXOPXutN8WXOv61qUGi2kVrawSt9rlhs04mUgbGJwMHg59aXx/GdP03S/wDhFP8ATdXt4JIbeytwHCXR25kJ7n0B4FK/RmsI8kIqSu3d/K1yDw1qErwapPqGmT+Xp0pnW/djGXdumR3Bx3qlr/iW1b7Vo+s38+m3Fx5ck11YsQGbsNw+8h7iuvv7PVNQ8EW1lq0LWt9qFjE98JWBeN0zvV+eFOeD2rmUtre8ubfTr+xt/s0V8senNANrR2kYO5tw5K5281cbXuTzqqm5K9zT1ALp3j3w1f3t3p8+mzWjwyW9sNrWjOAd6rj5VyB+NXv7Mg/6GbWv+/g/xrI8D2mnX+oa5q7y2wt4vNaWeaMAzKOmWPIUNtyK5j+1vHv/AEGfh9/5D/wpqDlp2IqzhQly3b9D0ax03RtaGi+OZbm4trtbA2N3bRHKzKcYVz1AU5+YetKug2Ot2V54e1SOOO2ijaK9eBAvmxsQVO4c9u1YFnbXRgs2hgvtOjtZJkms7oBDdQNjle3y8ce9L4eFz4F8YQWOq3017od3pZnbfGzNGBgud4GCoOMDOeelRKPmHIoKUYu99v6/AddpY6aNKkJMKeGLlNLsnjfKSCRTtL+o+UDA9a0bG3m1M6hp+taaiRXE6W11AkxXKop+Y898frTNEu4NW8GzazeWaySz3Ly2nkxblFsrYiuChHDbTnkZ5rWkaWDxvpmk2+kvf6bqFsZ5Na3lgnHzE/wkk4AHvSb6dhe1io37/wDAOX1Jl8R2vjDQdP1qGK2t7OJNNsLV8fZEjUeYzbfvHIPTNcrdXT6/BY3ujaufEcdnBZ2FrpsSyK6zB4w7XHH+rwGP5V3Eth4e8O3SapqWiHS9QgeWGwsLWT95fHYzYcr6gE4Jqlpr23hvwNrGq+CNPl0rWtctTdhbuMn7PNu5Qkj0J2g+1WnbYjypX8jQ+IdzaW/j210+/u8SXVtGBYxjEBQYDM59OCBn2q5ZrDqXw1haH7VpVxKHtFhJxIY/OYKcjovfPpWLZtf+LvDdrrkNxp41WG1TTdVur+3YJNESHbylxnfuJXkYz0rpbF5r2a20u4sYnsEZUW8+0qjSAdI9pIJ9wKhq1vIqNRuMYy+zYbNaahoehXFlo9/Lq13cOrGRQCzptClWk75xjOc1xXgnRLxNQm06K1gtvtE5lmtMlSHHck8k/SvU5L+3gsJtHntXt5LfT5L6eO0XmJQzbNoHJb5eBXndl4n8P69Fq3jK0ubn7GsiWVytwfLkglYBQVPRQeKINtNF0a9rxt8/PodcNGjnlS2dfOvLD5VhZQ0RRuuPUilsP7Rn8X6HANPWbShE9xNfRODHBKuP3RXOVPrxXG2kmmXGgjTLXW79rS3tjC0kDkXBJJIfzO+M+tWtLmtbL+0ruOW+stFmhSLUbkbpMqMjeFGcM2fmYDNKxpOhUa7HJ+NtUt9Z8arpukz/AGbTUvYxCQd4l6+ZIc8BFO38673xRHrd34l0y80q/wBN01RGYNQuFtVmuZI+MGOQAnBA6Z4rl7XStL0LXzrOlSO3h23UotoLcSiaM9GaRhwucng5revnk8LRWv8AavinRdNsruIi1dVbcynBO0gZ6d6p9OUqtytRhLS21/l/TILvWn0WWW2s4IR4eWQzog3NPGxO4tuHRif4c1e0zUdS1bS9RvtH0ufSbC5bzbu/uEEdxdjGcgHoAOM1Ff8AiGDw9NpNvpeNSstV01rrTVMIR57lNuWbcAQSpYjNU9E3a7f6N4rfVNVbSbyGaOXTrtOPlUoybRwF5JBHXApW0uzLnhvFL531+Xc5jVE1DSrXSb7wZoEF5DeXEkc0UMglAySWMhzxuGSPrXYSsItTtLaTSYNPtrS2eRLGIAARlS8q+mW+YY96ufBrRtF8OWWoP4dlvprW4kB23A+U4OAMeqjj14qr8Tlmj8Xo9qA011GqxBs7SQR1pSleXKdFGbq1nTkujKM2n3WnaBo+padoVzqEl3OGtNOkYRQafbFtxMgBz3J4Bq3Bp1zarDBp0UOpz3s8ziV8lYWKnygR/wA8w+M+1XfEuh3/AIhsdDkkutRi1Oxmw6rmKO5wN2GAx8o7Y696reEdWmTV/E3h+dIrvXLS2a8hgsGZY42HKxNJwdzHHAOMH1prVM5ZVJWcm/l2Jr6w1K18T+HGsrm38sxvDfGzRcGbHzEE4JX0zVPX9L1ZNNi0vQ9Tt3u4Lp79LxsBZhj5Y3I5U7gQe2Kb4UuHlu1k8QRQW/itcsttHIUXyiM4KHHOcjIGTS3ei2dzeadp2mvY2GjTTPLdF71vOWU9cbjgj/YP5UbOxcZaLm2Kmh6ppN5Z23ieK3hu9O1o/Y762uY184SLw0Y/vgE54znNbllB/ZsUh0GGyitZSY2THlogP90HBH5VH/Zum20a21wbRHtpD9m1YsESMeqp93d7qK3ofBWj3tnDcXt9c3DuA3nI3DDsfpUSaK56cFeo/wAN/l/T8jl/EF5barqC+JNM09LjxTZ4gtbO6dhHEB/GpXt1qrpiSnxC+p6pB5dv9oE8srHcCx6oV7AHoav6/pkOjPcSfaRY6bbx7pbt3IBPuBWdPeXen3EE7RBLNlVhMo81JQfuseoIPNPodFJQs/ZPdfga3icWd1rBtbS3Gq6L4g3W95CSNsEvVH9QMBuaw/B3g4abpz2kVjp2oWcGoC7t4oNQG6FkBGfvcnqSDVm4jEMk9+Ge2ublFmigjjKIq9C2ccg56e9c34R0Pw94fj13WNQsZPLNy0TyQStmFpASMDPQgnk+tUtrIh0mo6a/n5dV6XOhm1SXxDqt5qmqr5b20jQqqOMCMqQHjOeSCQfqKZrCQro1u+mG4EdkiF7m4wktywIzIdvfbkcVpwaj4N0rStC0STQ9Qjt5AywGPdceWT0LuM4z6E8Zq3aW0UEDWutXEVwY3bem3/UhshBgcngjpU3sOFWOnutcvTy+X9anMaVo+oy+KtdiFvfXF1HaR/YbhwXtohPgZXPDON+76itnUhDNBpXhq21O41q00yaO2vrx5Tu81n+fe2ecKegzjpTb+a6iurKW11a8snsIGjt1Uk2yIxId5FHBYKTjI4wO9ZY1jT57bQn8Lr5GkRvJcyzyRBXuZgxG8jvuYflVN3MoQqOpeXnb/P8AT5jNP8aHS7/T21GxstHivbqa0t5bBixWBOFd8f6xiwOAc1m6Bo9ta6R8RtG8WBBbWc0d7JcIJY/MYncGLkA/MMDaueldzP4W0qDS7yLw8un3Or6Lbg2UDbpGtLiRjIN45/ibIz09qx3svFtzpml6Rc6jZXOrW8Esl/bXHLXUh5UKG6gZHPampLpocqlz2s/UhvNbnm8TadFp5W2TVYEt4VBIIUDoCeflzk59aj8H2dv4OGkW99qEcd/M0skl2u590shABPGQox39a0b610+/8cQ3XkedcWkbFG3YWMlQJMDp2A/CueeM22j6RbX0tykjaTc3FzqSQiRVSMgop4I3jJ470Rd1Y66rUUrrdL8V+ZZsdfn1bUPF0XiG3Z9Ugt5rC6Fs+DPCmMlF6qeRyOKdo2opJ4Y8Ow+A9TtoykMitNrMYW4EW5Q0TADhTkcrnpVee783wrqVxr82nWeo6tE+ktr1urLmXK7CoxlVYZ3dOgrMt7DxZDq9vpdsdHg0jQLBc6jdCKUyKuCZgozIVPYEba00OZPVX0X/AAP0Op1/S7zSY7zSoCYorxSZHWJZi7t8zRhTwVJA98VwH2TXv+hT8Jf+Cwf/ABFdl8PLu+8WaP4l8RXGoSykXrJpM/l+WgVScMBgZY9PxrX/AOEx8ef9C7q3/gJDQpuOiszWK51fS/m7fozP0HxN4h1ny7TxXa/aVvJUnimKeUbW3bJVzwABx8wbpxXQ+MfFer3suk+HvDxs7PXrudZIy1u0kX2QfeO4grzxxWJYeMdO074deIbLxbrMWsSWNzJptzM1u0LYPRTgAsfXFbHhHUoCLHVLhZIIYNOiAFxhTlupA6r071Eu6RkoKa222OruEtNPRbW6MllYM8kcg8kqLh/u9VHyqQTgD8K4G8srfQvGGk+GLTU9QtotQt2t9MsbcsyWIKl3mct97G3AB6ZqfT9DudT+Ketwa34lefT5LdryOwYsXMLEbGyPkVVBwMYbnrVLQr+fxVpuoW4tDY22mTrbW97AC9xNAp4wzZPzYGT3BNJK2tyKSbvr/TM3UY/ET6hpVv4G12w1i404+ZfvqSBJUTO0zFpMfIFJAK84NdjBDBo9tq/iS61xH0GW0f7RHIpmi8wHAmU8nZj5QB7Vzxm8NeFNL1mHUdQ8688QwTlGcACMDKiEseQAcYXPapvh3o50PwHoFpcXLahHOrpcPaFZQoL7gjI+RtxxjGc9KcnoXUg02lt0/r+tiIiXX/hxaNeat9lsrmVLqHULWLDIA4EeVI5ZiAoGO4Jqte+HrV/EHgsayl9a6vCzy2+nNKrOwBJNxKVOAe+B9K6G5ispfi7p08VhfWuj6HYOLncFWyUkFk+Q9XBIwe2BXH6zrB8feIbh57GSaO4iFrZx2rMk8QDkht45GfyouaYelUrNtKyS1+ex12lXmvzHUNslvo9/NO8bz3MiSyTj+ExgZwPY96TxH4fsr24trJzFcGCXzWs4YREssrKAHlGAr4Iz3rTTRh4R8KT3yadFdeIhCNtvJLuIUfwoSeuBkkdzXOapY+INee0sdWu9L0e4mjR7IediW6YnLRtg7hgYwRjmlHV32Jcoc947d9P60Kus2lt9jslsFt9LWwnE15IM4aJOdmO2cnOfanQJqPiDxFZr4fuvKtLtP7OvW4KR26cthOm593UjPy8U74v6NcWMUSC3mfTtZie1vXh5a3nKqBk9ArdMn0rn/AllcaLq1xbw3ksSXKGOG6Y4EMxHyu+eCBjtVJe7c61L2lLni9P6/wCAdV4vg0LxhdW3gS016eyvNKDHULe0iYLIowSBgY3DHGeOTWLpXiOPWvEOnQWOj6Pc+B7BY4D/AGiU+02DKCCwDHLEnsAa6b4deIdTlt4tRudI0+xtpIpYbi8uU2Xs90pAWRhx+7bJ6jPFYes3utaZrFrouheDtPv7G423N7qOzd9qZjlyjjhcdeemO1T/AHWefCPPdNO/e/3sZ4i1/wAQ6b4n8HaDptr/AG9fSyO8+oNaqCkUjAhF4xHtHXp6V0em+LZL3xJrXh9rKLVDpHmOXtD5R80Z2R84AJAJ9OKqeIj/AG14kvrPQfECC4ltUgt7G3HzKA6l5zIODnGMA96qeF7lPEXxpv44dWMNrpjl1s7ayMaTPEDHJ5su35yGPqaLaXaFJqK/q6Nj4Qx3mj+FPtlxbzWNve3FzfXP9oEhopGc4RR6YPasjXrnUfEmuG80xCs1lF5iHGQir/Fj8M108jHWv7Qv7y5aPw1Yl5NznDu3UqueMdhmuZ8I6jqM8qXWmWTw6k6u7W6jevkZJQN/wHA+tZ7tyO7CwVJykl71vkvXz/IydXkvJ9Wg2+Nbpr9JYL5na2dmu7XKgpHHGMDD5U8dBzxXS2NlZaHd6ppFneq/ibXyWBCBDEmdxAPUkKd1YF14gk0lLW4fQTNaXEzwZTKyWjcs8YI+YZ5OPeult9Eso/EtlrOn3EdxDBA0ljZy589ZZF2O3mdxt457itJPTUyqUXT1jt+GhH4v0jUtNuPD0fhCC117xHp0iW811duu+BGP+slxyRyR7Yp/xY0DRdO0zUvFerOZ7EWTW9xp9uYkjeU5/eo7fMr5PGDk4FWPCNjoGl+KI7rUFTSPEbK7FWvCzXEZzuMik4GOvb1rH+IXiiFru2udH1zRtT8NQTsb3S44BM0gQAts4IYjrx61KvzKxxy5nUspf18hdD0fTX8PaLY3Fx5ltBMLmO3uypmhjkAyrL1wMfePrVXXYLLUrTUhHr02iQWuLizkbcUS3j+8HVf4TnjuabHBA3xHiudIVr1/E1g0tzdzcRwQKOUVfvK+MDB9sVjQCzuvEHh3Sr7RbnVNN1ewM87oWQRICQFOMblGDx1Oapb3O3nSg5N/09f0FEzJousafrN7FeeHNejCeH79Y3m8+V/uRsgywIIOcjiunuJjpMVp4b1yaD7fLbW8bIrCK3iKqflTpnPtWdbalaS+EE0/wjfJcPZzmWz08wiO606IZ3KysN2Bn73X3rLutP0vxpZaFcQeIZLjU9ESR3gWLc8koIyORzj16c099zOlKTtN6/1udD4ZuxqGl3019cajHYWdwbZYblEkKMvy5RlHzR88VharaLp+uzR294J4blVRZGUhVI6Fk6McccjvXR+Jr7XdK8OaFZ+A7Gye7eAT3EN7Mm8ISoLsM4IJI6fhTPFliLW+vLeX7OZIIoHkWBwRFKy5YhT8wUnpmoT1ujpw9VSlyS6+ncx/CWoa5baVe2cNza/2gLqQeRbkFmiIJ3lf4cdMVoeHtKVIJ9ZnvjFLaOIo0b52lkcY79Tzj2qre6m2lXHnadp8SqkJubmS2jLT3bBCqr69SBxxU/g/Vbm6srO9u9OmNrGwu5YNmHSXGMHPQg/pTlfc1bajKKVv8jldC1i91cTOUls3tLt7e4tX/jwx4OeuR/Oun8U6ismtWtloen2c9lJCPtC7in2MDn5McE5zVPWr+S4u9Vu9HtLOfXcC4mtXl2pHltokJzyAMdPStiz0xohb6hdwOkeFMeIz5cjEDeWxzg8haG+rL5otRlLdLp1Y+5t212w/tGHUDY3dvaujwQqIluLkAiOSaRcMcDbxnHFYXgz/AISLTvFVulxZ280EkH+kaq9wreS/V3LOcopGBjjpWg2tiXxF/Zy6a0aTQSTR3AI8hdgJ2SDrk4wD3J9qi1zSNP1m80Kzhs7Q2WoGSe9E908cbsqjavysO46GnF20Zw1IKLlyr/gC+GdUSdtWtZbF4XNxKp3AhpYkwQIz3DZPI61e8WyX9paT6HHGtpomoWrxz6krZEEzgYAT2x6c1pePFh0fWdEvLO4t5TpwVJLZeSg/hHsPrWFZWCjUVvNVu31C6eSWeSdQfssG4DEW3oduPvHpk0o23NJv2sYzWz39SO78KaT/AGToHhO78SyrNdW6SSt9k3rcovJ2lhhCeOTg8V12l+HvDU/iU6xHYym/iLW8EgP7ueLBxGF6bcA/erk7bTb+bxdo1+09vqZS0KXILeWYgR8skQOA305qKDV/ES+G4LayuLGDW4JzbXDgFfMww+dQ3C8ZHvniqab0TOaUG09dSW88TpregmDw/GuiWKztbwxxRqfs8in7+3oc4NY2/wCIP/RR5v8AwBX/AOJrpvGuh2uj+Cda1rSbyztgtxFcTbkZhB8wVgAPXdxmtL7P4S/6GI/98H/ChPsjZSw0opSW3qcT4m0/xfZ21u/jU2l417Oq29tbwxnyZTk7pMDnOPvH0q1pF5Dr1hdW8o3XM0ZWVznPHIPpxita5n1HStO0dfC3i7QLPwXDZrbi81IGd7mYn+PkEE84PGOaj8Z2ieHdZsZo4JIvtLw6fb3EERMZO1ufpxTuzXDYuM17Kokn0toQxaTrOq6fPZWOtqNPu7ERTxvHi4jm43bXAyYzzxmu5sYJfBvwzNppF1aC+jj8myknQqHm7gg8kZzj2rD0aXxLa2unS6cttqpsrln1FYsFvLIPyIBzvHpSavqN1f6fN4jg1SceGYVnN3bXlt/pVhMAyAooA4BOec8VLvLQ5q8FKXL9m/8AX/AM/wASad4suDojQab4Z1aycKNUgmTJilbmR+v3c5II9q7XStI03THY6ba28dldHaYrct95TjPJ6cZry7wve6zpWlDxVaXDXuuXFklhPZuw2Tqu3y7mIdyVABHPUmvQdG8T6fo2u6X4a1IMmr6lbPfXUYX91bIFLFi38OcHr0JqZppGNTnhHy/r+r9TKsbvxNY+PUj8ReJNJGgX7FILOaSNXKA44Q/MxJG3PIqPWtR8Valo2oJ4J8KRWl99rksbp7mLyGaEjCvGTjPXqOnWrl3Yx6rq2i64yaK+ni6MdvJcHzZFiI5Ebg4+bk5OetZWoxW/iHRbzxD4Gu7qfVNIjmsLURFyY8s25fLydx+Y4b/CqW6FJPfTp6fMtWd3bWeqaJrF/qM02nW1obWYupMUUsWWffKfl74HOWIxXMz2zp8W11LxTLLr0MTtqGji3jIkhAAZRx94HAA9xXa3OmxX3g/TNM8Y6hY2NzeCO0uIW4jupeG+Vcg7huHPrXN6T4fj1D4hK+k6hHpb+E1+wjTIyZJGszySTnqSzYP0pprcd073KK6raeIdM+IGiX9ncQh7xbyJLqR4n8x8BduSMcrwtdOLU6HqOg6bbWr6lb6iq/a7z5QNPcD5ZOeM8ng+lcj8SvFKX3gu38RaK8Z0+xukJEqjfNIWIilc9QY2DHafWtfwbMJfAVtcwSxXt1Mv2m7ub6Qo8aH+JVyM47HpTktE/wADez5JR29Dn/D9nqmit4wufGNpLHoSQZeKaUmWS6U4VoT/ALQY57DArS1PR5D4Z8I6Tpi3MOhzQPJfXt1fCK5gjJHAAIBJ+lVU0K4uvhzdeHviFqp06+1XVTdaZgNPNgkHseQfQdK6yGWeHVNS06eK1WzhSNLdn4eGFAcvKzcb24wAB9KJS6oS5pvS/wCn9f8ADGNc+EvD2mX+lnTNQvtF1vSoBOt+kJIe3YjbG4bOTjjFJa61dX99fT6PZW9npD3cia3dhGjmB3fIEUnL5GM7Pxre0vxE95qrR28EFiCSnmXCF1k9nY8A+nSjxJfW2kJDPHatfTo5jgW2hI2uT6enuc1HM9maRpvmt1f9ehq3t5YjwvDbamU0/SVuN9xNIpWNI85Xr/tbc5rG8ETO+vavd6bdwXWhBvNlvrWZWCBDvzx1BAwQKr6nrniTT9b0631PRI7uO4U+WrSL9mB2ksrk8bgAevpUujSwS3f9ueDb61tNKgiaLUNEiClMl8mVCOGqbWVwlGUYuKs1Lzvrfr+Xa4l7NJq2n6jqfhPXYdTsZTJd28Mmz/RZwp2gYGSC2OTnFVLe+u5zougXN5YQ+Ib5o5LuYuFOBhnSLt0ycd6vaPp1hpcniWXTkVbK7gWZLFcKuc/6wEdOeopuix2lxre7xFDAbDU40MU6pgRTpjBD/wAJwBTuiowag+X7O34Pbvuc6+r6fqmo+ItVuvC8tzDcXiWkUryeVLdxDEbkluiHBHy4zUnijS9As9MW68FjS7HU/DV3GLmWYEPaIcMUZM4cMDtzjnGKfdeF/Gem3V1byz3utz3VzJb21zGqqlrEEDxuwxgAsxUntgmpvB0d3Nrs2l+LrY3U8k6RPM6qj38kfzDcMfMi5A3e1aeaexzqz1Tul0OgvptP8KeBfFXjJ1eE6ovnwRyjBj3KFVFHbJyce9YuqaLbXXhXwV4Y1abWbXUxc+XDc6UuTA3BBlbBwvzDg1d8eRL448RjSIHF3bWLb47aP/VNIncnpx0p/inQ/EU/gTWYyJNOvLhRJJeJcqjfJ0UA8gc/X3rJO+45UnGkoyaTlZ269l+Bk6Vp+taVr+q22heFHbxbYWywLr+oowh1NM/MMjC5YYx6Y5rQ8MMmsxavY3Oj6ZpdxZ3P2NRp8ytIEkB3I5Bznjr7Vg/Cex1+K80W9fWGudOsIZoZsX4md94BAUdGYFeBjPNang/R9J0m3tXg3warrUjzXqzhlkJXIG4E5U5fpVS0uuoo0pKXLe/9Mz9DsLnTfGOqad4VLXI0ayFrHdXbBhNIg5iBPZQCD74qbTotP1C3udSsdQa4XUAEmwpzCxIaQSSHhmDDC44xmna74EHhvUvB8GnagsVpaJcy3e+QlriSVlLd8nuB7Uuk3ulvq13Hpmk3Fvo6ERy3crhDLtHKRQ4yQCMF+9U3daGtG75Z2f8Aw39aC3NzaaNPBaXmqi0iu5lhgCgM8u49j1xn8q6W7kg0nT57CO/Zlndrfy3jO4Scgjd/U1zGn3tw+lteXMFhBPFcSiy2QmRo0OdiRgk4kYYJJzj0rbME9poFnFf2E6CSQPI7OC8UrDK78jPcdO9ZtdzonNya5v0Oe8P6Ba2WsLB4X0W+ufEMcJW91OdtlsibsmMluG49K62W9L28ljay7zaRkXFqsgbZkZ2j254rlNd0XxHrDXOk+I9UlsdFiIuk+zyBXBUZYMByU25IHXNanhrX/DWpavf2VuLuGLTIUuJZmi/4+4gowRxkEY6HJxTkr67mEqlneXrp/X3GLHqktho+qabfxy6prFlH9paxtANn2Rv4UbGXZeW6nk1o/wBrWunWXh9NLsRdz6jMkNrCYjui3fflZTypAOOfSreoXtnPqb28tvPa6bf2U00M0YH2kqqk+Wp7Fh0XrzTvDfi+bUrvRtJ8KWcFnKJFW6N/h50jX7wbGMOR2qn3sOUpNOy8yTxd8PjY319r0+qGeJYY4oIHGPnyeWPQ9eM1iyGa68IX8NvcmK7iTaIcfLLET8x47j+tekfElpYfCkzTyiVzKihQMDBPPFcLdy6eLqe2069W3u5rBZEYuqkb8hlRT95uB0qIScldlYSpKVH39df8iz8R7Z9FsPCljobW9r4Xlia3vrpjysYC7cOeV6tyTVS5s/7B8JXmtFX1iK1gikjks13G4R/uvznoM5NUNMvoNE8IadoGuXcHiKSJWuI9MuYyJ5ApzlMEbsZ+7g5rR0b4jy3cp1/TrcSaObXyxYhljQAdh6MPSr1sZwoVUnCGv9f15GY2trajRb6A+dFrUzQxLcJvSZRyQwHy5UAnJ9K2f+E18Cf9Dnbf+AS//E1o3SaZr+t6bcyCQW88C3KWhj/eWcu0gAKBxlSwz3pP+EV8Cf8AQpJ/4BSf40+aP2jCrJuztr6HI+I/DsGt6XpsviaK70a/1qW3ifTY4fMFq6FtrFRjah5z36c115ivdJ8QXzat4gtb3TL6QwadYzQnfZTAHYo5/hGRn3rO8Oa1p+i61d6zqmo3OtX1xAE8xIzIqkf3R/Co/rWLp/izWNB0/wAVW12w1y4bfrFrNdQ7EMLEBoynUYyBjNPWWiLnSqxa5k7fcZ0fiy48PXdxo93po0exgMZ1K/spTL+8cHyySOoY84HIxXV6Neayuha9c6rDolxqluojS5jYvDPECMGRQevGM+ppfDR0S5OkWE12dO17WoFun0e5IkREwcADGQD/AAgknFP0BPCyeJZtMhu9Xa409ZZ50gGLK5Kn54+Qd+GIGMjmnJp9CeeOrV/1ILTUZ9Q8Ztf3yfYdLgtoDawhNokcxjeSem0ElQRjtUnim4g8SJLpN5AumQzIbeaYIZDJHjcMuMHjAPB7VkWmt61YaRHdww3/AIhl1HU3S2tZLfBs4zkmPHcBcjPYgVp2uly2Vx4h0PVtU1KezZUitH1FQ6RySruCwsMbnQsAR7VNrO5bqQi1Fx1tYtatFd+HNI0CHR9ct9J8N6aUM1w6Bo7/ACAAuT9we9U0+zab4XSeykstJ03UZXe6Ni+0Mu4/OCScg9CRiqWjJJIltoOvy6Je6vpN4sd3bXEmA0BUFJNmfvnI49a2tQjt7i51Ca9JlexLIFtHGY42XHlsuMbdpz7UbaCjGK2/4cwvEaeHZbrQtM1cSyalawM2jr52EuZW+6GY9zxj3q34N1RPBHh24kGmiKdcm4nnbDTSMSMzOeRjoB7VQOoWmua7p8+q2unxaLp91HBZfvNrR3CANHG3d+SG4xnOK9Q8M6PaXPh27u9f+z3ZupmuZ5m/1Z29Gx2C46e1EnypJinJQi3UWh5pJoml2EN1NbeHL3baRpEum3sot7DUGkJJnRmB3lc8gHpircrwp4avrqxuWfVntRGk8MW5oJpDhU8odfukAe1c34UsdTt5deuLC8Gq267rm1C3wubDUHJIZFGAY3wFGMnFa3hWfX1vo7bRhHoTzJ9ouU1NN8tqq5wgHGQCTz71TXmaU9acne/+Xl95veMPt8HjrTLKRL26kuwGhmeIOlmWXDeXgfu8Y6tmuT8OWvirw7caNpkHibR9Q0i41OUXLhhI8ijkROTz0Bpt7a+OdC1iy1PULq51q4mdbuax08g71GRjvlcHnGO1Xk0O4i8SeE/7J0u4i0nVpDLe21yv+kWjop2Bj2HJ5xzRsrXIaSST2sF3qV0/iaDVtNt9R/snU7qSz+xzKDAgjO0NkDjf1A68dadffbLPxa9vpviHULN9Mtnmnlmt/NjG4Z2k4x8pwtaM0uv63pc9pawTaMLU+Xb3FwBCgkLBi2w/e2gEbs96jsrK/fxraQ3M11HptzYTLczFQY0kDB97N33Krcds0kUmop9ERp441S0+GJ1Lxbq+iXVrc+ZbfbLcfaAzspVU2qRg4OSe3NR+FPDMngr4Y6RcxLDBqKyFpjFJ5omikJKkn+7yCBS6Cum6jav4d8E6ZpyaFdl7xtVl/wBJhNyHGQRx1UFfbNYaWGpxeI7vVNT8T2d3dW0LW32WD5E8svkK4JIZVXgEYxgUrK1thYeMnVTitP0OnnvbGzYMx4lkEKyKdqyMVyIix4XLHAPvVvTNJvblhp+sQ/2f9pia4gtd3mxwyAldm4YzkAHj1qsI9OvvDk2jTQRag000dx9lhG64XGMOoHYY3Z9KW3mGh6lDpsV3dvqeq6j59l50Jf7KgjVDzn7pKkn6motpoddSq1JqP9eZpaf/AGlpzyaRqtzqVrFGuU8mUfu/RlOMsvtS6ddad42gg1O0kLopCnUo1MUuAxX7p6ZIIP0qsNa1G+1rW9M8TWRi+yxq0GsKcRCQNwiL3z9a19WiuD4a8Sx6M1gmouv2fYzhEj3oBu9h3B9c1JjUbvzNa/hfTVHN6vqmjeEPHdpB4f8ADD6x4mtrYqYbeciVVk9RyD05OOKh0XRbG2XxJpNx4qaTVrp42bTr+4z9jL7iY1foznGBgY46Uvg3/hIB4Dv4E1nTNNgt4YltfEhUTPNHubzWOSCB0C5PUGmeJ9L0rWxZeKYS8Gl6DcLeXgFoXuNTK/dYHI4PPr1rRaaHFJyvKXVdTj9O0e0ltFOma3czadNqCz64zjypII4ydsmPX5jnGAfSvS76XVo7Ga8iaK6gW+jS0XTCrn7MVbEtyxzhOASRjpWZoOm+KPEenXln4j0vZoWoW7svlsqi2J/1TRqBkDG7cCT2rm/Dngu08P6zHJouq3VpPaQvBK8rF4LmUjAJXPzJjPy/rVNpvVnRL95fl3R29pf6Xf6XaXt3rVrq1xBGUlvdPkDxibsinnGefypZIrLT9GgutUv4bVZpXJu5RiSQsD+6Re5APOO4rD8J6ZB4Q8Pw6GJrbUpZDJeTeVAY0R3IIUAk5CjIqXxXY6SNVU+JbZ/sNlZR3FjcwXIM+ZCoYCLHCAt976etZJK5onKMYp318v0LGg6bb+G/scFnHNLZOGliu52xuJU/dB/iAPA9cVgeAYpbbxHfaVpMWrys9wtxeS6kpPmDdvAdjwGA7ADiuhvPD1z4q8SwWNvZxx6fpPklbiZiy3MeQ3GMbXDAVraTbeIdT1fxWni210+y0DypYobu2OyQg5BZjnqFJ59qbkktSJ1F8Ttexj+CNW8Hx+OfEFuW1W41K+8zzZb070EQBLbcY2oOQD7U7wFbweHbS/j166sbHTbq4kk0+0jXLXUWMKxycnHpmuaj03TtS02B/BF1PHp09s2k3GqX8XyLGGOCehJ3cg8cVrahbaXo40HRNJD3b6XCyW0vWSaeQEMwzn5Tn8KqTVtOo4UVUlaN7P8AJfkZHje/vfDOjeG9Q1aOTxdJDqTP/aiwmJ7RWwFjRR/EBjBORntXX2ngjTYvEtre6ehgsFY6hcyFz5ynaGAP1OQah1m9OjR+ILXUZnWysbOKd5IGAAlP/LI5B5PStv4Y+Io9d+HketXMDWTXMjeaHHLKvHB7jAqW5KN0YtOlG0Ho/wBTivE3jaTxF4mS2kJi0hjuhi/ibb/Ef8KkW0+1WtnBHpY+2TkSWdy33woPzH2U8Vz2lHR9WvrydLpdsNzJagwrmSJxgjj+6c9fau70O4m+22czeXJfmz+zxY7f7w7Gm/dWh7FT2dKCVJaL8/63NrS9DafRp4JNNdL3LRQ3EijcSOd6HGQprz2G4jj8RaWdYBmshdL58flgDPI5AxznFeu674ttdK8Ox6qGaUSSLawRRry85yAp9Bwa8su9Nu728uf7QC27bjJ5w+6s5O5QfQcGpi3q2cmAqSnzupon9/nb8Dr/ABnZ6L4i8Tappdpf3llqVhbxSahHZjypJYuGQByCMYGOPWsz+39H/wCgF4l/WtUalBqHjDw9cLqYjvrjSpHubKBBtupMLtDHsynoD7+lch/Znxa/6COpf9/Y/wD4mri0lqzz6UZL3ZLVd3Y0rrxT4x0211jTdY1HQdH1rUHUeH47gCMbc4YMOcdRgnNaWmeNLWytoPD11qNt4i8TNG0d9cQINqNwCvvj09q5cTaTp2iPe+K9NttTlN19r0aCW7M15OsnQfdBTO3pz0qCPXPC1jq00mnaZfaRrshWTyo7TBiRupkbPAPc/SrcL9CqVKDbk1p+H+Zo33w2nutYtb6G7C3NlLEkt9G3zTW4BPlEduQv0xVvT7XVbDQ9Z8QeENNtbrX21BrcwXZ2pHDu+bYO7E4JPfrUOq+IdIu/EmrzWXiS40rWoo4tOt/tC5s3kb5isaZ5LbD83akXwpeeHXvUS4N5f+JJfOu43k2rbxKc5Re5U4AbPNK7taRaTqPle7t/wTX1Lx3qnhnxVp+nahAk0S2DX2p7HBFsgbHyADl+cY71yqeFBqGqajFDLqOoxazPDqbu7EMkZYSI5P8AAQuExW/b2MelatNfaZPdX+tarsRLOYbg5RdomKfwADq2efSofC+t3kGu65YXdvJFPpiNeX52eYZyvHy9MnHKj0xU9PdRpCmqV6ml/wCtf69CPx/aXz6za/2TZMfFIjfyQrBiIFXK/aJPUsBgY6YGa0Fs9N8Myt4k8Q3mpPqmqpDBHp9vHmOGUgBgijr82SSTwDXm/iu8t7/Tbv4g+Dn1kTLdLBJbS/I/mYBBU85XpwK9f0PVLVba0t4tFms9Xjtkvngmj2pKzD955Z5y+M05aJGdZOysY/8AbPhbxb4Uhv5LG1060jugsQvE2Zuw5XA9X4BB9xWpZ3HiaXwxeW8kVjp93co4sFmlElvIF7PwNu7vXH6h4jl0XQrr/hJdN0rUdUt9RMdjp1lyvnMAymQAfI2GUZ5ya6u3t11KSfTLjS5LmDCu9ujfKrEAsA3fGaTVhRjeNmcBoeo+IPD/AIU1xW8PafpfiKJl8q3sYCFj3kgyYyRu4z+VdBqHgXWfEFpo2oNdR3F7JZiWaSU7AXf/AFnHfIC8e1b9h4g07xD5h8HX1hPY2G2C4j24kGOm09+9cdepqkWqaotn4gutQhun/dWFzHtNs567Tnke1UpO/ZmtNSmrw3J9M8P6VoZstU8Q61cW93pVxNPbQ2TFw8Bxi3Ud9vp7mvQPDl7o8Pha4uxdWs9leZlgMXyzHcOFKnJDfyrHuL2e80+20y3Fvc3qxC3SOPDtGR95pT0Tt0zWVfaLcx32k6lHbLDLaTm4X7HJvjljIIeJvzH0xUSfN8QlR51q7eV/6/U0NU0S08VW2mRta+I52soFa2e5OEDoMZZv4yep6ZxXQ+H20prBJpdTiuroZjnVlwScEFCM9eornfDmnQWNrdPYaxqS6FezyG4juroiS0c5/douDkZ461gWdpb21w2jvp62S3X70TSSbFCr1LdecZqHrpcuNDnTjsl+H9eRS1Hwpr0Xi+x0LwNfWmj+Hp5PtlzbRJ5TLzyHOTv44AGK0/GWi2+ux6hf391/YUNsRbxTw25kllVODJwR3GMUnh/UNPe1uNc0XV/t1tYxXDRQTR7JfNXOCVydydxz0qnqOo3t54D8MWGqa75dx4plZ01WNNv2Rz92NEHUMSFPI6k1or3XkJy9k/3b3+/z/BF2K7s/CHhufWvD/h+71DUdPMcKahetmS4hcAvMFHRASRj2xWVr7+I7LU9H8XaRd30dreSqb3RiwnADHlo+BtVl59ia5S5Pn+M5fDem3Gk2FveN/Y9wID8z7Y/nPPQl93512/g3ThrXh7X00y8n0oIi6arMnzRJGdrSFM9CAfmzVySjqyVBJuUnf7/u09TbOt+FtS1vWoY7a9tb7S4jLNNOflVNoZio7kA9KZ4PjnuddvvENprMN9o2o2237Uw2kbf4dvqPXtVvwToXhu1sI7rU0S4ltoZIIrox+X58TLtfC5OQRnvVZWgjS80C2az0i2u43s9KRU+VZWHyh/qT0rPTVRE27OMr6dzC0Cwk17T5tI1TRWit7C6byrJF/wBHnxyHYZ+brnOe/Sl8YQad4u0u10y/1k2+ly3e0LDMFYsnWPp1GRVl9UsrHSdGsfiHDqWg3r3qmOK3f9xK0R4JYdI+QSPelj8NaLe6hIJbJEzdn7FazphYpRyxU5+dTlSOlPzZp7SMm7rQ5SHxTdW2vTWV7qd1f3MfKKoKrGo4Ax9PzrptNtrPU7hLuEKIyQSrAlEI/ix3qDxDp9zZxCKW2sbSzubqKC71d5BsaPDAqR1V84xVzwXpsWlXtpa2ur2+rXNmohm+zNlI3UHcp9z6+1N2tc65VoNNR3N2O3ig1K7nuryURXICLFPHgoR9+QH+6TyKxPGMniTUdEsm8LR/8TXS9QjgnmVR/pNixypUnqoOzI7Gqeral4ivdVFj4bjeLV3vEeNHHDWmD5jbvTO3861PCdvqN1rGrzmzTThDM9rLYySbWKHPzAdwygsAOlTy295nFO2zdmjM8b6vZmJYND1efT9YvNSMIutGJdJ58kNGy98DOeeorevIbfwvFqNncalqd5qlxbqy+bNkEqM4Axxkiqun6FplvbaRpvhmGxuNOsr6S+ha/fE73B3fKuercn8BXP8AjOG9ur6+n1qEWeoEK6wN8pmG4Y59jRo9DTC0lN++0kvv+4r+HPFV14n8KWd9LfizvLW5lg1K0Kf8fKYOxSehI47Vv+CyF1yO4lZPthHlWpdchGbjP0ANZ2q2rRtBbm0t4bgIu/7OMIMqDk+p5rq7D+xPCek2Fx4k81pbpgYZFXcSxOMAemOT7VLfY6qvJRotLVyMeTVvD/iO+1nU7OwifaPI1IGXIvIFJVyUx8rcHHPpVPS9dv4/Bj6dPDZW08t0RawWi4jgtsDav16k/Wl8a6j4a8OJb6HoscFrpmqzmfULoruL56Ko+tV9Ekn1GPSw3h19HTzm2xXE25pY8DEhbHCn07Yq7K22hz0aaXLKd+6v5d/0XY5vTf8AintTubnV7TTtN8NmUqJ4xtnupwAT65AyM12VrqtpBJqxsXRL+K1heaWQYFsZt2xF9/lOfwrP8Z2s134UngtrJLm9luYxBbzH5S5YjeP0rb1vSY59Vl08RwRzLBaWzxqMCVvm3GRu2PWm2nqaTd5KLenX0/4dkhNtrKeF11K8kbU4TJPaxom6NWXH7yUduvBrK8V6beyX1zeWl7PHaRXSrPOp/iGfl29warNptnqzC70DVLnXptPljW4+zuVcW0WQIUQj7rbvvZ5210vw90KfXZ5r3UQ40uG43xW7Pw8g7n1xSl7mplTqRhGVTov1fQLO9Og2mhzxWFlBqFxM8swn4cpnru/h4Nehf8JpoX/P9H+tea6lPcW/xkvYtRspJdOtdN80OzfupnbBWMDHAHP5VF/wsO0/6ANj/wB9f/WqXHmsckqP1j3+V6/r6ia7N4T8Ja9L428Wx3MusTyKkNvagvvdQRkR9OM9Say9fhvdDsb7xkNCu9Q1jWJfsotJrjzFW1kO7dsx8mNoAHvV3Sf7a1CHw6+kTi7tJLdL241W/hU+eecqoJygBxnAPWt3w/aNb61J/b1vc3+ulftM32KUm1lcgnYoOBhcY59a1bsK2t7nL6zp+naR5dhZeHBrPiXWCmptptwokS3hBAaONz9xxu3fRTW3421S803WNVjsraS5v4xbW+nwKvCowH8X86zPEdymqaVa6+LvWNIj0+786f8As2MyTEucLERxnGee2M1Y8Q6hqF/450fVvDNoNV06JXs7+8PyrZyx8HcvXdx+tS7vc1pyVOo3N7r8dP69DX0++tfD3ie0tb3LXep28omvVUlYp1ypj3D+EHPHHODXP3ni3VDb3emw3v8AZOqwXcUNrPqcW6O5jwC8akZ5IyR65xxXXanfJE1qljqun2l5dMJpdPdSEmUDcxUY5fAJx3IzWTcWFp4Q8L6tr+ovf31mbkaik1yfOmiUj5VRTyhJIHsDUq3YzlJTvzdTQ8YaXq0empZ+FbPw9BcAq9kb7lYXbl2CYwrHJwcmsnU/iBrMGnzPod7o2rLobQR6vIuS8ZZgsjJ2OOfyq2vxEsbhPCkMeiXUlv4kjeXb5ZIgKsdrHdjJ3DpVK20qS18WtplpZaRa+HEtZZ9at4I9puZm3BC5IBOTt47c0R0+JGSTlurjp73SvC83iHW9EtRqV41vJqF3eTH7zqm9FQfw9uaZHqtw0mj6ppV+LSHWtIkkSyfmVLgglXVvduD7CoPBa297dz3lvdpeRajI/wC6aH90sYXY9uVbGU2r+tXr7VrK68VXXmaVcRjRrMPayWy7ElhyQViHdhzgcU1udc4K9o7WMT4OzDS/DXiXxTcWNtYWMqsJoI0Ks12OGCpjCrjbgAnkmnyrHd6XDYW0xtNR1KFXs5R8ocEndGZP4WbjH0q/rd7L/wAIp4WkknNxZiRpLyAp5bygn5d2OkgqPW5Y7S78FadBbJc6XqoFrcWgnZJy6nIcDGCq7uQSM5p7yv8A1oNe5T5v5n+Rj2dpr+ieD7nTPB0EWoa5aytBNZRAf6L53J8zsSuzr33Vqa1r7eH4I9PkjsfscUCHUpLKbbJZXXGUZsdDz9cVt+FdfNr4j8ZWYWyubyG8+zwWttB5D+WoOzc2MO3XnPauJ0zxHodn4Xn1Hxnoa2v9u6qI7lrmHdFdLGTiSRf4T834093qjD2kp+/bQ6DVNZm0fQ5dS8S2sZe9ufs+mXejxb5Vt5ASjzLxhgB1yc5qnJ4Ku00u906GVNRFyiTWl7dyhSZVH3AOseeSTzk10N3bafpXiO1Om+IrOzsNXjV9PtZIPMSRQOi9ggyMDjqKdFcaOdRkg8VWVuzTszR3qReXIm08gqOQB6jNZ3a2NaOkeZO/5r8vzfoee6Lp3iHSWSTX/DaaRodqsn2q9tZAzMZSYyUA/j3P09M13cF14Z02LSfD19bxx3uhyI+mj7xJIyHYdic89cE1n67q9poFrbpHqM+pWbXQbyLSJXRomGVkcEjO1toPvzVLx/aXV3eXcrQ2+n+IIxE1hfxDf9oUqC0bE48sHnn3qm+e19CpLmdm722tp+ZP4h+E0Gq+OBrkum2f2SSN726VJv3lxcjJEaY/hwAT75qrpev6he+ANUuYp5E1jVmkQo0fNhbrlNm70+U9uppumeG9bg1jQb13vYUtyzIHkUQWjupDY5yw5OOK2tZv7fQzDp0Vuk9ndN5wvvMJlnuA3zIUI+7getF/s7lU42aUtf66mRYWmrQ61oWnJfQ3FlbWnnzi5jBaK5xiMoffAz+dQ+MNPk8UeKtOlu7mE2Nharqc0Nu+y8inVmA+b0O0Ypl/qdxZax4kaHTr27upbVNQlM8A2fZwcOiHOFbCnGK1/hfInjjw60lzpkCNdagJL+ZI/LBiiAaMEHqTyM+1N7cxM3FavXv+pf1+S+17TrW61C2iXS4tgRLuMb5CeHyPYAVny2eif8JJ/bt202q6rEAbKH71vY46CNe5HrxWrq9hqvxB1q9hjnXTrCzUraylA6jtuxnBP8qw9J8NW9jp97pGtarNq+qOzFZtIIiNpGP4i+QFPqM1nfQ1hGly8st97Lp6v8y7aeDvDOvQ6zqWu3iB9VgWO8iMnCsnSQL2cdj9ahS0hgnW28PwyLb3Dw25u5D805QEDHoME1DqPgy01SW3EksmmThIkWQ3LSyXSrnZ8gGMnnJzzV+8u7jwg2nwarDNa+aHhsNVuCrW1rO44Lx546de2aer0TEnTpOU46vXT+tyzqnh3V9Y8T3umw6lcaWtikMltNaqDK8adUPI+VuPpXE+K5rnVPGmmvqFjrVtexXpvil3JtS0to8giPH3t2R6da6Hwt/wkfg2PU4tZvY9c8b6ohNgkLl1lHQOXIGEX3roYfD/AI3v9PsdP1+40C/m3f8AEwueRKYc7hEAF6EgdcdKq/K9TmU7O8mrWX/Bt8zgdZ0n/hLPDdzPdXd5dGbUDc2XkxKtzpsZPyhl3e471uWkmpeKtKn0zVobqO30Zo7aPU76HypLpiQMYyc+9N0rS9J07x/rdlqOn6nb2OrRiP7Qr7I7YqN21SDkL8uc+tcvD4hsrjVvtc/ifWpLXTJys9lqIZoJLVWwsobscgcjkiqautDSDtJcvT9fM6TTzb2pvYrqQNLHIwOf4lXgnPYAD8q1L/XVutNnt20g6tPp8ixqyxhxGHUFZVOeRyB+FV9Z0Sz1KTUtIju1t01+FJNN1WE5VVfBZfxBI981iWtveaJ4s0zSPD7Xyf8ACOWBGqB08uO8i3FSxI/iA5A+lZpJ7m1epGbTXWzX9fgVZ9On8Q3Egl06NdOsLdrr+2JpciOYZ2KYvTcOfatGHR7i18EudZvbi1muLFovttunDKxOXVc8cEcUs2mvYapJ4tScRC6sHsUs5V+VoWLEyFu5G7v6VueGI5NQgup7rzrqz0myYraxDc0hIJG0dCeOBTcuxpK6jKc3pt8v+HG+EUTXfA9jqMN2JLi4k/dG6Gw+WnG5uvPBIrlZfE011dMmm6YbrT9aujp91bXlt5d1CBjeWkyfkbPynttNelfB82WraXPctbzRtFMQsVzGI5FU9NygkDoehrkNH1LxBF4N1WPxHuTX5NUksoREgV5okIIJx1Ubjz70RlZs45S563sv+Atf0Rmaf4itNP1qe20/7Z9oimFhFcSy+a8iKDtQA424ycj6Vu6rretafZaKNFtxbaULH7RdapLPtt7Z/wC6yY+ZjUdp4Ws7XxJ4jvrWX7c+szrcbTDg2HXfg/iOnpVPXNLsG1zQdB8RalNKiTPcWdpEMLegkEbvUjGB9aq6ky/dcUtn+hpa7q2qS6ELzTvst7qkscYZXfOCSByOw2lsVL/wisX/AED4/wDv9/8AWqj4l0zTY/HGlTWzR6RcCETS6WqkSToOAXIzlhnGO1bX9pW3/QK1X8jU37G1NtRTh1/ruY/jxZrL4neGbWx0i51LU4LL5QJfIsmI7IqkhWxkkEAHipLHxhY2cni59O1jzLSV447RghOybo0KKwBbryfpTdNi0aTxra+IdavtW0W48QzSRRaTfNx5qYGQASATnj05rL8cxX2qeJtNa0ttK0/UbK+kttIWbLrdZI81tqgjfwOuOta6P3WcEFok/wCv6t2O7SPUm1HSfs941nawg2whiO37UzKWHzdf4awPDfiu30LxXe+GL6KY30yGe6EMAWC3dhuLu/8AGxOMn3q9JeNeata3zBp3spjafZi5RIyPlL8chqIobvU9Z1Tw5caFPdaV5qvDqwYxs/B+Vj1O3oCeoFZLazNqlPlSUjI8feOIbOHQ9WtfCw1u+S6SKCfGEjuD8vPfJQtjita30a/tfFfiXxL4hmn0/TdUskt2sZ9s0ayYVVKjJyeM4x3IrF8Z2UcGmRHw/qoudN0m7WbyUJk8udeCZnXLbc8DGfypLW6udYXX9LEd7DeyWaaoNQluDJBBMWBAVXOEGDkZwavlVtDHlje/+empo3Pg6y1uxsoR4o1ea4sJo3S4inK73GPk8rOE9ABWrqV/9v8AGVrYtpirLcMkd3cNISyIpHykDjn655rh9Glv9A0bVdStre21OexVZxLazblnZ8B5md8KWVieM9q6WHTJTqOi68biRIreIssaOoW6lmXDSSYP8O7GOnFTLzZtHl5207tFrxbqVpbXl20VrOssEc8VgLWNSipBH5rjBIALZIHfNZGma2dT0l7S+vUOrWZW4eAKYprYy8IrgcFjjkAnjFT+LbAX7y6bDPGL/SrxNQhQuVhmjYKHVsdTwcCqOuf2Zd2t0t2839q211Bctd2cG1ppM/Ikigfc4Az2xmnFJoqKlFq22h5hpvjjUn1GexvpHuNl2ZixHzBumT+Veq63fLB4N0HxQlvDdJBZ3F7bySMQ5uztCoPrg89scVy2g+GdMg1u9uLKJnkmSTzo5ZfMNuSB8zZ+b6Zr0r7Zo1n4D0zRGsPt6xQo7wOM+QMnEh9ADnpSdk7pHfmFVVVCEI636fMyr7TH1zwRp2rSa/b2eoK1teSJK/yoy7sx5+/k57jtWT4lTwzqem+Lbsapf6ymryJHPaunmrp8iHogPI68YHAqz46i8Iw3M9xfWkUHjDURGY1ErGBnH+rdiOBkZ9+DViKHTNSg8RWr6bqmjXOj3a391f6afM+1yDPMTZ3c+lPRK55S6Sknv2JrmLw3Ha6TaazdCJtJsBeW9rHK0c625wcuoHKjA+X1A4rl/st7darJLHNceLNI1KeLGqWshW+06OUh1XacFUOASB1FWLxdGm1SXxm8Oqvrs9n9qj0a5Qfa5/LITkD7qHdnYOoHtWuvifRvAXhm78Vf2WRd6tJa/a4Y7gtIrFfmDD+BUyQB9KNVsS5NK+/yI57PR/HFjrEJ0m40u+0TUGtWnjJgiuApYh8jqCF9O/pUubXUbCObVL1JJJVMUnB8tlU4SPIGGxgd6ivtV8Qarql3/b2p6RpOkmRpbNbuXa89qwOGKnuVOM9eayrvUbTwf4quFt75TottBbvF4chXzWn3leYlf5cHO8t160lF7XOinUaj72r/ABt22Z0UrQ3HjmGfUrYy6Pbad5cEijCo/ThTxuHY1YstDa/8SWmo6m9uiQIUS3l5befusQeMkYrndWtdRl1PxDZ654itBdahD5ttap8r2kG3evHQORiMY+tWPBHi+2u/CM1944sI7FbZjBYMJH8y8EceSOeWcY5ahxaV0S6iUU4r+vIZ4n1axTT9ba/1S9vfBBCC4s7SdlvbG5D4IVh1iIAyM4GTXb6VqOi3mmW2n+HrmOO91PS1e2gL5kEIyN5J+8ev5V5z4T1rT9Rn169tPDkUF6lpKZdOVy6XSKu9SP4TnOGArMvblNS1LQdf0bTo9OWy014dUkV9jaXACS+AOc4Y4zTcOhEqPK2zvZYZYJ4/DEYmto7MFru+iYRW6gjIyc5y3oBWZdaFous6Pq3g+LUZrRY3jnv57CMYlQZPlEkjcPU/Sr39n2fi7wN+91E607SrqkEcbrb3Usa8BZFyMg7epqn4SuvFWpael3q1pomhQNfgSpJGB9osl+8qMMnd6E4qLWQ5VfaRa3X5vv8A5GFqniKwTxhqNp4bF9FHdLBcXE8U7LIsaA4ghX7qKBnODk56U631HRvHUsnijxNZ6hp/hTQAzRx3HMN4Tj5JFPLMDjsc1v6Nf2S6pJNrWg/6XBdSG3gskXckRxsebdgEnnBGayPGDah4uuZ9A1KaRYlngvrNbS3UR220NvWQjh85BzzjHvWl0OVNtcsV9/8AWp3Gk+JtN0jR7a5GlO141sWtoYowv7liCAM8gcCuH19r6wjm8aeVfJq+oXscNwI5XCw2uMBwg+9t+VefWm66viK68R315GU+xwvbWemZGUZWBMhDDk7cY59a6jRtX1O78aaxpaWQs9J06NFbUbmUszKcFkEZ6898dqzXu6o2cYQipxWr3+XT+tzC1o6zea9oi/2fPeaVIs0d/chlKsoz5TEE8HO0EUSWq2i2ulaibfzXhaU2y7ZVKjhS6d1DYyD2rY1qexbV724V/LtoGC+SmfJlB/i46HNK+gW0El54kslsba+FuGaSEeYXiAxtyBS5tjeMuRdk/wCrHIaLY3mm6Lb6ZdRIiW8zXbXgkGJnYnAjXoiKCAF9q3L3xFf3tu9vdXY+zKhaV1GGkGMBSfQmsfxJDa6joyz/AGi1txZIt5bSNJtieTPypIR1G7AxW9p8767oGqWZ0l4NdjVHuZWQJAy7Q37v/Z5/OnJX1NU6dNqDW34XKNgieINBl0a9uLlmeF4Yok+ckMOdoPHQ4rY8E+f4P+zy3MGonTfLFld3FwiBotpyhIViQRu59sVxfiF7LQfC+mTeIdY1CxS8nlfTptKQeb8qDAkY4wQ2eAcHjNeo+DrHUbvQNR1SeUSRa3CGCSxiOVPk2hnA+UscZzn0pyVo+RyYmvG8l9na3z/pmdqF3B4a8ZzXM2tJYwS20UlnFFE0nnwgsWVxjG7rhj61z+lT6/efFFLq5to4vD7RT3cSyndMFwMEjtu9B6Vr/D/w5DdadBD4mlvm1aGDDyR3CmPy9zbELKSuRycZ71Sg1JNMvEsdLsbn/hJ7iU2378M0NlCOsjSdMY9DQlq0tyPaQs1Ftyta9un9blrw7Lez31/E2plLiFZTcW8nEccj9E9gMfWsbwdpdzollLrvj2ew1O90yXFi8pCPbynOEB6Mp7c8YrPk8VWelPrF/qNiFhaeY3TRsHW7IKhXO3OG5PXit/WNO0vWobbSr2I3l0Ct1aWKt+7TB4Zx0Lexpu6G4c6K2vLrK6brOuxxrH4pulU6aCAfK+YEAZ4G4A9a5D/hMP2gP+gdH/4Cwf8AxVdo1/dT+IvFMelmG+drUSTSXW/y7WZWUeR5YHIClsMB2qX7ZD/z6T/9+5P8KaTRlUorES5mu3oVfC154faaXT9eha6sNK142+my3Vy008Mw6M7k5+bJ4zjitTX9WMfxEvdA+2abDZQWsYMxiRLi0nlUk3AcgcnGMg9xWVe+HtFF5rE+raVDZ+Ctqale3hmcXEN1HwI2CnJwX4I61l6jZyavBp95dJaeIdX1+CRT4jWForSzsNykB0wMuCBjIzzzVaN3MI2jNRaN6005rpLOTTP+JVq1m/2ZrPUbhQ+qLGR++XnLFsdT1zVcXGuX+sarrmnteQteXMVncRPMfJSHaVkAUnhg2BlRmrvjXStQ13xjoTRQ6dLo2mwJ5mutJGssbAgncONoODgDGc1Pp/iCaDxXdyPEj6bc3haO3dP4RnbIp6DI55qXpqjrpc1anZq7itP8v62MfwlpWmTS67onhjV7iO7sbtbpjBEgJSH5DEwHLkkdX5J5rqre0uri6vbjWojpekai2bq0kRHlu1ZfLCuFyV6jkcCmx2th4c8UTzaFqNpFqWvRk2S3FtiJ2zl90iDlhycE54rChlt7/XdT8T+FF1HxH4hRxplzFJMLeAOgG4Ro5GR8u7ge9JvmdzB1JJW0s++/9frsXvCVlpvg34c3VlP4evF02e8lDadqEqPuBcgKgYnIIAbmqupzWejR3l1eafPZWkNoby05DQhTlRE465BGeBwK5b4mavo2ry2llf6hJdxwt9nvJlkdZNOuGHAHZgCeevA45ruZLu3n1rSPBN5b3N1eW9huW7ER+zSArwcsMtxjjmnytasqCjTSb6/p/VjI8JW2mXbaVZaz4ogl1K6tzdQ2iJtEiZLGQvjIAHGGI+7Vfx5bfbdMv9Ej1E6QsTC6N/bszefb9xvHLd8D1pmraXN4as0n8VaWNb1jVZJNKgm0y3CLY2Tja7MVAAIBPJ/Pis6+0NNH8MW8NvqMNza6DK1xpqiYE3DRfOsM5ztwzMRgcVSte6ZdOq5zlzar+tjQj8OaUi3F1pkssN/rGm7Lt55jvwBwxXOUz7gGui0fTvIt7aztpWmiFsqCUt88rjOS5PGwZrITT7bwn4HufEevSeVq2rbJ76+KGXbO33IwMH5F4wOnNT3Tta+GZI9euJLm21LTP9Kmt0ELqsvAKDjb932qHqtGWpuS031GG60fTTb3Ek2l3+jx3qx6nPdpITA65CCABfnGScN096uafqOpJda3o/2qwh1rTwsqSWZKom/lRIvoQD9O9cJ4k8OTaDp2gJos00UkAa/s1u4JJzdSpjdAyKCNoyu3jHWurtr6bVZvJsPsun+N9S02C61VLm2KIkAHzjOPvnK8HpTcVbQzlJ83M3vv/X5nQXGsPYW+m654kh06z1yRvIjuAhkVxg8BlBIGM1R19lfXpby0i0rZf2KywWzxKRPISNz7SMMVJ6N3q74dt91jc6R4i0+G0WO5NzDbiTzAkAPyHcScEjrXGeOPF+mnxtdWt5bS+Vp0AuhFbxgSyDICmL0ySOO9TFe87BCMW9v+G6Is6XomkeJLi6tdZMHijWNMBu1lvFELxndgRuE+UICc7fbpXcNbRJeS6l4m0yxks9Msjcvfoi7kYDJiXHzbQvIzXMeEJb+30HV9XvdFsbTxBq0qywaWWKyFARtefHI45x046Uuh6/4l0zxHeL4o1G11zS5rcsbHT7NB85YL85IGQBkYzyACaGr7MzcZyV4Ly8zNvr7wt4n0Y6poEU51fXYZbi1N3H/qjb5BZ2HYBOOaI7vT7DUfBOqatrNnc2dzZuEtp4i0Ly87mhLD5SehzjP410+ua9pF59m8MXejtpK3aFYURVjPlMcFQV4XcSRt6nNVCPDXirw9Pp+mWcF1b6bfJaWwuRtO+MKWaPHIC9DjglTmi+mqZceZJKf4/cdouk6E+j2en6Hbpb+YG8h7YYaDJJYkjp1PWvNfDTeFNFsdWs9L8QQBri/+z3eq3kAn/tGT+O2ZWBG3Bx8vqa0rbS5Lx5bOO8uLa3kPltcQSFH4+6MA9Cc49a4mbRH1HwNcWvhezQast4yLb3WyN4WXGZCDjY3cHgmiC6NmjwyjGUebTz7/ANdDtb7w1DaeKLrWtJ0lovEmoL9ikcOzwhSAD5anhQVx97GKm8cxeCnfw/Za7ri2GoadKo+z2sjyLKz8CN8ZHJU4B6Vu+M/EVlpfh24nbVZbO2tylveXtqqyFGwPkGc5Yk8456Vx1n4XfW/E2o33htfDlxHbqrrJcpIsizgZRpUx15PIFKOurOeMk0m3y2OlfwhpdvAsB1ttR1mC0/sxx54DOh5AkCn5SAPvGuM0HUlvPE+nW8esQ21kZ2gXS4BmSdVBw4f+FfUMRn3rbv8Awq3hKCwu7rSZNc1/WLspqN/YzGJkZuQyqSAVHPWs7Uk8M6Nq+mSC3Iv7uJpYLxAsUUKJ8vmyscAjLAY96cddNzWlVXK/ev8AIyJ5dVt/GVyNM3SeG4UZ/NYhYQ5YEHceh+ldf4igtbeFtc1u7ijjkUNLdRO2Bbgc/Ub9vIrJ8Ky629jHYa7plrcR2t580TsFimyCUckfIVwDjHFO+Il9feIPEOl6TYWlrH4fEJinXAZ5GdcqioP4RjIOMcU2tbG8pOU4peepTj8Ua0NRhttLsdOvNHvYEuLUQoHlEeRvZs9Q3J+boKf4S1G58P6zfah4r1C0h8P3aS/YUttuwLzuC7eGwMk98jFZWoQ6hB4KHh/TLKHQop9lrFM86peTxKwEoBJyAzDgD+E4NR6b4R0bRPiTNZa3DPJ4ZsLJF0u3eX5VmkC+YvJ5JYt+JqmlazMpe8+WK0d9t2b15o9rpumxWKLa39vJH9rRnQFZVZsqdp/2SPx5qrZeJLrUdXvFiuzLoOl6fJcapb+URNNIqny4Ysjpwv3eKzvG11d3I1qawWS0aykhhO6MgInygRoCOeOM9M12U9zYeBvDNrrGqaZdajr12oMFnAhLKMdyOAAOST+FR+Z1VtKMdbyfbv8A8Ay9L1O0ufCNndeI9Bt5UvLc3FvaznIhIYjae6sVA5461s6NqttrFq9i8dzBpt9Z/ZgwlZGgUkjHPRh2I9qxor288V6Apm0wWGoaldqLYMuFCDBOe5qzotrHokviWSW5l1JdPj81sIZFSRRnbgZbn0pNdDGcYOLc78y/q5kaL4W0HQ/BmoeFG8WXtlFd34e2aSIrKJeMABRgqcCrtzKsfjSDRb+/nubXWbb+yra0hlxH5QH7ydiDjeMjjrV2ZodT8e6ZrfiWCO1lhtzBptuZF230kg+9GoO4Y45YZriLHXbHw1PHo+st52o/22rWK2MBabDt+8BZhx/DkDmtFdnOopRep1ek+A7fwPZNcacrXmnagY1K3igtGq5/1ing5z29Km0E6jPcvq2lW0KXEbMkkjY2svY4+lPvNQi1jxzrejXd6z6jDG5t7QMdojwMtnpnpj8aTwhqMOhyiDWBIIgG2BlK+ZkelQ23qztjFqi1vL9GYHirXLweKrTQvBupJa3M8Rl1q6aDcxROpzjIGOAR1yKT/hM/AX/QS8R/9/p6dHqFxPeteSQWtpp12THcWMoAuQQw2gzLxsPXbnHFd7/asP8Az76F/wB9Q1b0SRlySj0f32KFq11DY2aaxcWt881u41JVTdFclSN7H0PI4pY9JnuLfxB4de7glsb3Z/ZdpZI0fkWwBIR/4ew56mp9Tt2vNcaHRsLDeyeQnlgGIhuZ5EPcHC81WhmbUJ5dVj0tILjQruW2065lkcObcYDStEpBdSPu5BqVvcwqr3Ytb/1a/wCRyeh2uma54Ru/DdnA1rDLemWaaaQgMy58zzSTkBDgDtW/4HIu9avNFnmhg1ezi+0WqhxcC6tlIAmBXIUElcKeeeKl0qzXxlb+INNlitJfDutQulhqWnt5cgAI3KwbndnGfpzWD4V0N9NutJvPh/Yr9k0YT2uqapfsftE7xnBgVAeR6HGBxVuzumRKtOCcYO33fia+naxa66XeyEiQz3W62Pl7Qtyh2SABx8pPzHjvVe98PavfarFqevajBBBYaglxp8+nulu05DbHikVsfN1Bboecda0vHtjqWo+HrLX9JJtLqMpNd6PujbCk535UZDjgkjg81j32gaR4m0Brm+1e9tJILkanLGjKwcRrghB1G7HfqTmoXunROPtqSn20ZqazpFm+peJr7xLaQaxDbXC6hY2VtGtuzAKAUZuA+CM5JOan1TWNT8Z22jQWduukw39nMupSiQG40+FgypsA7njmrkp8RzeJra7GmwXHhy8s0a23ELKpKjEbA9z6+9UfANlpqf8ACY+LNJ1CS91C5k+zSRmFo1tGjAGzDdQCOSODio13ZzOMbJX123Of1fVPEUbabfeD9YtJPh/p0H2R/OlXN9ImQYX3fNvc/LkYAzmpraz0eC48N6e9jFY6c8h1O4s5JBIwdjygxkuBgHjPWqjaHp9nr66+mq21topg8n+zJFCRtdMSS6lvkC5IJbr1wa1V0jVZfFWiXlnqFo2rW832qbyYPMElucAwgkEJkDg8dc1q2rWN6NOVK8lvr5fP/gkkELeIfHuj3l9Fqq2t8LnydMYD7NbwqoHmzA9GPYdsVpeK3nistV8u6MV1cTLBpUlzGhT5PuqiEfODk8EH2o8QJe+LZ7rS9MvJNNWSXz31KBsssicrFjsoPXPWq0vh25bXLnxHfGz1HS9LeW8tkhlaSSWUqoCkZwuwqTwB96lp1Mk+WX3DD47/AOEdstNufGV1PNf3ts8E7WSAx2xTAMiEDKn5hnt0rOg1C01Jf+ES02x13UrPXLNmOv3EeI3z8wdnADhRjpnvWdaahrWs6Xp15olnaabYwC4kv7WRVZIJMrh5C+SVbn5FIJx7V0FjqN3rl7d6dAJLOOC3Sc3cs6RBD/DAIVwVQ8847U2uUcqK16Lb+v8AhyMNarPp7aPeNe3WlaathJEzc3eABuy3XaRznnmquyS8uE1wXMD6lpsLRwWjxKYjN0yXA3Eg87c446Vatzr9trdv5vh/SluPMdLmQ7g9xngC3wcDgkktnJqFtD0mDSIrKza40m0TUHto5lk8+WK8bLCRyMjAI2kH1qbnRFKK5WtF/WhH4P169bw1repzXw1TVtLg2yXM6LH+9dgCpOAehO0HoMVtaZZ6nDbGfQLFW1mXT9ubqQJHE7ng8Y3Ng4H4Vy3i/Vp9MlTw54o+walqk7xzuLGMxRTOBgNNjBZ8/Mqj0GRXTeK4dNi8PPa3093BpxEYa5hnCzJMwBLknhTn5cHpQ117kqSlolv91vwuY/xC0fUta1jwlFc3xs9Vs1W+uvOTIiWPgvlRgjK5Ge9RQ3mnLdxahpGnSQs6Tw+ap3LzuZmIHC7iSc8dcVc8a32rCytFtNNkvrSK0WD7XLOqs6HHEjd2J7Co0tvsmm2N2hW1sb9JIggOWKpGWCnt94H3oWx0UkuWKktShotndW2r/wBv2MtzI+ppGJombKK6N8ioOwyAfqTXXLpXhyyu59XSMXmrajKlxdSmcrFJMv3I9zHapyMYrkvBuoT2PhvXtbuhNNptjFuhhVcO1xk4jVevHytn3qt8brvUl1bRIEt7iHw81l9qKQhIYopJBj9/IwxnIPQg+nNNR5pWZhipRjUtHu/6/E1orW98dvfab4rl8OabotqBfiPTLpX8wqTiWQBjgDHJOCcVZ8TeHNBl8K22g3XiVo9SsbVb2ea3fY81qDy5K8tx0yTWZJp2j2em6fpd5ocEFxr9jNLe/wBnSglLdVBTa+cEMd361neHn8PaxdH4l+TqOm6bYxmyutMmh83zxgKuwgY2HnPYYot9xhs7X09N+nmem+IvEmjR+DtO8TWi3N1bxRg2flB/NeM4UsU6n8qwZtWil8Vx+Hl8NJceHvsIeSSYZSMtz5Rz0z1x7Va8c6U+oWFra6HKbS3jubeZnjxsjjQMWiUjjbyMnp0rI8T+Jdf1fTvDt74UbS5rRpdurTRSquyYfcHzHlevPOazjFW0/wCGM0uVeRkr59zPJ4f1DUpZdShklm0ry4jGDaE827ggAkDoe2OtXfCHl6Druo6zeCaLSE01YrYkq88JwCQBySTjAPvVrx9aW/iDR7S9u4E/4SiI/ZEv7F2Mdu/3mLYPfaR7ZpNL1CO40B9Z0mw+2XsMbxJbLIHSWeP5MKe4B59wK03ibwmvZuCWhy+vSaL43v8AQtY037TY6hDaSYN4GdLMltu5vViCWHviuyPhLS9eh1iC+up7/Uba2gt7aSRjH8+xSJx0+b+LFZ2uavPb+G9Gj1PSDBd6jeQx38cIXYH2785AyvzAAqxqDUoda8Pahro1yGNVvriK8GqIWCOvCeSozwyqcHHBAod7WjoEYc0klpfT+v62JrC8vfDvhi+m1RJNd0q28qOTaM3U05kC7jnjCr8wx6Vehtb+z1bTBpj2+rLqjM91NLcmNrePHDxKWG9gOGUA9Olcrof2+/8ACun6Hf3t5Ffa1rsohMaDzTBGhZSOP9WcDLHtnmuw0m4uJ76NtFudPOj2qy2suoRx86dOoO5gXyMY6np1pNWCrJc0knb+v6Rwr6p4vuDZ+HNcmlmgm1QRW2r2KqJLOHcAGGBjHXcT0ArrLkxXuoav4I8OeJ207xZcXSXkV09uxM8KKN24qNuchvriqPiPW7/SpPDMgvLA+HZWNqk0TKbe6DuRM0rjlSVyVwQM1qWMtlqHiTWdHl1m2t9Tkg+0yy2kB+0WluBjAlxhRgDjrznvQ9bOxm0nB62T/wA/+Bcr+IvEGh6nq6rY6cupeIfDscgtbuTMapMqjewAwMZwQPWszwRpeoWmnWdzPDFqeprNKY5pYiXDSYy4xyMY6nmrcY0/T7C7vPB7A6Etutx9pchmvJWJHcbuSvUYFcja3Gr6xrvhHVbQzQy827Rlyv79TyXA6pgj61cVpZHTTpw5OaK/qx2hXTY/Hv2a6hnhuBYx3EmoxRbpJ5JM/IFA4UY57etbXiV7bVHtotTuGcGIrY3/AJeFRh1D4GDzjgVg+Nt+mWOt3turSRQ3RW8KPmREXGVUjkA5qDT7u3C3/h7TJpJzcR2+oh7g5SIMrFolHYjHNRy3V0UnaUW3/X9fejlLnwzrUOmSWVxqcOr6gbn99YgbXZCciSMjGRitj/hDV/u3f/gGf/iavaXFaeK9Gu9W0GaXT7vR7pVWdhxIc9EbuO2PevQ/7Z8a/wDPpb/lVubWhrOvKPwNfPTt3ucp4vs72TTG0Tw9qBtPE1xCtzCuNkaWgPzxB+iM3BP+7WtPaXupX3iSJb2/bQ9QSOwsjFEALYYJMiyY5TI/WqC6w2s+HLzT5tZ0+XxFbQqdWubUZgEBPKCTu2McKRXN66Lm0J1jw3q0Qs/7KfTtP0eVijyIpUTRpGTnfjnJyeKai9jzpNy97d/1/SLeoeH9NtrXwx4d1/xAfMu5JYba3tUZEuGVgN+9SNkn14J7UzWLlV8MRSmbV9Es/COpEXUFwo36hltqybgAD15PoTmp9Z0m9l8HeFv+EPihk0h2guY7hpB9rsk2/wAO7JY88n2rpCmsTakolliiLkQSy3RVkv0CEsqIRySR1o5ra3BR543vsY2k3l1r3w+uIvh1qENtrdzfyyIt4y73txL+8EbH70eeAwzxxU+rae9r4hi0owSG+uIYZEu7eIiD5ZF3gk9gQeP7orItDpHjPxheeHl0a90mys9LW1bUUPlGEtKknloMd+nvyauLe67ey6lBFJHpiK62mkxNcK8k0MAxIy/3nKocgfSptcqlOUJv9TZn8RQaFr0F3JrF+tl4geS2tre4AEcVxDnDxgjIRym0f7wqLWUk1pJPD91ci01C7aLUJxbgRLIVcZiJ/iGFyQOTk1reGdWs/FOkWMt9Z2jfYnZJftcf72EMxQMo/hY8Vz6Wd5DfX934kjg03+xpGFnql5MEiw/ygbu7bSKlL7yYJRcufQzPHWpmz19tK1Hwt5vhSJlgitVtnkfVZCAdykfdWPO73q7r2tarr3hvURoi2kMTQxxJOAYDbEkqWznllAGF9q1da0TUZJft8ctprujT2om+zyXPyicc7oyCDjpkg4rOTxNqdtoX2bxXaaXuvFby7S1YIip0HJzlvU1atZW3CMHPVamaJlsB4j1D4bj+3vEkt3brdW8xIWJCMbygIwCQ2a3vHPiTU4vDOjaLY6baTPqsbQapd6dKI4rI4G7axyATk4LZHFYEmrWiNbro+l28MmsBrXUp7HPmTKBgANnC9Tk1tap4U0bS9AtvCYttTumkH2yW1tVZixzyZJKLK6bCdDllap8v6/r5GHdR2PiG507w0bTUbGx1q2N/dTwTKXgdOjysBtZD6jArM/tPQNY8Q6dqHlsmpAPp99HLIVaZIsKsZGeSQc5HPFa9ta6Fdafq12seoS6Z4d046FNpKtibYzAuzP3OQMY9DWl4xsvs+lXN34d0SwtdSupUs7f7X+5kVhncQzcMx4xj0NF1excJ+9aWyKWv2ttqujz2fhnXpDqlt5c9vEwYCzRCAU3E5zgnBzV+48HR+JtPh0fz3txZ339pq8L8zb8sTJjqSTWei2NrdLBex20etLGsM8658yRsfMpIOOvfFb+mXTaFZTsLeWS7dSkMSN80+eAAfQd/YVnK62OqUZKnbft/X9eZn6X4p+3+L7rQ/wCy47JrZWu7mdAs8s6p8pJOD5Z9M9qxXub7xfcjUPDptR4JQiB7QqZJJ5NwLb16sQcsMdMVc0lNZtfD97F4xvol1gXQextIZEEzbkKheBkxlSTtOTnHNS6N4Zt/7TsL7Rr+80e5t7eaFLRgEhadgV8zkYBXO7B5OKv3YM5Um4uSW39f8MaOnaC3iTwy0SwXek2w1BVFteTAsrowIk4xtBAGFPrXO39tMZ76WJnj0azlaJkkkBaGVjhzjuGHTHc1l+JvD5h0zU7W/wBQ1jV71byK5vNRMnkx+ckQGAuPu4GSe1a19eTaj4GuR4f8u/k1GZYLS4Q7VkYIBxnrtfPPfFLU6cLzL4nq/wCn+A3Vda0/RLe0ma8Fre319FHp0LwNMXT5Q7Oi9Cw4BPpWn4l8TaVYPfw6vDdeINMuVeMeSvnASooZkkA4UqCCB1GahvfDFnZX1jruoBb7+xrTyftFt+9lWULk8DggMTjjrXM6NPZ6hJfX2l6NG2jahbTf2hpglMc7TgcRYJzufjLjGARmmopq5hVlzSclqjt9QvLvw8+hy6WBF4Mi09Ud0g868nZy21NmNwC9eB3NWfC2j2uiaIND17X4r26sb8TTGRRCAj8hdh/hHqeOann0zw34r8R/2be6ReWupXWliGeWGRttuFH+rD/d3DPUCqHjTSPB+habbeGhDbXWoz2y2jXN5KXdEU5UykEE5yemKz306nPGTckkrS/r+v0N7xxbx3N6nh+OJ4bKfdPLIJRGrIR86j1/h6VwfhGxi0z4ZS6j4F0e71XzL42ep6ff4DzRplSVwBgrnjHOCc5xTZLHT9Q8ceJ7nT/EN5pWt2Xky3V/csGt4IXBzbRqeAGwOuT8oroE17VLPw7f3JQW8ViyPbpBAzsYx8rM23/WMwbORjpVJWjZDjGTgrdNzBkh8OeHbiz0OLSbzUDeTnU9sF5jyfLYRjaf48eYfl6+vSrHi691rw7rCjTIrifTra5yq2IjBt4WBZ/NYLtXDYwcDgVr6dqmkaf4j0jQdSvjNd6iHl0idLUmZIZQdySH+DtnI7Vk3ll/wglzHpmj3EllGrHdBcZnS5jbhml7hGOBknjNNO72NFZzlZ3/AK8/I09N0i4i8RWE/hIW9zouqxG41TUDKZYpeedrElQcZPHOaqeIor/VtAmispre40KwMoea5JfMJJACEH7/AEAJzxVvw5pFtc6Hruk+D7XTtKupLczfYobozRifGNwIOAjZIx75rl7W3u7XQp9NSzlSS1hC3MEMwZIp2TBB9U3Hj2qVudFG7k+b4lb+r9+hfjudb0vS4tM0S0jg1wQQzWl3O6hYo94+Xe3ABTg+pOKdon9kaNp2v+GraB9SvtUkN7BpspI+0SSjy5flXB8sYYn2Ga3dT0+Dxz8M7KUwo2o2dusd1bJJhgsbeo5IBXcB3rEGh38nhmAeEdQg1PxFIAl1qN2RA1vbZ/1MRPK++cnk80001ZkVlzSc2tb2fl/wH0Ogs7PQdO8Oz6W2m6BdWmlWjHUraGYultMuXRVjLFhlj1PNYuqW+rx+F4T4RsLdPE/iNfMv9VwFSytl7yFuMY4H0rSsNEjt576KIJevfBBdXKYAn2gfID3AOck9aparpWr6pbaNDplxNYLYy+ZfIoOyeEH5Yx6nr7c1KZLoe5ZPe39f15Be6VbaZ4UjtWvoLtdLhjguriMhSZckjKjgDJ4HWtG1TR4tS0fS9VXy7zXLd7sop2m1jQAhif4c5PPTisfQvDtslmftrGy0iG/e6uoXfe7Nx80jfxM2AAB0x0qx8ZdOsU8DzeJNe08jUZyloXsJdkzWxJ2RBjkAHJ3cU1q7XLrSlCEaaeuv/AX6k19c2On6nNNp08eqafd7XWT78cpGeSRw2O+PaucsxoVv4nsptRLnWIbSe+iNs+2DyHwCXB53jIwM460zXzqaaZ4H0fTNLmsLa5Kz3Flb4LxxnqHfGAzcHAx0q5qjaXcaZO9ze29kLAhLpMhjAV6jA+Y7zjjParSLdpU1zdevkW9F8K/2JZ+GINLh/tDTIzNJqJkYrGiN8wfj7+MYyO+KX/hMfh7/AHdc/wC+ZP8AGhBLZeN/BGr6CmrPF4hZv7QkY4t0t41OIypGFH8X/Aa9K/4TrwR/0G/D3/gTHSeu9zinimpPf5O36HC/DyTw74m8JPomiaTfaVZWzeTNa30P/H6gz/GMbmHX24qtZWGmWd3YahZR32r6jYs6Q2F0PJunxwG2kfNtzzjGarix8V+K7rQdXOr3WmTWUMd1/ZqIEilVc79rf3+RkGpdR1rTNK+I+rarq+m3PyxJcWuqwKSPLOB5ZboG56Y9avZ2RSUo3i/6/IvafHc+Hte2a9q81097YKySiPYkEnA6dFABI/Gsm8urTR/F2lQyXF3JeQb2097VDJBIp5ZW/usvr7U/WL9BJ4nHiyLUf7EsYvtVjqaQnLQSsGW2K/xbTjv2qaDV7i9vvC2qx2fl2ktuFU7NrvEFJyF7HOAalbnVTknG3W2pH4w0XW5ZdGk8MNa3Omyh544z8vlzs/zysc5IKlhg9M0muaTpfhaDRtO0a0n/ALbgmdrC/lJlS2mmz5jt/eVSzYHHQdar6nf+MLHVNHjgSbVrXWrksEljwlhAuQVDDp/eHsK6fV5Ebw3cjXdPl+x3M7WlujNtnuByvy8cAgZ3UNvRbmMoRkry6f1/ViHX/wDhJbbxZ4ZfQbqykktDHb6tPcOsUN8GwW2r3YZLcHg1n+M9D8P6LoviSzlvLm60/Urtri6a5BnAuANyxgDGFHBrPutNS4sPCNpq3hW5sYdMuWnjhtbzK2kcbZUyjGXZtoPUfeq5rGt6xc+LvF1pZ+HbfULG5SFYLa/bal47KoBA7AZ5PfGKOqMqcOaza6fiv6/Qg1C3e30nwj4k8OQadr96IdqRTzGGJYBw3kR5+8MEEnOMVJ471OBLGw1y28OaDqvhZ7kRDzrwIzyEAL5T9Bh94Ixzis3xFqeieJLeC78Y6fcaV4XgK2On/ZIzHMJgMSKyDogOdrdDXXfEC9gsH0c6vLLovhfSbqOMExiWDUd6jy8qMbQpySe3NO1mjJzlypxdm/kQWGrafpN5f3Fl4XnS/S7jsLCAOHjnLAEyocdBnn2FZGpaVqy/EWLxddarLJAtpFp9sts3F3cOWyFA+6o75zVrU7Gz8MT+FNR1HVLaTSLSSe5uL29y04lcDaYgDwvAx1q3psU2peJYQlraPoUFjLd3TW5zGWb/AFXlDPJOGyal7XR0pJtynrbv/Xf/AIJLqd9Ja3F/pOtaEdZtdaIQ3mmREbof4N5H3nHOWGKz/E3hIa1FcDVtYvNQ0mztLeG0tTLsdrlM7ZVk7sRuyMZqz8OdLggjstfuNCvdHuPJbTbeGeYlbe2H3ZNh7HJqkrabpF1La3Di38qGSPTLExl55EUjcUGfvt6/Wlqn7o6UIPfp+f8AX4GZc3lpc+MtGtEsN94zEyFjtiREB3TSHucA/LxyRW74Q8V2ev2niHxRotrJHZWsb6fbRk5d2yMSD+7kAmuV8O3keuan/aHh6yvt0APmaXeptkLg9FbuDzx2OOtdPDq+patY+J9MgtbjS/E62qzCO1t/KERYh40XOQ0ioCG9eelOUTavJNpJ6NWt8zkPDWk6M3i251K11fU9S8VaXa/aFt7tCFEgwFLP0ICnb075r0fWvEekax4M0qLXI7iC71mRmWGNd/kSxAu2WGNoyvB9K5ePU47Cw0zV9RF0niRm8t7CzttsuoyHo8q/w4781tWP2pbvTLu30qS6D3oF5CY9klup4ZmBzuGSemOKU9XcycLvmejX9W/4Jkaxqk9pokd1eRHU1ETS2cMS+YtwxJXacdV7H8ak0V9U1LR/Dcurrp2mXFhO03l6f8lvBGnzn1wAOvvmiew8QTXvizT/ABVBeNoXmeVZ/wBkAfaY1d+dv92MoTk/WrvhldPvNL1DTbPyrG1+wyWNun3ygYFASO5PU+uaWljZzbfOlsvlr5GbpGnwW/i/UfHuka5BL4VlWWXyIUO87V+ZQpJDDILZx3qDwND4h1zwlrGrR+Jms9c1Bv7Qs7m4gXyI7VXI2nAGC20g9wAKrfDGTTbULow0m708+G52niur1iqzx4/ftjHULk454xW74DuV8TX/AIl0+b7JaaNJATplkq+UGgYn96Y85wzbuc9ulXK6T8jiltaRiSeJL618F+LtU8Nrf6nfCUW8NzBAQU3AAtjn5QQee9S+E9DN34tg123uNPv/AAvqlupKud0guCOHKk5+8Dn6VP8A2XfabdWureGoL6NLJk099Ez5alWJDSyMQd8Y69B9ab4n0qe21HTpfBlnDez+YY4DDPiOEcblKY4Jz1z2our6aXNkm27sr6td29hbyad8VtRH9oNK15BNbWZjhuUjGNjv0cDdwOMZrmfFdlqSaB4JvvD2qW1hp0W9YfNnxEFkZSmCfvHAPWu4uNN8QrqutaPdair3Go2qTKzw/wCh6cozujEh6np6UWGl2OtavpHhiS60PxBa6fbR/wBqp0kWRFOxoMHtzke9NPl1IvyxV9t0YXiTQ9Y1vWtZuNbs4I4W05LWF1nET3U+5clDjqvOMVsXpXVPC1lAthc6bf6UE0eMak+172EYGeecFlBqrrDeE/tuq+Lbtb/U9QimjsWs1Bf7M4+6Co6H5RzVB7WGy8R6tqUkUuoa/dL5g0dLrM0u/gpHxw0akknsVpbo2jaDU30NrxnpNxp/w+TwTo1var4g1hi10y3OxbZFcOJGfH3AVCY9WxTNGB0nx5e2MtzbiWewgW9t153ukQG5f9ncM5qwfD/keC9Q0LXby0fQxEJra3uZi9+iFt5aR+Nw34xgDisTx/b6hY+GtJ1jSbRXZ4lgbAy5AwBtPsP0qb9LlYOm5OUqj+LT57/p6nTeDpP7J8MajqOopcpHp5luZLy2G7zIQxJhI7nrW9JeaVqVxJcx3C21pc2cd4uwbJJIj0H+yR3NbOhSro2kaLbQabc3UckIeeWNcqm4ZLN68nFcdfainjPxxcy6JYWuqeHrbTprS+l8zAMmGIhI9TkfTOay+JsylU5qs5vRa2/rzMLR9Y1jw/b6l4r1mbQv+EdtoG+zWVm+/fliEctnBYsMEe1XbIanqfjRYdUgma0ubVLpZ4X8pZM87dvZQMU3T9dsYNK1DSLCzguv7GtQG0WyGSJSSUTnO5QSDnsSaiGsXtvHYzeGdEm1XWZER75mXzYrVGJDJu4+dcfhW1r9BxbjeXX1/V/1sJr+qz3GoiPS7KEWEd6tveCUEbbf/nqvqc5/Kugu9S0/WfDOqC50ltY/s6I3FvhChlkPVUB6kADmobrWNO8N2yzeJNaji1jW8WtotrF5iW3oxHc5PLVUe48SjXtE1Gzs/wC0iIGt57iOYAWsbfxlMfKTjgnPSptdDqTTuo9Ot+vlocdYWd/4jl0yDw1eDRvCNyiSLf3EmZUuDnzLdW7tkDj2rUfwnYf2pq897E9xazxiBYT91pV5ZCe2SAcn0rZvxpcN14T8UeJrcaQbeKR7a0uLsbbac/xMQuHY9eg6VWsLXxRe6Fplxpuo2V3pw1pXjurRwxntiGy0nv0yK05m/IlVHa7ehd0zxTrNrZWFr4stNJstBkM8F9cWM37mI/djgTr8xBOQDnisv/hVHgb/AKFGb/wYD/Ctb4l6jdQ+Hp59LttPxp1yGVQwkjU5wZ2X+Ernrz1rjv8AhJb3/oqenf8AfQojDnV0Y+yW7Oo+GunPpnhDWI7fUdQaW5u2DzyTbpFxj7pxxnPNM+Nd1J4P8CvqWibYrrzI7NWcbgqsCSwB/i+Uc0UUk/f+Zptt/WiOi8HWI+IXgGOz8R3Ny8ZitrotC/lsXKEnJx0z2rHurvf8Z9E8HC3t10VNNNyqqmHDkgnDehNFFEuvzIg2ptLz/Ib4P1LUrXUfiIh1K7uLfTJP9FgnffHGGQ5AGOnNWfD1/NqngfTtZvNj38zGxWTH+pj3Y+Qfwk+tFFOy1NKis9O6/M5bwfEZNV8YWdxNNOkOl3UivK+5ydrJyfYVFq95NZ/CLwh4khf/AInC2XkeeeSUjclAfoRRRVvf5/odM/8AeF6foy58Wn/sOx1bxbaIj6vPa2+4zDfGPkVuF6Dkmtbxd4mvNMu9J0pYbS507UbW3mlt7mLzERmHOwZ455oorPojlaXNBdLfqix4leK1uL4zWttfKmmSqEu08xdoUELjjjk1N4enYfDt3twtsZYoogIRtEaKWIVfQcmiil2LqbW9PzLPiy1TXPC3hd79nb+2b+1FyFYqBlHJ2f3egrjNd06K/wBM8I6xdvLJqFpNLaLKW5eNCMB/WiirhsZ0NZpHolppFlJpk2vpCIb+5hXeIvlQFRkFV7HiuQt/F2r6l8VL3QbydXsbPRotRh+QBxMwjyS3cfO3FFFZLXcad7PzKvxGeXV7zSLS5nlSGSVkcRHaWG0kc+xAP4Vl6xrN02mX4l8uV9D1nTIrSRxlsOI1Ysf4iQTRRWj0ijWurUNCX4jeINX0fx9p02majc2z3WqfZZtjcPGQBtI9u1aHg62/szxd4hsLWabZAAElZsyctuJz65Jooo+x9xcEuSfz/JE3jHXr3UotekkKQ3Fhr2n6VFPCu12t5GQurHvu3kH2ravND07wvousXGi2y29zdFPNm6uwByBn09qKKzb0SOHBat37o5vR/iRrd1YatcXEdhJImg/ajmDh2VnGG55XHUVZ+J0A+HPw6ttT8JvJZzG5tnMe7dG3m7t4IPb5Rj0oorSyU0kZxbU2lsW9e8QXv2O6sx5QifRPtjkJ8zyHHU+noKwvht4WsNUgN5PJdR3FvALpHil2nefX1HtRRRtF2PRpbM6DXdHsfA+l6tquhwj7VfyJHP5/7xWDHJOPX3pscVsmsWdylnbLdjT7t1nCfOuATgH0zzRRUx1V/wCtjGb3/roefaRr+oeKfCekza3KLi4t7aULKRhnAbcAx7jIFd7pWpT6r8Ir6W8EbPbvDLFhcbGLL0oooq/qeglalTt3X5nsEUjHw95gO1za53Dgj5M1xVzYQ6R8N9dl0svaTTREvJCdrMxAy31560UVzQ3+aPGo7teaOY8B+HNLtviLeWiWqsmnafCyu3LztKPnMp/jPPHpWlpHwv0TT/E4hs7rVYrb7XNcmBbohCzIuQRjp7UUV0czu9TorPmlr2R4r4Nu5fFPjWHS9eIvLLS9ahs7RJB/qomkYFQfwFfRmi+GrDR38QSwedK2qoxuPPk3jCZCqvoAGPFFFVWdhVH7lv63Mux8O6ZdaLrvhe4tlk0i1jZYY25ZCvRgT35PNeWXksngX4YtqvhyR7e4vNaj06RGO6PySGyAvY8DmiiiGt0O/uy9Y/oeu/2fbxeE7G4VT5sKAHPIlVsZV/7wqv8A2FpP/QNtP+/YoorKMmhVpO79X+Z//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Interstitial thick bands of fibrosis separate tumor cells into lobules of varying size, giving the lymphoma a pseudo- carcinomatous appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Warnke RA, Weiss LM, Chan JK, et al. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_45_40663=[""].join("\n");
var outline_f39_45_40663=null;
var title_f39_45_40664="Normal uterine position";
var content_f39_45_40664=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57272%7EOBGYN%2F82473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57272%7EOBGYN%2F82473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 471px\">",
"   <div class=\"ttl\">",
"    Normal gravid uterus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 451px; height: 550px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Incarcerated gravid uterus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 551px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The sacculation originating from the anterior lower segment faces the maternal umbilicus, while the uterine fundus remains in the lower posterior pelvis below the sacral promontory (inverted polarity). Concomitantly, both the bladder and the cervix are pulled into the abdominal cavity, towards the umbilicus. The cervix can be stretched to 10 cm in length or more, with the internal os located above the symphysis pubis and occasionally above the bladder.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_45_40664=[""].join("\n");
var outline_f39_45_40664=null;
var title_f39_45_40665="Efavirenz: Pediatric drug information";
var content_f39_45_40665=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Efavirenz: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"    see \"Efavirenz: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/34/24101?source=see_link\">",
"    see \"Efavirenz: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F164370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Sustiva&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F164371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sustiva&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1052455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiretroviral Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       HIV Agents (Anti-HIV Agents)",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12864278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Not recommended for use; limited pharmacokinetic data demonstrate that target trough concentrations are difficult to achieve (DHHS [pediatric], 2012); additional studies are needed to determine the appropriate dosage.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1052447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"      see \"Efavirenz: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adolescents:",
"     <b>",
"      HIV infection, treatment:  Note:",
"     </b>",
"     Use in combination with other antiretroviral agents; dosage adjustments for concomitant drug administration may be required; see below Dosage adjustment for concomitant drugs:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children &lt;3 years or &lt;10 kg: Not recommended for use; limited pharmacokinetic data demonstrate that target trough concentrations are difficult to achieve in children &lt;3 years of age; additional studies are needed to determine the appropriate dosage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;3 years and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Weight-directed dosing: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     10 kg to &lt;15 kg: 200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     15 kg to &lt;20 kg: 250 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     20 kg to &lt;25 kg: 300 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     25 kg to &lt;32.5 kg: 350 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     32.5 kg to &lt;40 kg: 400 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;40 kg: 600 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     BSA-directed dosing: Oral: 367 mg/",
"     <b>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"     </b>",
"     /dose once daily, maximum dose:  600 mg; recommended by some experts due to concern of underdosing at the upper end of each weight range (DHHS [pediatric], 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      HIV infection, treatment: Note:",
"     </b>",
"     Use in combination with other antiretroviral agents: Oral: 600 mg once daily (DHHS [adult], 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for concomitant rifampin:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pediatric patients weighing &le;50 kg and Adults &le;50 kg: There are no dosage adjustments provided in manufacturer&rsquo;s labeling; however, efavirenz dosage increase may be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pediatric patients weighing &gt;50 kg and Adults &gt;50 kg:  Oral: Increase efavirenz dose to 800 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for concomitant voriconazole:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;3 years and Adolescents: There are no dosage adjustments provided in manufacturer&rsquo;s labeling; however, efavirenz dose reduction and voriconazole dosage increase may be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Reduce efavirenz dose to 300 mg once daily (use capsule formulation) and increase voriconazole dose to 400 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;3 years and Adolescents: There are no dosage adjustments provided in manufacturer&rsquo;s labeling; however, drug undergoes minimal renal excretion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: No adjustments required (Aronoff, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Children &ge;3 years, Adolescents, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild impairment (Child-Pugh class A): No dosage adjustment recommended; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate to severe impairment (Child-Pugh class B or C): Use not recommended (not studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F164344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sustiva&reg;: 50 mg, 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sustiva&reg;: 600 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F164328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11368729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Efavirenz oral solution is available only through an expanded access (compassionate use) program. Enrollment information may be obtained by calling 877-372-7097.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1052459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer dose at bedtime to decrease CNS adverse effects; administer with water on an empty stomach (administration with food may increase efavirenz concentrations and adverse effects). Capsules may be opened and added to small amount of food or liquid, but efavirenz tastes peppery (grape jelly may be used to improve taste). Tablets should not be broken.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1052451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1052458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV-1 infection in combination with other antiretroviral agents (FDA approved in ages &ge;3 years weighing at least 10 kg and adults).",
"     <b>",
"      Note:",
"     </b>",
"     HIV regimens consisting of",
"     <b>",
"      three",
"     </b>",
"     antiretroviral agents are strongly recommended.",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F164405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Abnormal dreams, anxiety, depression, dizziness, fatigue, fever, hallucinations, headache, impaired concentration, insomnia, nervousness, pain, severe depression, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: HDL increased, hyperglycemia, total cholesterol increased, triglycerides increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, amylase increased, anorexia, diarrhea, dyspepsia, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Neutropenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased, AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Allergic reaction, ataxia, body fat accumulation/redistribution, cerebellar coordination disturbances, delusions, dermatitis (photoallergic), erythema multiforme, gynecomastia, hepatic failure, hepatitis, immune reconstitution syndrome, malabsorption, mania, neuropathy, neurosis, palpitations, pancreatitis, paranoia, psychosis, seizures, Stevens-Johnson syndrome, suicide attempts, suicidal ideation, visual abnormalities",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1052462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity (eg, Stevens-Johnson syndrome, erythema multiforme, or toxic skin eruptions) to efavirenz or any component; concurrent therapy with bepridil, cisapride, midazolam, pimozide, triazolam, ergot derivatives, or St John&rsquo;s wort",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1052446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with a history of mental illness; serious psychiatric side effects have been associated with use including aggressive behavior, severe depression, suicidal ideation, suicide, paranoia, and mania. Use with caution in patients with a history of substance abuse due to a predisposition to psychological reactions. Patients should be instructed to contact healthcare provider if serious psychiatric effects occur. Use with caution in patients with a history of seizures; convulsions may occur; efavirenz may decrease the serum concentrations of antiepileptic agents that are metabolized by the liver; monitor anticonvulsant serum concentrations periodically.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Efavirenz may cause a rash, which usually presents as pruritic maculopapular skin eruptions; incidence is more common and more severe in children than in adults [incidence: Adults 26%, children 46%; median onset: Adults: 11 days, children: 9 days (range: 6-205 days)]. Most rashes in children appeared within 14 days after starting therapy [median duration: Adults: 16 days, children: 6 days (range: 2-37 days)]. Median duration of rash in children who continued therapy was 9 days; rash may be treated with antihistamines and corticosteroids and usually resolves within 1 month while continuing therapy. Discontinue efavirenz if severe rash (involving blistering, desquamation, mucosal involvement, ulceration, or fever) occurs.",
"     <b>",
"      Consider prophylaxis with antihistamines in children due to frequency and severity of rash reported in children.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with known or suspected hepatitis B or C, those receiving other hepatotoxic medications, and those with mild hepatic impairment; weigh risk versus benefit in patients with persistent elevations of serum transaminases (ie, &gt;5 times normal); not recommended in moderate to severe hepatic impairment. Cross resistance with other non-nucleoside reverse transcriptase inhibitors may occur. Elevations of serum cholesterol and triglyceride concentrations may occur; monitor during therapy. Fat redistribution and accumulation [ie, central obesity, peripheral wasting, facial wasting, breast enlargement, dorsocervical fat enlargement (buffalo hump), and cushingoid appearance] have been observed in patients receiving antiretroviral agents (causal relationship not established). May cause diarrhea or loose stools; reported incidence in children is 39%. Cough may occur; reported incidence in children is 16%.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Immune reconstitution syndrome (an acute inflammatory response to residual or indolent opportunistic infections) may occur in HIV patients during initial treatment with combination antiretroviral agents; this syndrome may require further patient assessment and therapy.  Autoimmune disorders (eg, Grave&rsquo;s disease, Guillain-Barr&eacute; syndrome, and polymyositis) have been reported in patients experiencing immune reconstitution; time to onset is variable and may occur many months after antiretroviral treatment is initiated.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1052445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Efavirenz is a mixed inducer/inhibitor of CYP450 enzymes and numerous drug interactions occur. Due to potential serious and/or life-threatening drug interactions, certain drugs are contraindicated. Other drug interactions require dosage adjustment; standard doses of efavirenz and voriconazole must",
"     <b>",
"      not",
"     </b>",
"     be coadministered; however,",
"     <b>",
"      adjusted",
"     </b>",
"     doses may be administered concurrently.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Resistance emerges rapidly if administered as monotherapy; always use efavirenz in combination with at least two other antiretroviral agents; do not add efavirenz as a single agent to antiretroviral regimens that are failing; initiate in combination with at least one other antiretroviral agent to which the patient is naive. Do not administer efavirenz with other efavirenz-containing products (eg, Atripla&reg;), unless needed for dosage adjustment with concomitant rifampin treatment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Efavirenz may cause CNS effects (eg, abnormal dreams, insomnia, impaired concentration, hallucinations, dizziness, or drowsiness). The overall reported incidence of CNS adverse effects was 53% vs 25% in controls; nervous system symptoms in children were reported to be 18%. Fever has been reported with use (children: 21%). CNS symptoms usually begin within 1-2 days after starting efavirenz, and generally resolve within 2-4 weeks of continued therapy. Patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Tolerability of CNS effects may be improved by dosing at bedtime. CNS effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Teratogenic effects have been observed in primates receiving efavirenz; human birth defects following efavirenz exposure in the first trimester have been reported, including cases of neural tube defects (including meningomyelocele and Dandy-Walker malformation) and one case of anophthalmia. Women of childbearing potential should be tested for pregnancy before starting efavirenz; women receiving efavirenz should avoid pregnancy while receiving this drug and for 12 weeks after discontinuation of this drug (due to long half-life of efavirenz); barrier contraception in combination with other (hormonal) methods of contraception should be used. Avoid use of efavirenz during the first trimester of pregnancy and in women with significant childbearing potential; women who use this drug during the first trimester or who become pregnant while taking this drug should be apprised of the potential harm to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F164394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2B6 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (moderate), CYP2C9 (moderate), CYP3A4 (moderate);",
"     <b>",
"      Induces",
"     </b>",
"     CYP2B6 (weak/moderate), CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F164337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Efavirenz may decrease the serum concentration of Atazanavir.  Management: When used with efavirenz, the atazanavir regimen should be atazanavir 400 mg/ritonavir 100 mg daily for treatment-naive patients; treatment-experienced patients should not use atazanavir together with efavirenz.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Efavirenz may decrease the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atovaquone: Efavirenz may decrease the serum concentration of Atovaquone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bepridil [Off Market]: Efavirenz may enhance the arrhythmogenic effect of Bepridil [Off Market].",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Efavirenz. Efavirenz may decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: Efavirenz may decrease serum concentrations of the active metabolite(s) of Buprenorphine. Efavirenz may decrease the serum concentration of Buprenorphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: Efavirenz may decrease the serum concentration of BuPROPion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of CarBAMazepine. This mechanism applies specifically to efavirenz.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caspofungin: Inducers of Drug Clearance may decrease the serum concentration of Caspofungin.  Management: Consider using an increased caspofungin dose of 70 mg daily in adults (or 70 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     , up to a maximum of 70 mg, daily in pediatric patients) when coadministered with known inducers of drug clearance.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Efavirenz may enhance the QTc-prolonging effect of Cisapride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Citalopram: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Citalopram.  Management: Limit citalopram dose to a maximum of 20 mg/day if used with a moderate CYP2C19 inhibitor.  Patients using this combination should be monitored closely for evidence of citalopram toxicity (e.g., serotonin syndrome, QT prolongation, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Efavirenz may decrease the serum concentration of CycloSPORINE (Systemic).  Management: Increase monitoring of cyclosporine concentrations when starting, stopping, or adjusting doses of concurrent efavirenz, particularly within the first 2 weeks.  Cyclosporine dose adjustment may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inducers (Strong): May increase the metabolism of CYP2B6 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Moderate): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Strong): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Moderate) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of Efavirenz. Efavirenz may decrease the serum concentration of Darunavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dienogest.  Management: Avoid use of dienogest for contraception when using medications that induce CYP3A4 and for at least 28 days after discontinuation of a CYP3A4 inducer.  An alternative form of contraception should be used during this time.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dihydroergotamine: Efavirenz may increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations may vary depending on international labeling. Consult appropriate labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergoloid Mesylates: Efavirenz may increase the serum concentration of Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergonovine: Efavirenz may increase the serum concentration of Ergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergotamine: Efavirenz may increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etonogestrel: Efavirenz may diminish the therapeutic effect of Etonogestrel.  Management: Use a reliable barrier contraceptive if efavirenz is used in combination with etonogestrel.  Continue using barrier contraception for 12 weeks after discontinuation of efavirenz.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Etravirine. This has been observed with the NNRTIs efavirenz and nevirapine. Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Etravirine. This has been observed with delavirdine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: Efavirenz may decrease the serum concentration of Everolimus.  Management: Closely monitor everolimus serum concentrations when starting, stopping, or changing doses of efavirenz, particularly during the first 2 weeks after any change.  Dose adjustment of everolimus may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: Efavirenz may decrease serum concentrations of the active metabolite(s) of Fosamprenavir.  Management: For once-daily fosamprenavir/ritonavir with efavirenz, an increased ritonavir dose to 300 mg/day is recommended.  No ritonavir dose adjustment is required if using twice-daily fosamprenavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Efavirenz may increase the serum concentration of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Efavirenz.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse drug reactions, consider increasing gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers.  Carefully monitor clinical response and development of adverse reactions.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Consider increasing the guanfacine dose by 2-fold when adding a strong CYP3A4 inducer.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with strong CYP3A4 inducers when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: Efavirenz may decrease the serum concentration of Indinavir.  Management: The appropriate dose adjustments for indinavir when used together with efavirenz are unknown. The use of higher unboosted indinavir doses is not likely an adequate approach.  Use of a ritonavir-boosted indinavir regimen could be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Efavirenz may decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine.  Management: In patients with a resting heart rate over 60 beats per minute receiving a moderate CYP3A4 inhibitor, ivabradine initiation at an adult dose of 2.5 mg twice daily may be considered.  Monitor heart rate closely under these circumstances.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: Efavirenz may decrease the serum concentration of Lopinavir.  Management: Avoid once daily use of lopinavir/ritonavir with efavirenz.  Avoid use of this combination in patients less than 6 months of age.  See lopinavir/ritonavir prescribing information for specific recommended dose increases in particular patient populations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: Efavirenz may decrease the serum concentration of Lovastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the metabolism of Methadone.  Management: Methadone dosage adjustments will likely be required with efavirenz and nevirapine, and may be necessary with rilpivirine as well.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylergonovine: Efavirenz may increase the serum concentration of Methylergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midazolam: Efavirenz may increase the serum concentration of Midazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of Efavirenz. Management: Use efavirenz with caution, and monitor for increased adverse effects, during and 2 weeks following discontinuation of mifepristone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: Efavirenz may enhance the adverse/toxic effect of Nevirapine. Nevirapine may enhance the adverse/toxic effect of Efavirenz. Nevirapine may decrease the serum concentration of Efavirenz.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NIFEdipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.  Management: Consider alternatives to nifedipine for patients who are using strong CYP3A4 inducers.  At least one specific brand of nifedipine (Adalat CC) lists this combination as contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Norgestimate: Efavirenz may decrease serum concentrations of the active metabolite(s) of Norgestimate.  Management: Use a reliable barrier contraceptive if efavirenz is used in combination with norgestimate.  Continue using barrier contraception for 12 weeks after discontinuation of efavirenz.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PACLitaxel: Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the metabolism of PACLitaxel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Perampanel.  Management: Avoid use of perampanel with strong CYP3A inducers other than enzyme-inducing antiepileptic drugs (EIAEDs).  Increase perampanel starting dose to 4 mg/day when used with EIAEDs such as phenytoin, carbamazepine, or oxcarbazepine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Efavirenz may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Efavirenz.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Efavirenz may enhance the arrhythmogenic effect of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: Efavirenz may decrease the serum concentration of Posaconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pravastatin: Efavirenz may decrease the serum concentration of Pravastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proguanil: Efavirenz may decrease the serum concentration of Proguanil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quazepam: May increase the serum concentration of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltegravir: Efavirenz may decrease the serum concentration of Raltegravir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifabutin: Efavirenz may decrease the serum concentration of Rifabutin. Rifabutin may decrease the serum concentration of Efavirenz.  Management: If efavirenz is to be used with daily rifabutin, increase the planned rifabutin adult dose by 50%.  If used with regimens where rifabutin is administered 2-3 times per week, consider doubling the rifabutin dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Efavirenz. Management: Increase efavirenz adult dose to 800 mg daily in patients weighing over 50 kg (per U.S. manufacturer; CDC sets this at 60 kg, and Canadian manufacturer recommends the dose increase regardless of weight).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Rilpivirine. This mechanism applies to coadministration of delavirdine. Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Rilpivirine. This mechanism applies to coadministration of efavirenz, etravirine, and nevirapine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: Efavirenz may enhance the adverse/toxic effect of Ritonavir. Efavirenz may increase the serum concentration of Ritonavir. Ritonavir may increase the serum concentration of Efavirenz.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining strong CYP3A4 inducers with roflumilast.  The Canadian product monograph makes no such recommendation but notes that such agents may reduce roflumilast therapeutic effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: May enhance the adverse/toxic effect of Efavirenz. Efavirenz may decrease the serum concentration of Saquinavir. Management: When used together with efavirenz, saquinavir should not be used as the sole protease inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sertraline: Efavirenz may decrease the serum concentration of Sertraline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Efavirenz may decrease the serum concentration of Simvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Efavirenz may decrease the serum concentration of Sirolimus.  Management: Closely monitor sirolimus serum concentrations when starting, stopping, or changing doses of efavirenz, particularly during the first 2 weeks after any change.  Dose adjustment of sirolimus may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Efavirenz.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Efavirenz may decrease the serum concentration of Tacrolimus (Systemic).  Management: Closely monitor tacrolimus serum concentrations when starting, stopping, or changing doses of efavirenz, particularly during the first 2 weeks after any change.  Dose adjustment of tacrolimus may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction: monitor for decreased effectiveness - no standard dose adjustments recommended.  Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Efavirenz may decrease the serum concentration of Telaprevir. Telaprevir may decrease the serum concentration of Efavirenz.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Triazolam: Efavirenz may increase the serum concentration of Triazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Efavirenz may increase the serum concentration of Vitamin K Antagonists. Efavirenz may decrease the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Voriconazole. Management: Consider avoiding when possible. Use efavirenz with voriconazole only if voriconazole is dosed at 400 mg every 12 hours and efavirenz is dosed at 300 mg daily (adult doses) throughout therapy. Avoid Atripla (efavirenz/emtricitabine/tenofovir).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1052465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsules: Compared to fasting conditions, high fat/high caloric meals increase efavirenz AUC by 22% and peak concentrations by 39%; reduced fat/normal caloric meals increase efavirenz AUC by 17% and peak concentrations by 51%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablets: Compared to fasting conditions, high fat/high caloric meals increase efavirenz AUC by 28% and peak concentrations by 79%",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F164340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F164354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in primates receiving efavirenz. Efavirenz crosses the placenta. Based on data from the Antiretroviral Pregnancy Registry, an increased risk of overall birth defects has not been observed following first trimester exposure to efavirenz; however, neural tube and other CNS defects have been reported. Due to the low number of first trimester exposures and the low incidence of neural tube defects in the general population, available data are insufficient to evaluate risk. Other antiretroviral agents should strongly be considered for use in women of childbearing potential who are planning to become pregnant or who are sexually active and not using effective contraception. Nonpregnant women of reproductive age should undergo pregnancy testing prior to initiation of efavirenz. Barrier contraception should be used in combination with other (hormonal) methods of contraception during therapy and for 12 weeks after efavirenz is discontinued. Neural tube defects would occur following exposure during the first 5-6 weeks of gestation (most pregnancies are not detected before 4-6 weeks gestation). For women who present in the first trimester already on an efavirenz-containing regimen and who have adequate viral suppression, efavirenz may be continued; changing regimens may lead to loss of viral control and increase the risk of perinatal transmission. Pharmacokinetic data from available studies do not suggest dose alterations are needed during pregnancy. Hypersensitivity reactions (including hepatic toxicity and rash) are more common in women on NNRTI therapy; it is not known if pregnancy increases this risk",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum antiretroviral (ARV) drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health. Although earlier initiation may be more effective in reducing the perinatal transmission of HIV), also consider maternal conditions (eg, nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1052454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Monitor CD4 percentage (if &lt;5 years of age) or CD4 count (if &ge;5 years of age) at least every 3-4 months (DHHS [pediatric], 2012).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Prior to initiation of therapy: Genotypic resistance testing, CD4, viral load, CBC with differential, LFTs, BUN, creatinine. At initiation and with any change in treatment regimen: CBC with differential, electrolytes, calcium, phosphate, glucose, LFTs, bilirubin, BUN, creatinine, albumin, total protein, lipid panel, CD4, and viral load. After 4-8 weeks of therapy: CBC with differential, viral load; then every 3-4 months: CBC with differential, electrolytes, glucose, LFTs, bilirubin, BUN, creatinine, CD4, and viral load. Albumin, total protein, calcium, phosphate,  lipid panel, and urinalysis every 6-12 months (DHHS [pediatric], 2012). Also monitor for signs of opportunistic infections, signs and symptoms of rash, serum amylase, and CNS and psychiatric effects.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1052444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A non-nucleoside reverse transcriptase inhibitor which specifically binds to HIV-1 reverse transcriptase and blocks RNA-dependent and DNA-dependent DNA polymerase activity including HIV-1 replication; does not require intracellular phosphorylation for antiviral activity",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1052461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Pharmacokinetics in children &ge;3 years of age are similar to adults",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Increased by fatty meals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: CSF concentrations are 0.69% of plasma (range: 0.26% to 1.2%); however, CSF:plasma concentration ratio is 3 times higher than free fraction in plasma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99.5% to 99.8%, primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4 and CYP2B6 to hydroxylated metabolites which then undergo glucuronidation; induces P450 enzymes and its own metabolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 42%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Single dose: 52-76 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Multiple doses: 40-55 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 3-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: &lt;1% excreted unchanged in the urine; 14% to 34% excreted as metabolites in the urine and 16% to 61% in feces (primarily as unchanged drug)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1052453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/34/24101?source=see_link\">",
"      see \"Efavirenz: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take efavirenz on an empty stomach at bedtime. May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. Avoid alcohol. Efavirenz is not a cure for HIV. Notify physician immediately if rash develops. Some medicines should not be taken with efavirenz; report the use of other medications, including nonprescription medications and herbal or natural products to the physician and pharmacist; avoid the herbal medicine St John's wort. Inform physician of any history of seizures or  if taking seizure medications (blood samples to check the level of seizure medications may be needed more frequently when taking efavirenz). Take efavirenz everyday as prescribed; do not change dose or discontinue without physician's advice; if a dose is missed, take it as soon as possible, then return to normal dosing schedule; if a dose is skipped, do",
"     <b>",
"      not",
"     </b>",
"     double the next dose. Do not take Sustiva&reg; with other efavirenz-containing medications (eg, Atripla&reg;) unless directed to by prescriber for specific clinical situations.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     HIV medications may cause changes in body fat, including an increase in fat in the upper back and neck, breasts, and trunk; a loss of fat from the face, arms, and legs may also occur. Due to possible teratogenic effects, female patients of childbearing potential should be tested for pregnancy prior to starting efavirenz and should avoid pregnancy while receiving this drug and for 12 weeks after discontinuation of this drug; barrier contraception with other (hormonal) methods of contraception should be used.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1052463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An oral liquid formulation of efavirenz (strawberry/mint-flavored solution) is available on an investigational basis from Bristol-Myers Squibb Company as part of an expanded access program for HIV-infected children and adolescents 3-16 years of age; for further details call 877-372-7097.",
"     <b>",
"      Note:",
"     </b>",
"     The bioavailability of the investigational liquid was found to be 20% lower than that of the capsules in adult volunteers; a recent pediatric study used initial doses of the liquid formulation that were 20% higher than pediatric capsule doses; these higher doses resulted in AUC values that were similar to AUCs achieved with the capsules (Starr, 2002).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Early virologic failure and rapid emergence of resistant mutations have been observed in therapy-naive adult HIV patients treated with tenofovir, didanosine enteric-coated beadlets (Videx&reg; EC), and either efavirenz or nevirapine; the combination of tenofovir, didanosine, and any non-nucleoside reverse transcriptase inhibitor is",
"     <b>",
"      not",
"     </b>",
"     recommended as initial antiretroviral therapy.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aberg JA, Kaplan JE, Libman H, et al, \"Primary Care Guidelines for the Management of Persons Infected With Human Immunodeficiency Virus: 2009 Update by the HIV Medicine Association of the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 49(5):651-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/45/40665/abstract-text/19640227/pubmed\" id=\"19640227\" target=\"_blank\">",
"        19640227",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Adkins JC and Noble S, &ldquo;Efavirenz,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1998, 56(6):1055-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/45/40665/abstract-text/9878993/pubmed\" id=\"9878993\" target=\"_blank\">",
"        9878993",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, 77.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, \"Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents,\" February 12, 2013. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children, \"Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,\" November 5,  2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov\" target=\"_blank\">",
"       file://aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, &ldquo;Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,&rdquo; July 31, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov\" target=\"_blank\">",
"       file://aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maddocks S and Dwyer D, &ldquo;The Role of Non-Nucleoside Reverse Transcriptase Inhibitors in Children With HIV-1 Infection,&rdquo;",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2001, 3(9):681-702.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/45/40665/abstract-text/11688599/pubmed\" id=\"11688599\" target=\"_blank\">",
"        11688599",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Piscitelli SC, Burstein AH, Chaitt D, et al, &ldquo;Indinavir Concentrations and St John's Wort,&rdquo;",
"      <i>",
"       Lancet,",
"      </i>",
"      2000, 355(9203):547-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/45/40665/abstract-text/10683007/pubmed\" id=\"10683007\" target=\"_blank\">",
"        10683007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Starr SE, Fletcher CV, Spector SA, et al, &ldquo;Combination Therapy With Efavirenz, Nelfinavir, and Nucleoside Reverse-transcriptase Inhibitors in Children Infected with Human Immunodeficiency Virus Type 1. Pediatric AIDS Clinical Trials Group 382 Team,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 341(25):1874-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/45/40665/abstract-text/10601506/pubmed\" id=\"10601506\" target=\"_blank\">",
"        10601506",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Starr SE, Fletcher CV, Spector SA, et al, \"Efavirenz Liquid Formulation in Human Immunodeficiency Virus-Infected Children,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2002, 21(7):659-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/45/40665/abstract-text/12237599/pubmed\" id=\"12237599\" target=\"_blank\">",
"        12237599",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13267 Version 51.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.81.197.98-F7DA7CD4CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_45_40665=[""].join("\n");
var outline_f39_45_40665=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164370\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164371\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052455\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12864278\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052447\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164344\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164328\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11368729\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052459\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052451\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052458\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164405\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052462\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052446\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052445\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164394\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164337\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052465\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164340\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164354\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052454\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052444\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052461\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052453\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052463\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13267\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13267|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=related_link\">",
"      Efavirenz: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/34/24101?source=related_link\">",
"      Efavirenz: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_45_40666="Perioperative medication management";
var content_f39_45_40666=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Perioperative medication management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/45/40666/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/45/40666/contributors\">",
"     Visala Muluk, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/45/40666/contributors\">",
"     David S Macpherson, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/45/40666/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/45/40666/contributors\">",
"     Mark D Aronson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/45/40666/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/45/40666/contributors\">",
"     H Nancy Sokol, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/45/40666/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least 50 percent of patients undergoing surgery take medications on a regular basis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/1\">",
"     1",
"    </a>",
"    ]. Clinicians often must decide if chronic medications should be continued in the perioperative period. Unfortunately, there are few outcome data about the majority of medications taken in the perioperative period.",
"   </p>",
"   <p>",
"    This lack of medical evidence is reflected by the large variation in perioperative management recommendations among anesthesiologists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/2\">",
"     2",
"    </a>",
"    ]. The recommendations in this review are to a large degree expert opinion, based on information from other reviews [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/3,4\">",
"     3,4",
"    </a>",
"    ] and textbooks, along with clinical experience and theoretic considerations.",
"   </p>",
"   <p>",
"    This topic will focus on medications known to have perioperative effects, those known to interact with anesthetic agents, and those in common use will be discussed. An overview of preoperative patient assessment and details about perioperative management for specific medications are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41735?source=see_link\">",
"     \"Overview of the principles of medical consultation and perioperative medicine\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/17/33046?source=see_link\">",
"     \"Perioperative management of hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/50/35626?source=see_link\">",
"     \"Management of anticoagulation before and after elective surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17384?source=see_link\">",
"     \"The surgical patient taking glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRINCIPLES OF MEDICATION MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following principles inform the management of chronic medications in the perioperative period:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A complete medication history should be obtained, and all clinicians involved in patient management (eg, surgeon, anesthesiologist, medical consultants) should review the medication history. Medication use reported by the patient should be verified (medication reconciliation) to address accuracy of drugs and doses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/5\">",
"       5",
"      </a>",
"      ]. This should include all over-the-counter and",
"      <span class=\"nowrap\">",
"       herbal/complementary",
"      </span>",
"      medications, as well as prescription drugs. In addition, substance use information (including alcohol, nicotine, and illicit drugs) should be elicited.",
"     </li>",
"     <li>",
"      Medications associated with known medical morbidity if withdrawn abruptly should be continued in the perioperative period, or tapered if feasible. Intravenous, transdermal, or transmucosal medicines should be substituted when absorption will be impaired because of loss of gastrointestinal function or restrictions on oral intake. Medications thought to increase the risk of anesthetic or surgical complications and not essential for the short-term should be held through the perioperative period [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Medications not meeting either of the above principles can be discontinued or continued based upon clinician judgment.",
"     </li>",
"     <li>",
"      The many medications administered perioperatively during a relatively short period increase the potential for drug-drug interactions.",
"     </li>",
"     <li>",
"      The metabolism and elimination of medications and their metabolites may be altered during the perioperative period. In particular, gastrointestinal absorption of oral medications may be impaired due to changes in splanchnic blood flow and edema [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CARDIOVASCULAR MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef62659 \" href=\"mobipreview.htm?42/50/43820\">",
"     table 1",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    For elective surgery, preoperative planning and care should be optimized to reduce risk and minimize the need for acute changes in medication management perioperatively. For example, we suggest control of clinical signs of heart failure (HF) for one week or longer preoperatively if time permits. If surgery is required in a patient with decompensated HF, invasive monitoring may be helpful to guide medication management. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/0/18440?source=see_link&amp;anchor=H15#H15\">",
"     \"Perioperative heart failure in noncardiac surgery\", section on 'Optimization of HF control'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/0/18440?source=see_link&amp;anchor=H16#H16\">",
"     \"Perioperative heart failure in noncardiac surgery\", section on 'Invasive perioperative monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Beta blockers",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Benefit/risk",
"       </strong>",
"      </span>",
"      &mdash; Beta blockers have a number of potential beneficial effects when taken perioperatively. Beta blockers reduce ischemia by decreasing myocardial oxygen demand due to increased catecholamine release in the perioperative period, and may help prevent or control arrhythmias. Patients who take beta-blockers chronically for management of angina are at risk of ischemia with withdrawal of beta blockade. Acute withdrawal of a beta blocker pre- or postoperatively can lead to substantial morbidity and even mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/7\">",
"       7",
"      </a>",
"      ]. Withdrawal issues are of less concern when beta blockers are used for hypertension or migraine prophylaxis.",
"      <br/>",
"      <br/>",
"      Whether to initiate beta blockers as prophylaxis for ischemia in the perioperative period in patients at increased risk for coronary disease, is complex and discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29402?source=see_link&amp;anchor=H17#H17\">",
"       \"Management of cardiac risk for noncardiac surgery\", section on 'Role of beta blockers'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Potential adverse effects of perioperative beta blockade include bradycardia and hypotension. Nonselective beta blockers can interact with epinephrine, used for infiltration anesthesia or management of intraoperative anaphylaxis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29402?source=see_link\">",
"       \"Management of cardiac risk for noncardiac surgery\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3704?source=see_link&amp;anchor=H5#H5\">",
"       \"Major side effects of beta blockers\", section on 'Beta blocker withdrawal'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Continue/discontinue",
"       </strong>",
"      </span>",
"      &mdash; In light of the potential benefits of perioperative beta blockade, minimal adverse effects, and consequences of acute withdrawal, we recommend that beta blockers be continued in the perioperative period and continued throughout the hospital stay. Since adequate beta blockade can take weeks to achieve safely in patients with systolic heart failure, we prefer initiation of beta blockade in the preoperative period only if acute decompensated heart failure is not present and surgery can be substantially delayed. If surgery is urgent, we prefer postponing beta blockade until a later date. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/0/18440?source=see_link&amp;anchor=H12#H12\">",
"       \"Perioperative heart failure in noncardiac surgery\", section on 'Beta blockers'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Formulations/alternatives",
"       </strong>",
"      </span>",
"      &mdash; Intravenous forms of beta blockade, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35544?source=see_link\">",
"       labetalol",
"      </a>",
"      should be given if the patient cannot take oral medications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]. We have a slight preference for beta 1 cardioselective beta blockers (eg, metoprolol) since they are less likely to cause adverse pulmonary and peripheral vascular effects; however, patients who are taking a nonselective beta blocker (eg, propranolol) chronically do not need to switch to a beta 1 selective agent perioperatively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Alpha 2 agonists",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Benefit/risk",
"       </strong>",
"      </span>",
"      &mdash; Administration of centrally acting sympatholytic drugs such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      may possibly improve perioperative outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/11-13\">",
"       11-13",
"      </a>",
"      ]. Abrupt withdrawal of clonidine can precipitate rebound hypertension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/14-16\">",
"       14-16",
"      </a>",
"      ], which usually occurs after abrupt cessation of fairly large oral doses (eg, greater than 0.8",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      but has also been noted with transdermal clonidine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/17\">",
"       17",
"      </a>",
"      ]. Withdrawal symptoms have also been reported with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/15/28918?source=see_link\">",
"       methyldopa",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/17/32023?source=see_link\">",
"       guanfacine",
"      </a>",
"      withdrawal but are less likely because of their slower onset of action [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/50/1827?source=see_link\">",
"       \"Withdrawal syndromes with antihypertensive therapy\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Other potential benefits of continuing alpha 2 agonists perioperatively include [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Decrease in the stress response to endotracheal intubation and surgery.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Sedative/anxiolytic,",
"      </span>",
"      analgesic, and antishivering properties [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/19,20\">",
"       19,20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Continue/discontinue",
"       </strong>",
"      </span>",
"      &mdash; Given the potential benefits of continuing alpha 2 agonists perioperatively and the possible negative consequences of withdrawal, we recommend that these drugs be continued in the perioperative period.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Formulations/alternatives",
"       </strong>",
"      </span>",
"      &mdash; Transdermal",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      is available for patients who likely will not be able to resume oral medications by 12 hours after surgery. The decision to substitute this form of therapy must be made before surgery; an equivalent dose of the transdermal preparation should be started three days prior to surgery while the oral clonidine is tapered. The persistent effect of transdermal clonidine for 24 to 48 hours after patch removal should be considered when transitioning back to the oral form.",
"      <br/>",
"      <br/>",
"      Other centrally acting sympatholytic agents (eg",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/15/28918?source=see_link\">",
"       methyldopa",
"      </a>",
"      or guanabenz) are rarely used today. Withdrawal from abrupt discontinuation has been reported but is less common because of their slower onset of action [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. For patients unable to take oral medications perioperatively, we recommend withholding methyldopa and guanabenz and using other parenteral hypertensive agents if hypertension becomes a problem [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/14\">",
"       14",
"      </a>",
"      ]. An intravenous form of methyldopa is available in the rare cases in which abrupt stoppage appears to be leading to a withdrawal syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Calcium channel blockers",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Benefit/risk",
"       </strong>",
"      </span>",
"      &mdash; Data are limited regarding the risks and benefits of calcium channel blockers in the perioperative setting. Small trials have shown a more stable intraoperative hemodynamic profile in patients treated with continuous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      , compared to placebo, during coronary bypass surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/23\">",
"       23",
"      </a>",
"      ], but these studies are not large enough to demonstrate improved outcomes. A meta-analysis found that use of calcium channel blockers was associated with reduced ischemia and atrial arrhythmia in patients undergoing noncardiac surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/24\">",
"       24",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      There are no serious interactions between calcium channel blockers and anesthetic agents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/25\">",
"       25",
"      </a>",
"      ]. A withdrawal syndrome is not typical of calcium channel blockers, although abrupt discontinuation of these drugs has been reported to cause severe vasospasm in patients undergoing coronary revascularization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/26\">",
"       26",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Concerns have been raised about a possible association between calcium channel blockers and an increased risk of bleeding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/27\">",
"       27",
"      </a>",
"      ]. A randomized trial in valvular surgery patients found that, compared with placebo, patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/20/16710?source=see_link\">",
"       nimodipine",
"      </a>",
"      had increased bleeding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. Reports conflict on whether there is a greater incidence of anemia in patients receiving calcium channel blockers after hip surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. Two large trials in cardiac surgery patients did not find any association between bleeding risk and use of calcium channel blockers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Continue/discontinue",
"       </strong>",
"      </span>",
"      &mdash; Despite little data regarding calcium channel blockers during the perioperative period, these agents appear safe and have theoretic benefit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/33\">",
"       33",
"      </a>",
"      ]; data regarding bleeding risk are contradictory. Thus, we recommend that calcium channel blockers be continued in patients who are already taking them preoperatively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Formulations/alternatives",
"       </strong>",
"      </span>",
"      &mdash; Intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      is available for patients who are unable to tolerate oral agents, although we recommend using intravenous beta blockers rather than calcium channel blockers in the perioperative period as these are more proven to prevent myocardial ischemia. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Beta blockers'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29402?source=see_link\">",
"       \"Management of cardiac risk for noncardiac surgery\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Most calcium channel blockers are formulated as extended release and should not be crushed for administration in enteral tubes. Short acting calcium channel blockers are available (diltiazem,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      ) and can be substituted with appropriate dosing interval adjustments. &nbsp;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"       Amlodipine",
"      </a>",
"      has a long washout period, and short acting substitutes may not be necessary.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     ACE inhibitors and angiotensin II receptor blockers",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Benefit/risk",
"       </strong>",
"      </span>",
"      &mdash; The management of patients taking angiotensin converting enzyme (ACE) inhibitors preoperatively is controversial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/34\">",
"       34",
"      </a>",
"      ]. ACE inhibitors and angiotensin II receptor blockers can theoretically blunt the compensatory activation of the renin-angiotensin system during surgery and result in prolonged hypotension. At least two clinical trials have investigated this issue:",
"      <br/>",
"      <br/>",
"      In one study, 51 patients undergoing peripheral artery surgery were randomly assigned to ACE inhibitor continuation or withdrawal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/35\">",
"       35",
"      </a>",
"      ]. Patients continuing ACE inhibitors through the morning of surgery had significantly more episodes of hypotension requiring treatment with pressor agents compared with patients who stopped therapy at least 12 hours (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"       captopril",
"      </a>",
"      ) or 24 hours (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/19/8505?source=see_link\">",
"       enalapril",
"      </a>",
"      ) before surgery. No difference was noted in the incidence of hypertensive episodes.",
"      <br/>",
"      <br/>",
"      A second study randomly assigned 40 patients with good left ventricular function who were undergoing coronary artery bypass graft surgery to continue or omit ACE inhibitors before surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/36\">",
"       36",
"      </a>",
"      ]. Patients who omitted their ACE inhibitors required less vasopressors during surgery but required more vasodilators to control hypertension in the early postoperative period.",
"      <br/>",
"      <br/>",
"      Angiotensin II receptor blockers (ARBs) have similar physiologic effects as ACE inhibitors on hypertension and renal perfusion. It is not surprising then that a study in vascular surgery patients found a statistically significant increase in the number of hypotensive episodes in patients treated with ARBs prior to surgery compared with those treated with beta blockers or calcium channel blockers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/37\">",
"       37",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A retrospective review of 267 hypertensive patients undergoing surgery in a general hospital found that taking either an ACE inhibitor or ARB within 10 hours of surgery, compared to holding medication for at least 10 hours, increased the odds of moderate postinduction hypotension (OR 1.74) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/38\">",
"       38",
"      </a>",
"      ]. However, there was no increase in severe hypotension or need for vasopressors.",
"      <br/>",
"      <br/>",
"      Nonrandomized studies suggest a possible myocardial protective effect of ACE inhibitors in patients undergoing coronary artery bypass graft surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/39\">",
"       39",
"      </a>",
"      ]. However, reports conflict on the effect of ACE inhibitors on the risk of acute kidney injury in these patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/40,41\">",
"       40,41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Continue/discontinue",
"       </strong>",
"      </span>",
"      &mdash; These findings suggest that continuing ACE inhibitors up to the time of surgery increases perioperative hypotension, but possibly reduces the incidence of postoperative hypertension. While the data do not lead to clear recommendations, in general we recommend continuing ACE inhibitors or ARBs in patients who are taking them for the management of hypertension or heart failure. Substitution of shorter acting drugs (eg",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"       captopril",
"      </a>",
"      for patients who can take ACE inhibitors) may allow more flexibility for patients with postoperative labile blood pressure. On the other hand, it is reasonable to withhold these drugs one dose interval (or reduce the dose) before surgery in patients who are taking them for acute decompensated heart failure, particularly if the baseline blood pressure is low, to avoid significant hypotension during anesthesia induction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/4\">",
"       4",
"      </a>",
"      ]. It is also reasonable to withhold these drugs for surgery where substantial fluid shifts or bleeding are anticipated. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/0/18440?source=see_link&amp;anchor=H11#H11\">",
"       \"Perioperative heart failure in noncardiac surgery\", section on 'ACE inhibitors and diuretics'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Based upon limited data, we recommend resuming ACE inhibitors or ARBs postoperatively as long as the patient is not hypotensive and has normal renal function.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Formulations/",
"       </strong>",
"      </span>",
"      alternatives",
"      &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/19/8505?source=see_link\">",
"       Enalapril",
"      </a>",
"      (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/22/20839?source=see_link\">",
"       Enalaprilat",
"      </a>",
"      ) is available for short-term intermittent intravenous administration, although used infrequently.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Diuretics",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Benefit/risk",
"       </strong>",
"      </span>",
"      &mdash; The two major physiologic effects of loop and thiazide-type diuretics of concern are hypokalemia and hypovolemia. Hypokalemia can theoretically increase the risk of perioperative arrhythmia, although observational studies of patients with structural heart disease have failed to find such a relationship [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/42,43\">",
"       42,43",
"      </a>",
"      ]. Additionally, hypokalemia might potentiate the effects of muscle relaxants used during anesthesia, as well as provoke paralytic ileus.",
"      <br/>",
"      <br/>",
"      Systemic vasodilatation induced by anesthetic agents may cause hypotension in patients who are intravascularly depleted from diuretics.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Continue/discontinue",
"       </strong>",
"      </span>",
"      &mdash; There is no consensus whether diuretics should be discontinued prior to elective surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/2\">",
"       2",
"      </a>",
"      ]. Since diuretics may increase the risk of hypotension if continued on the morning of surgery, and a quick diuresis can be initiated by intravenous administration should the need be discovered during surgery, in general we recommend they be held on the morning of surgery, and resumed when the patient is taking oral fluids.",
"      <br/>",
"      <br/>",
"      In patients receiving diuretic therapy to treat heart failure, diuretic use and volume administration perioperatively is based upon assessment of volume status, which should be optimized preoperatively whenever possible. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/0/18440?source=see_link&amp;anchor=H11#H11\">",
"       \"Perioperative heart failure in noncardiac surgery\", section on 'ACE inhibitors and diuretics'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      For patients who require diuretics perioperatively, clinicians should pay close attention to volume and potassium replacement.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Formulations/alternatives",
"       </strong>",
"      </span>",
"      &mdash; Intravenous preparations of loop diuretics are available, if necessary, and are commonly used.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Non-statin hypolipidemic agents",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Benefit/risk",
"       </strong>",
"      </span>",
"      &mdash; Niacin and fibric acid derivatives (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"       gemfibrozil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/23/17784?source=see_link\">",
"       fenofibrate",
"      </a>",
"      ), cause myopathy and rhabdomyolysis. The risk is higher when these agents are used in combination with statins, and surgery may also increase the risk of myopathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/44-48\">",
"       44-48",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33802?source=see_link\">",
"       \"Statin myopathy\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Lipid lowering agents that are bile sequestrants (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36374?source=see_link\">",
"       cholestyramine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/26/12710?source=see_link\">",
"       colestipol",
"      </a>",
"      ) interfere with bowel absorption of multiple medications that may be required perioperatively.",
"      <br/>",
"      <br/>",
"      The benefits or risks of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"       ezetimibe",
"      </a>",
"      in the perioperative period are unknown.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Continue/discontinue",
"       </strong>",
"      </span>",
"      &mdash; We recommend temporary discontinuation of niacin, fibric acid derivatives, bile sequestrants, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"       ezetimibe",
"      </a>",
"      perioperatively. Discontinuation is likely to be safe since these agents are given for the goal of long-term reduction in vascular morbidity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/45\">",
"       45",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The optimal interval to discontinue these agents before surgery is unknown; we recommend they be stopped the day before surgery to allow for drug elimination.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Statins",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Benefit/risk",
"       </strong>",
"      </span>",
"      &mdash; Evidence has become convincing that HMG CoA reductase inhibitors (statins) may prevent vascular events through mechanisms other than cholesterol lowering (eg, plaque stabilization, reduction in inflammation, decreased thrombogenesis) and may be of benefit in the perioperative period. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/32?source=see_link\">",
"       \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29402?source=see_link\">",
"       \"Management of cardiac risk for noncardiac surgery\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Two trials, DECREASE III for patients who were not taking statin therapy and were scheduled to undergo elective noncardiac vascular surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/49\">",
"       49",
"      </a>",
"      ], and DECREASE IV for patients at intermediate risk for cardiac events who were undergoing nonvascular surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/50\">",
"       50",
"      </a>",
"      ], found a similar reduction in cardiac events for patients randomly assigned to receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"       fluvastatin",
"      </a>",
"      before surgery, compared to placebo. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29402?source=see_link&amp;anchor=H33#H33\">",
"       \"Management of cardiac risk for noncardiac surgery\", section on 'Statins'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Continue/discontinue",
"       </strong>",
"      </span>",
"      &mdash; Based on the current evidence, we recommend continuing statin therapy in patients undergoing surgery, particularly in patients at high risk for cardiovascular events. Furthermore, we recommend that clinicians should start statins for patients undergoing vascular surgery, both for the benefit shown in a randomized trial and because most will have an indication for long term statin use.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Formulations/alternatives",
"       </strong>",
"      </span>",
"      &mdash; An intravenous statin preparation is not available. Patients treated with extended release",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"       fluvastatin",
"      </a>",
"      had fewer perioperative cardiac events compared to those receiving shorter acting statin medications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/51\">",
"       51",
"      </a>",
"      ]. The risk of myopathy appears to be lowest with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      and perhaps fluvastatin.",
"      <br/>",
"      <br/>",
"      Statins can accumulate when there is hypoperfusion of liver (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42312?source=see_link\">",
"       lovastatin",
"      </a>",
"      ) or kidney (pravastatin), increasing the risk of myopathy. Doses should be appropriately adjusted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     GASTROINTESTINAL AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef56778 \" href=\"mobipreview.htm?8/30/8684\">",
"     table 2",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26237687\">",
"    <span class=\"h2\">",
"     H2 blockers and proton pump inhibitors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Benefit/risk",
"       </strong>",
"      </span>",
"      &mdash; There are several potential advantages of continuing H2 blockers or proton pump inhibitors perioperatively. The stress of surgery and other conditions (eg, intensive care unit stay and mechanical ventilation) can increase the risk of stress-related mucosal damage, which may be minimized by administration of these drugs. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/21/18776?source=see_link\">",
"       \"Stress ulcer prophylaxis in the intensive care unit\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In addition, gastric aspiration during anesthesia, though rare, can lead to severe pulmonary injury. Both H2 blockers and proton pump inhibitors decrease gastric volume and raise gastric fluid pH, thereby reducing the risk of chemical pneumonitis from aspiration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/52,53\">",
"       52,53",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31017?source=see_link&amp;anchor=H6#H6\">",
"       \"Aspiration pneumonia in adults\", section on 'Chemical pneumonitis'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Neither H2 blockers nor proton pump inhibitors have been shown to interact with common anesthetic agents, although",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/54/2921?source=see_link\">",
"       cimetidine",
"      </a>",
"      can alter the metabolism of several drugs.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Continue/discontinue",
"       </strong>",
"      </span>",
"      &mdash; Based upon the potential benefits and lack of contraindications, we recommend that patients who are taking either H2 blockers or proton pump inhibitors remain on these medications in the perioperative period. An increased risk of C. difficile infection has been associated with proton pump inhibitor use. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/18/36137?source=see_link\">",
"       \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/18/36137?source=see_link&amp;anchor=H7#H7\">",
"       \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\", section on 'Gastric acid suppression'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Formulations/alternatives",
"       </strong>",
"      </span>",
"      &mdash; Patients who are unable to take oral medications for a prolonged period should be switched to an intravenous form of H2 blocker or proton pump inhibitor (",
"      <a class=\"graphic graphic_table graphicRef56778 \" href=\"mobipreview.htm?8/30/8684\">",
"       table 2",
"      </a>",
"      ). Intravenous H2 blockers are less costly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PULMONARY AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef56778 \" href=\"mobipreview.htm?8/30/8684\">",
"     table 2",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Inhaled beta agonists and anticholinergics",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Benefit/risks",
"       </strong>",
"      </span>",
"      &mdash; Inhaled medications used to control obstructive pulmonary disease such as beta agonists (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/63/34806?source=see_link\">",
"       salmeterol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/52/14151?source=see_link\">",
"       formoterol",
"      </a>",
"      ) and anticholinergics (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"       ipratropium",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"       tiotropium",
"      </a>",
"      ) have been found to reduce the incidence of postoperative pulmonary complications in patients with asthma and chronic obstructive pulmonary disease and should be continued perioperatively. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/51/13113?source=see_link\">",
"       \"Strategies to reduce postoperative pulmonary complications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Formulations/alternatives",
"       </strong>",
"      </span>",
"      &mdash; Inhaled beta agonists and anticholinergics are normally administered on the morning of surgery. The drugs can be administered through a nebulizer or in the circuit of the ventilator when use of metered-dose inhalers is not possible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Theophylline",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Benefit/risk",
"       </strong>",
"      </span>",
"      &mdash; There are no data whether continuation of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      in the perioperative period decreases pulmonary complications. Theophylline has the potential to cause serious arrhythmias and neurotoxicity at a level just beyond the therapeutic range and theophylline metabolism is affected by many common perioperative medications.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Continue/discontinue",
"       </strong>",
"      </span>",
"      &mdash; We recommend",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      medications be discontinued the evening before surgery.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Formulations/alternatives",
"       </strong>",
"      </span>",
"      &mdash; Other medications for treatment of obstructive lung disease can be initiated or adjusted, including inhaled beta agonists, glucocorticoids, and anticholinergic medications. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/51/13113?source=see_link\">",
"       \"Strategies to reduce postoperative pulmonary complications\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Benefit/risk",
"       </strong>",
"      </span>",
"      &mdash; Patients with pulmonary disease who are maintained on glucocorticoids (corticosteroids) are at risk of adrenal insufficiency if steroids are abruptly withdrawn, particularly in the face of increased stress related to surgery. Additionally, glucocorticoids in such patients may be necessary to maintain optimal lung functions.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Continue/discontinue",
"       </strong>",
"      </span>",
"      &mdash; Both inhaled and systemic glucocorticoids should be continued during the perioperative period. Issues related to preoperative stress dosing are discussed below. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Endocrine agents'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Leukotriene inhibitors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Benefit/risk",
"       </strong>",
"      </span>",
"      &mdash; The leukotriene inhibitors",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/33/17940?source=see_link\">",
"       zileuton",
"      </a>",
"      (Zyflo),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/54/20325?source=see_link\">",
"       zafirlukast",
"      </a>",
"      (Accolate), and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      (Singulair) help maintain asthma control but are not used for acute therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/1/30746?source=see_link\">",
"       \"Agents affecting the 5-lipoxygenase pathway in the treatment of asthma\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The elimination half-life of these agents is relatively short, but their effect on asthma symptoms and pulmonary function continues for up to three weeks after cessation of treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/54\">",
"       54",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      There is no evidence of a withdrawal syndrome with abrupt stoppage of these agents. We are aware of no evidence of harmful interactions of these drugs with anesthetics.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Continue/discontinue",
"       </strong>",
"      </span>",
"      &mdash; We recommend that leukotriene inhibitors be given on the morning of surgery and resumed when the patient is tolerating oral medications.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Formulations/alternatives",
"       </strong>",
"      </span>",
"      &mdash; No parenteral substitution is available or necessary given the long duration of action for leukotriene inhibitors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ENDOCRINE AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef77781 \" href=\"mobipreview.htm?24/4/24652\">",
"     table 3",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Benefit/risk",
"       </strong>",
"      </span>",
"      &mdash; The management of patients taking glucocorticoids preoperatively is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17384?source=see_link\">",
"       \"The surgical patient taking glucocorticoids\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In general, the duration of use and dosing of glucocorticoids should identify appropriate management:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients who have taken glucocorticoids for less than three weeks, or who have taken chronic alternate day therapy, are unlikely to have a suppressed hypothalamic-pituitary-adrenal (HPA) axis and should continue usual doses of glucocorticoids perioperatively.",
"     </li>",
"     <li>",
"      Patients taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      at a dose greater than 20",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for three weeks or more, and patients with a Cushingoid appearance should be assumed to have HPA axis suppression and may need an increased dose of corticosteroids perioperatively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients who have been taking glucocorticoids in a dose equivalent to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      5 to 20 mg daily for more than three weeks may have HPA axis suppression, and either should undergo testing or receive empiric glucocorticoid coverage. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17384?source=see_link&amp;anchor=H5#H5\">",
"       \"The surgical patient taking glucocorticoids\", section on 'Evaluation of HPA axis suppression'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Diabetic medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of diabetes mellitus, including management of oral agents and insulin in the perioperative period, is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/63/29688?source=see_link\">",
"     \"Perioperative management of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Oral contraceptives",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Benefit/risk",
"       </strong>",
"      </span>",
"      &mdash; Oral contraceptives are the most frequent cause of thrombosis in young women because of their widespread use. The risk of thrombosis increases within four months of initiation and decreases to previous levels within three months of stopping treatment. Surgery itself is a risk factor for thrombosis, and compounds the risk associated with oral contraceptives.",
"      <br/>",
"      <br/>",
"      Oral contraceptives with greater estrogen content (&ge;35 mcg) have a higher risk of thromboembolism compared to those with lower estrogen content (&le;30 mcg). Nevertheless, even the lower estrogen content pills are associated with an increased risk of thrombosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/55,56\">",
"       55,56",
"      </a>",
"      ].",
"      <span class=\"nowrap\">",
"       Estrogen/progestin",
"      </span>",
"      patches also increase thrombosis risk. Risk also varies with type of progestin. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=see_link&amp;anchor=H11#H11\">",
"       \"Risks and side effects associated with estrogen-progestin contraceptives\", section on 'Venous thromboembolic disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Continue/discontinue",
"       </strong>",
"      </span>",
"      &mdash; The decision to continue or stop oral contraceptives before surgery must balance the risk of unwanted pregnancy against the risk of thromboembolism. It is reasonable to continue oral contraceptives in patients who are undergoing low risk surgery (",
"      <a class=\"graphic graphic_table graphicRef58607 \" href=\"mobipreview.htm?38/34/39468\">",
"       table 4",
"      </a>",
"      ). Definitions of low, moderate, and high risk procedures are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link\">",
"       \"Prevention of venous thromboembolic disease in surgical patients\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In general, oral contraceptives should be discontinued four to six weeks prior to surgery in patients with increased risk. Other forms of contraception must be used to prevent unwanted pregnancy during this time. Oral contraceptives might be continued in moderate to high risk women who could have difficulty complying with other forms of contraception, recognizing that this may increase their risk of thromboembolism and that thromboembolic prophylaxis should be planned accordingly.",
"      <br/>",
"      <br/>",
"      We recommend a serum pregnancy test prior to surgery in all women of childbearing age, particularly important in those who have stopped oral contraceptives preoperatively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Postmenopausal hormone therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Benefit/risk",
"       </strong>",
"      </span>",
"      &mdash; The estrogen content of preparations used for postmenopausal hormone therapy (HT) is much lower than in oral contraceptive pills. However, use of HT, with either estrogen alone or estrogen plus a progestin, still appears to increase the risk of venous thromboembolism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/57,58\">",
"       57,58",
"      </a>",
"      ]. Although a case-control study did not find an increased risk of thromboembolism in women undergoing arthroplasty who received HT (OR 0.66, 95% CI 0.35-1.18), the results may have been confounded by women at lower risk for thromboembolism being more likely to be prescribed HT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/59\">",
"       59",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The risks associated with temporary discontinuation of hormone therapy are minimal, other than discomfort from hot flashes and other menopausal symptoms.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Continue/discontinue",
"       </strong>",
"      </span>",
"      &mdash; Women undergoing procedures associated with moderate to high risk for venous thromboembolism (VTE) should stop hormone therapy at least four to six weeks prior to surgery and resume treatment postoperatively once the period of elevated risk for VTE has resolved. Hormone therapy can be continued for surgical procedures associated with a low risk of venous thrombosis (",
"      <a class=\"graphic graphic_table graphicRef58607 \" href=\"mobipreview.htm?38/34/39468\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link\">",
"       \"Prevention of venous thromboembolic disease in surgical patients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Selective estrogen receptor modulators",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Benefit/risk",
"       </strong>",
"      </span>",
"      &mdash; The indications for use of selective estrogen receptor modulators (SERMs) such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"       raloxifene",
"      </a>",
"      include breast cancer treatment, breast cancer chemoprevention, and, at least for raloxifene, the prevention and treatment of osteoporosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44246?source=see_link\">",
"       \"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/32/41481?source=see_link\">",
"       \"Selective estrogen receptor modulators for osteoporosis\"",
"      </a>",
"      .) Both tamoxifen and raloxifene increase the risk of venous thromboembolism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/60,61\">",
"       60,61",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Brief discontinuation of SERMs used for prevention of breast cancer or osteoporosis is unlikely to result in harm. For patients with breast cancer who are being treated with SERMs, the risk of disease progression with preoperative cessation of treatment is a concern.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Continue/discontinue",
"       </strong>",
"      </span>",
"      &mdash; For patients receiving SERM for prevention of cancer or osteoporosis, we suggest discontinuing medication for four weeks for those surgical procedures associated with a moderate or high risk of venous thromboembolism and restarting once the period of elevated risk has resolved; drugs can be continued for low risk surgeries (",
"      <a class=\"graphic graphic_table graphicRef58607 \" href=\"mobipreview.htm?38/34/39468\">",
"       table 4",
"      </a>",
"      ). The decision to discontinue is more difficult when SERMS are used for cancer treatment, and consultation with an oncologist is recommended.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Drugs used for thyroid disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of medications to control hypothyroid and hyperthyroid states is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/2/4137?source=see_link\">",
"     \"Nonthyroid surgery in the patient with thyroid disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Continue/discontinue",
"       </strong>",
"      </span>",
"      &mdash; In brief, patients receiving chronic thyroxine (T4) therapy who undergo surgery and are unable to eat for several days do not need to be given T4 parenterally.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Formulations/alternatives",
"       </strong>",
"      </span>",
"      &mdash; T4 should be given intravenously or intramuscularly if oral intake cannot be resumed in five to seven days. The parenteral dose should be reduced to approximately 80 percent of the patient's usual oral dose, to reflect the fraction of oral T4 that is absorbed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Drugs used for osteoporosis/osteopenia",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Benefit/risk",
"       </strong>",
"      </span>",
"      &mdash; Bisphosphonate use, especially in malignancy, has been associated with osteonecrosis in patients undergoing dental surgery. The absolute risk is low, but osteonecrosis is difficult to manage. The duration of effect of bisphosphonates on bone remodeling is long, and the discontinuation of these agents for weeks or even months before surgery may not decrease the risk of osteonecrosis. Dentists should inform patients of this risk and consider strategies to lower the risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     MEDICATIONS AFFECTING HEMOSTASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients undergoing surgery are taking medications that are intended to impair normal hemostasis or appropriate thrombosis (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , or other antiplatelet agents), or take medications for another indication that have an unintended effect on hemostasis, such as nonsteroidal antiinflammatory drugs (NSAIDs) (",
"    <a class=\"graphic graphic_table graphicRef68515 \" href=\"mobipreview.htm?1/10/1196\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Aspirin",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Benefit/risk",
"       </strong>",
"      </span>",
"      &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      irreversibly inhibits platelet cyclooxygenase, which may increase intraoperative blood loss and hemorrhagic complications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/63-68\">",
"       63-68",
"      </a>",
"      ]. However, the same effect can help to prevent perioperative vascular complications, in particular cardiac and thromboembolic complications.",
"      <br/>",
"      <br/>",
"      Observational studies suggest that withdrawal of aspirin preoperatively is associated with increased in-hospital mortality in patients undergoing coronary artery bypass graft surgery (CABG) or surgery for peripheral artery disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/69-71\">",
"       69-71",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/26/40360?source=see_link&amp;anchor=H2#H2\">",
"       \"Medical therapy to prevent complications after coronary artery bypass graft surgery\", section on 'Aspirin'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In addition, stopping aspirin therapy for five days or more in patients with underlying cardiovascular disease may increase the risk of an acute coronary syndrome or stroke [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/72-75\">",
"       72-75",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link\">",
"       \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2618?source=see_link&amp;anchor=H2#H2\">",
"       \"Antiplatelet therapy for secondary prevention of stroke\", section on 'Aspirin'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In patients undergoing cataract surgery, the risk of ocular hemorrhage in patients taking aspirin is low and similar to that in patients not taking aspirin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/76\">",
"       76",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/19/2362?source=see_link&amp;anchor=H18#H18\">",
"       \"Cataract in adults\", section on 'Aspirin and other antiplatelet agents'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/44/7881?source=see_link&amp;anchor=H15#H15\">",
"       \"Anticoagulant, antiplatelet, and fibrinolytic (thrombolytic) therapy in patients at high risk for ocular hemorrhage\", section on 'Ophthalmic surgery'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Aspirin also may prevent venous thromboembolism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/77\">",
"       77",
"      </a>",
"      ]. However, other agents are more effective [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/78\">",
"       78",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link&amp;anchor=H25#H25\">",
"       \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Aspirin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Continue/discontinue",
"       </strong>",
"      </span>",
"      &mdash; The optimal perioperative management of patients who are taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      is uncertain, and significant practice variation exists [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/2\">",
"       2",
"      </a>",
"      ]. The decision to continue or withhold aspirin should reflect a balance of the consequences of perioperative hemorrhage versus the risk of perioperative vascular complications.",
"      <br/>",
"      <br/>",
"      Patients believed to be at high risk for perioperative vascular complications in whom perioperative hemorrhage would result in minimal morbidity should continue aspirin. This includes patients on maintenance aspirin therapy who have coronary stents or who are undergoing CABG or peripheral artery surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/69-71\">",
"       69-71",
"      </a>",
"      ]. The 2012 guidelines from the American College of Chest Physicians also suggest continuing aspirin around the time of surgery for patients at moderate to high risk for cardiovascular events who are undergoing noncardiac surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/79\">",
"       79",
"      </a>",
"      ]. The guidelines also suggest that patients at low risk for cardiovascular events who are receiving aspirin therapy should stop aspirin 7 to 10 days before surgery.",
"      <br/>",
"      <br/>",
"      Aspirin should be withheld prior to surgical procedures in which perioperative hemorrhage could be catastrophic (eg, central nervous system surgery) or impact surgical outcome. Specifically, aspirin should be withheld for intracranial, middle ear, posterior chamber of the eye, and intramedullary spine surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/75\">",
"       75",
"      </a>",
"      ]. Patients undergoing prostate surgery are at increased risk of bleeding because of local fibrinolysis due to urokinase, and some would also discontinue aspirin in such patients.",
"      <br/>",
"      <br/>",
"      Aspirin can be safely continued in most patients undergoing cataract surgery or minor dental or dermatologic procedures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/79\">",
"       79",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/19/2362?source=see_link&amp;anchor=H18#H18\">",
"       \"Cataract in adults\", section on 'Aspirin and other antiplatelet agents'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/44/7881?source=see_link&amp;anchor=H15#H15\">",
"       \"Anticoagulant, antiplatelet, and fibrinolytic (thrombolytic) therapy in patients at high risk for ocular hemorrhage\", section on 'Ophthalmic surgery'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      If the decision is made to stop aspirin, 7 to 10 days should elapse before surgery is undertaken [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/79\">",
"       79",
"      </a>",
"      ]. Use of the bleeding time to assess the effect of aspirin or NSAIDs on bleeding risk is not recommended as it is a poor predictor of perioperative hemorrhage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/80\">",
"       80",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/43/32439?source=see_link\">",
"       \"Preoperative assessment of hemostasis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The 2008 ACCP guidelines on antithrombotic therapy recommend resuming aspirin approximately 24 hours (or the next morning) after surgery when there is adequate hemostasis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Formulations/alternatives",
"       </strong>",
"      </span>",
"      &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      is not available in parenteral forms, but is available as a rectal suppository for patients who are felt to need ongoing therapy but cannot take oral medication.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Other antiplatelet agents",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Benefit/risk",
"       </strong>",
"      </span>",
"      &mdash; The platelet P2Y12 receptor blockers,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"       ticagrelor",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"       ticlopidine",
"      </a>",
"      are used in patients who have had previous cerebrovascular events, recent acute coronary syndromes, or recent percutaneous coronary interventions with stenting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/82\">",
"       82",
"      </a>",
"      ]. The risk of coronary artery stent thrombosis after the premature cessation of clopidogrel is relatively low but stent thrombosis may be catastrophic. Elective surgery should be postponed whenever possible until the minimum period of therapy with P2Y12 receptor blocker therapy is completed. The bleeding risk from continuing clopidogrel for patients undergoing peripheral artery or carotid surgery appears low and no different from those who discontinue these agents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/83\">",
"       83",
"      </a>",
"      ]. Issues related to reinstitution of clopidogrel are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10634?source=see_link&amp;anchor=H11#H11\">",
"       \"Antiplatelet therapy after coronary artery stenting\", section on 'Early noncardiac surgery or gastrointestinal endoscopy'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"       Dipyridamole",
"      </a>",
"      has both vasodilator and antiplatelet activity. With the publication of the ESPS-2 trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/84\">",
"       84",
"      </a>",
"      ], its use has become more common in patients with past stroke or transient ischemic attack (TIA). The half-life of the modified-release preparation is approximately 10 hours. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2618?source=see_link\">",
"       \"Antiplatelet therapy for secondary prevention of stroke\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/33/32281?source=see_link\">",
"       \"Secondary prevention for specific causes of ischemic stroke and transient ischemic attack\"",
"      </a>",
"      .)",
"      <br/>",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Continue/discontinue",
"       </strong>",
"      </span>",
"      &mdash; Many patients take both",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and platelet P2Y12 receptor blocker therapy to prevent coronary stent thrombosis. Premature cessation of dual antiplatelet therapy is associated with an increased risk for stent thrombosis. Except for emergent settings, we recommend that surgery be delayed and therapy with P2Y12 receptor blocker and aspirin be continued for at least the minimum recommended duration for each stent type. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10634?source=see_link\">",
"       \"Antiplatelet therapy after coronary artery stenting\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      If surgery must be performed before these minimum time periods, it is best to consult with the treating cardiologist and surgeon. If the risk of major bleeding appears greater than the risk of stent thrombosis, P2Y12 receptor blocker therapy should be discontinued for as brief a period as possible.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       Clopidogrel",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"       ticagrelor",
"      </a>",
"      should be discontinued at least five, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      at least seven, days before surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/81\">",
"       81",
"      </a>",
"      ]. They should be resumed as early as possible in the postoperative period. In this setting, we suggest that surgery be performed in centers with 24 hour interventional cardiology coverage. Aspirin should be continued during this period if at all possible.",
"      <br/>",
"      <br/>",
"      For patients who are continuing on dual antiplatelet therapy but who have already received the minimum duration of therapy for their stent type, the P2Y12 receptor blocker may be stopped, surgery performed, and the receptor blocker restarted following surgery.",
"      <br/>",
"      <br/>",
"      Continuing&nbsp;clopidogrel&nbsp;in the perioperative period for peripheral artery and carotid procedures is reasonable as the bleeding risk appears low.",
"      <br/>",
"      <br/>",
"      There are no data on the safety of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      if continued in the perioperative period. Like aspirin, factors to consider in deciding whether to continue or hold dipyridamole reflect a balance between the risk of bleeding and risk of ischemic events. If discontinued, the drug should be stopped at least two days before surgery. Aggrenox (combination aspirin and dipyridamole) should be discontinued seven to ten days before surgery.",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Benefit/risk",
"       </strong>",
"      </span>",
"      &mdash; The antiplatelet effects of nonsteroidal antiinflammatory drugs (NSAIDs) are due to reversible inhibition of COX-1, an isoform of cyclooxygenase, leading to decreased production of thromboxane A2 (TxA2). TxA2 is released by platelets in response to a number of agonists, leading to platelet aggregation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=see_link&amp;anchor=H15#H15\">",
"       \"Nonselective NSAIDs: Overview of adverse effects\", section on 'Antiplatelet effects'",
"      </a>",
"      .) These antiplatelet effects increase the bleeding risk perioperatively but, like",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , may reduce the risk of perioperative vascular events [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/85\">",
"       85",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The selective COX-2 inhibitors, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      , have minimal effects on platelet function, although the potential for renal toxicity remains. Most selective COX-2 inhibitors and nonselective NSAIDs appear to have deleterious cardiovascular effects. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13066?source=see_link\">",
"       \"Overview of selective COX-2 inhibitors\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39351?source=see_link\">",
"       \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/4/24648?source=see_link\">",
"       \"Nonselective NSAIDs: Adverse cardiovascular effects\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Non-acetylated nonsteroidals, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/14/5350?source=see_link\">",
"       salsalate",
"      </a>",
"      , do not have an antiplatelet effect.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Continue/discontinue",
"       </strong>",
"      </span>",
"      &mdash; On balance, we recommend discontinuing NSAIDs, including selective COX-2 inhibitors, prior to surgery. For patients whose pain is dramatically responsive to COX-2 inhibitors, consideration may be given to continuing these agents since they have minimal effects on platelet function.",
"      <br/>",
"      <br/>",
"      Although some experts recommend discontinuing NSAIDs based upon drug-specific elimination half-lives [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/86\">",
"       86",
"      </a>",
"      ], the elimination half-life correlates poorly with cyclooxygenase inhibition and effects on platelet aggregation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/87,88\">",
"       87,88",
"      </a>",
"      ]. In healthy individuals receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      for one week, platelet function appears to return to normal within 24 hours after the last dose [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/89\">",
"       89",
"      </a>",
"      ]. However, the relationship between time of discontinuation of NSAIDs with intra- and post-operative clinical bleeding is not well defined. For most NSAIDs, platelet function normalizes within three days of discontinuation, suggesting that NSAIDs should generally be discontinued at least three days before surgery; ibuprofen can be stopped 24 hours prior to surgery.",
"      <br/>",
"      <br/>",
"      Nonacetylated NSAIDs can be continued in the perioperative period, and may be considered as alternatives to other NSAIDs for pain control.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The perioperative management of patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/50/35626?source=see_link\">",
"     \"Management of anticoagulation before and after elective surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27162260\">",
"    <span class=\"h2\">",
"     Dabigatran",
"    </span>",
"    &nbsp;&mdash;&nbsp;The perioperative management of patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    , a direct thrombin inhibitor, is discussed separately. Due to lack of an antidote for reversal of its anticoagulant effect, careful consideration should be given prior to resumption of dabigatran (or the factor Xa inhibitors",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    ) following surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/50/35626?source=see_link\">",
"     \"Management of anticoagulation before and after elective surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1744185635\">",
"    <span class=\"h1\">",
"     MEDICATIONS AFFECTING RENAL FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several medications and agents used during the perioperative period may lead to acute kidney injury, including nonsteroidal antiinflammatory drugs, ACE inhibitors, angiotensin II receptor blockers, diuretics, antibiotics (eg, aminoglycosides, penicillins), and intravenous contrast agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/90\">",
"     90",
"    </a>",
"    ]. The benefits and risks vary based on each drug. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'ACE inhibitors and angiotensin II receptor blockers'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H8\">",
"     'Diuretics'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H28\">",
"     'Nonsteroidal antiinflammatory drugs'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/34/24104?source=see_link&amp;anchor=H28#H28\">",
"     \"Aminoglycosides\", section on 'Nephrotoxicity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/2/26663?source=see_link&amp;anchor=H17#H17\">",
"     \"Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects\", section on 'Renal reactions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/42/35498?source=see_link\">",
"     \"Prevention of contrast-induced nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Optimizing volume status and medications to prevent acute tubular necrosis are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/10/42154?source=see_link&amp;anchor=H7#H7\">",
"     \"Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     PSYCHOTROPIC AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The perioperative management of patients taking psychotropic agents varies with the class of drugs used (",
"    <a class=\"graphic graphic_table graphicRef66948 \" href=\"mobipreview.htm?8/34/8749\">",
"     table 6",
"    </a>",
"    ). Evidence-based guidelines for these drugs are lacking; data are primarily derived from case reports and open trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Tricyclic antidepressants",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Benefit/risk",
"       </strong>",
"      </span>",
"      &mdash; Tricyclic antidepressants inhibit the uptake of norepinephrine and serotonin at the synaptic cleft. These agents may increase the risk for arrhythmias in combination with some volatile anesthetics or sympathomimetic agents. Abrupt withdrawal of tricyclic antidepressants can lead to insomnia, nausea, headache, increased salivation, and sweating, and should be avoided if feasible [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/92\">",
"       92",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/20/36169?source=see_link\">",
"       \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Continue/discontinue",
"       </strong>",
"      </span>",
"      &mdash; There is little primary literature on perioperative management of tricyclic agents. Recommendations in textbooks and reviews vary; most recommend continuing these agents in the perioperative period [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/2\">",
"       2",
"      </a>",
"      ]. The US Food and Drug Administration advises that tricyclic antidepressants (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/41/41624?source=see_link\">",
"       imipramine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/21/30040?source=see_link\">",
"       nortriptyline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/14/39144?source=see_link\">",
"       desipramine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/20/43336?source=see_link\">",
"       clomipramine",
"      </a>",
"      ) be discontinued prior to elective surgery, when possible, and this information is provided in package labelling for these medications. However, the nature of the patient&rsquo;s underlying psychiatric condition needs to be considered prior to tapering the medication; for patients with major depressive illness, discontinuing medication may precipitate serious illness. When medication discontinuation is not possible, either because of the patient&rsquo;s psychiatric condition or the need for urgent or emergent surgery, the anesthetist should be informed that the patient is taking a tricyclic medication to assure appropriate monitoring for arrhythmias.",
"      <br/>",
"      <br/>",
"      We generally recommend continuation of tricyclic agents throughout the perioperative period, in particular for patients on high doses. For patients on low doses or in whom the risk of perioperative arrhythmia is increased, the agents should be tapered off over a period of 7 to 14 days before surgery.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Formulations/alternatives",
"       </strong>",
"      </span>",
"      &mdash; No parenteral substitution is available.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Serotonin reuptake inhibitors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Benefit/risk",
"       </strong>",
"      </span>",
"      &mdash; SSRIs may increase the need for transfusion with surgery, perhaps because of their effects on platelet aggregation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/56/31626?source=see_link&amp;anchor=H12543449#H12543449\">",
"       \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\", section on 'Bleeding'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Stopping SSRIs could lead to exacerbation of mood and other disorders. The wash out period for SSRIs may be as long as three weeks, and reinitiation may not lead to clinical benefit for several weeks.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Continue/discontinue",
"       </strong>",
"      </span>",
"      &mdash; The decision to withhold SSRIs perioperatively should balance the consequences of bleeding with the severity of the underlying psychiatric disorder. Patients undergoing surgical procedures in which postoperative bleeding could lead to significant morbidity (such as central nervous system procedures) should have SSRIs discontinued several weeks prior to surgery. Patients with severe mood disorders should generally be maintained on SSRIs through surgery.",
"      <br/>",
"      <br/>",
"      Consultation with a psychiatrist is recommended to consider alternative therapies during the perioperative period for the rare patient with a severe mood disorder who is undergoing a procedure in which bleeding could lead to significant morbidity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Monoamine oxidase inhibitors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Benefit/risk",
"       </strong>",
"      </span>",
"      &mdash; Monoamine oxidase (MAO) inhibitors require special attention preoperatively. These drugs are prescribed far l",
"      <strong>",
"       ess commonly than ot",
"      </strong>",
"      her antidepressants, but are used in patients with refractory mood disorders in whom withdrawal and recurrent depression may be problematic. MAO inhibitors are also used for treatment of conditions other than depression (",
"      <a class=\"graphic graphic_table graphicRef78294 \" href=\"mobipreview.htm?18/55/19324\">",
"       table 7",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Use of MAO inhibitors results in accumulation of biogenic amines in central and autonomic system neurons. Concomitant administration of sympathomimetic agents, like ephedrine during anesthesia, can result in massive release of stored norepinephrine and severe hypertension. Administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/46/18150?source=see_link\">",
"       dextromethorphan",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/44/11976?source=see_link\">",
"       meperidine",
"      </a>",
"      with MAO inhibitors can cause the serotonin syndrome (agitation, headache, fever, seizures, with possibility of coma and death) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/93\">",
"       93",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16376?source=see_link\">",
"       \"Serotonin syndrome\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      A designated MAO-safe anesthetic technique is used in patients requiring emergency procedures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/94\">",
"       94",
"      </a>",
"      ]. This involves avoidance of meperidine and use of only direct acting sympathomimetic agents such as isoprenaline and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/36/39488?source=see_link\">",
"       phenylephrine",
"      </a>",
"      .",
"      <strong>",
"      </strong>",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Continue/discontinue",
"       </strong>",
"      </span>",
"      &mdash; The decision to continue or withhold MAO inhibitors before surgery requires close collaboration with the anesthesiologist and psychiatrist.",
"      <br/>",
"      <br/>",
"      MAO inhibitors generally should be continued when two criteria are met: (1) the anesthesiologist is comfortable with use of MAO safe procedures; and (2) the psychiatrist believes temporary withdrawal of the agent will exacerbate or precipitate a depressive syndrome.",
"      <br/>",
"      <br/>",
"      In the absence of either criteria, we recommend discontinuing MAO inhibitors before surgery. Many MAO inhibitors are irreversible antagonists, and recovery of MAO function requires two weeks after discontinuation of the drug. Thus, patients should taper and discontinue MAO inhibitors two weeks before elective surgery.",
"      <br/>",
"      <br/>",
"      If MAO inhibitors are continued perioperatively, the patient must be prescribed a diet that excludes foods containing high amounts of tyramine while an inpatient (",
"      <a class=\"graphic graphic_table graphicRef80345 \" href=\"mobipreview.htm?26/39/27259\">",
"       table 8",
"      </a>",
"      ). Intra- and perioperative drug interactions must be closely monitored. Specific interactions of MAO inhibitors with other medications may be determined using the drug interactions tool (Lexi-Interact Online) included in UpToDate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Mood stabilizing agents (lithium and valproate)",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Benefit/risk",
"       </strong>",
"      </span>",
"      &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"      has a number of physiologic effects that may be important perioperatively. Lithium decreases release of neurotransmitters and may prolong the effect of muscle relaxants. Chronic lithium use has a multitude of effects on the thyroid. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/29/42453?source=see_link\">",
"       \"Lithium and the thyroid\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43065?source=see_link&amp;anchor=H182696807#H182696807\">",
"       \"Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects\", section on 'Lithium side effects'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In addition, nephrogenic diabetes insipidus has been described in up to 20 percent of patients taking lithium. Patients who have impaired renal concentrating ability maintain euvolemia and a normal serum sodium through polydipsia. Access to free water may be impaired during the perioperative period and lead to volume depletion and hypernatremia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/32999?source=see_link\">",
"       \"Renal toxicity of lithium\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Valproic acid is another mood stabilizer used in patients with bipolar disorder. There are no reports demonstrating problems in patients continuing valproic acid perioperatively.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Continue/discontinue",
"       </strong>",
"      </span>",
"      &mdash; We recommend continuation of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      perioperatively with increased attention to fluid and electrolyte monitoring and a low threshold to check thyroid function tests before surgery.",
"      <br/>",
"      <br/>",
"      We recommend that valproic acid be continued.",
"      <br/>",
"      <br/>",
"      Serum levels of lithium and valproate should be monitored regularly. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43065?source=see_link&amp;anchor=H182696800#H182696800\">",
"       \"Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects\", section on 'Laboratory tests and monitoring'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=see_link&amp;anchor=H6#H6\">",
"       \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\", section on 'Valproate or divalproex'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Formulations/alternatives",
"       </strong>",
"      </span>",
"      &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"      must be held in patients who cannot take oral medications since no parenteral substitution is available.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       Valproate",
"      </a>",
"      sodium is available as a parenteral form. Valproate or second-generation antipsychotics (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"       aripiprazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/39/4728?source=see_link\">",
"       ziprasidone",
"      </a>",
"      ) may be used in lieu of lithium for patients who cannot take oral medications. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=see_link&amp;anchor=H3#H3\">",
"       \"Bipolar disorder in adults: Maintenance treatment\", section on 'Pharmacotherapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Antipsychotics",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Benefit/risk",
"       </strong>",
"      </span>",
"      &mdash; Antipsychotics are effective in controlling psychoses that may become problematic perioperatively in patients with underlying psychiatric illness. However, findings from a large observational study indicate that use of antipsychotics, both typical and atypical, is associated with an increased risk for sudden death [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/95\">",
"       95",
"      </a>",
"      ]. Both typical and atypical antipsychotics may prolong the QT interval and cause arrhythmia, particularly when coadministered with volatile anesthetic agents or drugs such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      , quinolones,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/24/7562?source=see_link\">",
"       \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=see_link\">",
"       \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=see_link\">",
"       \"Acquired long QT syndrome\"",
"      </a>",
"      .).",
"      <br/>",
"      <br/>",
"      In a randomized trial of 495 patients at risk for delirium undergoing joint replacement surgery,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      versus placebo was administered to prevent delirium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/96\">",
"       96",
"      </a>",
"      ]. The incidence of delirium decreased from 40 to 1 percent, although those who experienced delirium in the olanzapine group had more severe and longer-lasting delirium. Resource use during hospitalization (sitters, consultations) did not decrease. More patients in the olanzapine arm were discharged to home versus rehabilitation facilities. Further studies are needed prior to widespread use of perioperative antipsychotics for delirium prevention.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Continue/discontinue",
"       </strong>",
"      </span>",
"      &mdash; Antipsychotics should be used cautiously in patients at risk for exacerbation of psychoses. These agents should be withheld in patients whose baseline or follow-up ECG demonstrates prolongation of the QT interval. Shorter acting and low dose antipsychotics should be considered and complete discontinuation may be preferable after consultation with a psychiatrist.",
"      <br/>",
"      <br/>",
"      For all patients receiving antipsychotic medication, caution should be used in selection of antibiotics and other medications to avoid drug interactions.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Formulations/alternatives",
"       </strong>",
"      </span>",
"      &mdash; Several parenteral antipsychotics are available, including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/38/30312?source=see_link\">",
"       chlorpromazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"       aripiprazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/39/4728?source=see_link\">",
"       ziprasidone",
"      </a>",
"      . If a prolonged period of bowel rest is anticipated in a patient with a difficult to control psychosis, the long-acting parenteral form of haloperidol (haldol decanoate) or risperidone can be started well before surgery, in consultation with a psychopharmacologist.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Antianxiety agents",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Benefit/risk",
"       </strong>",
"      </span>",
"      &mdash; Abrupt withdrawal of chronic benzodiazepines can lead to an excitatory state with hypertension, agitation, delirium, and seizures. Many of these agents have active metabolites, and withdrawal can occur several days to weeks after discontinuation.",
"      <br/>",
"      <br/>",
"      Benzodiazepines are commonly used short-term to relieve preoperative anxiety and are generally safe, with proper monitoring, in the perioperative period.",
"      <br/>",
"      <br/>",
"      There are no data regarding the safety of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/19/30006?source=see_link\">",
"       buspirone",
"      </a>",
"      in the perioperative period.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Continue/discontinue",
"       </strong>",
"      </span>",
"      &mdash; We recommend that benzodiazepines or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/19/30006?source=see_link\">",
"       buspirone",
"      </a>",
"      used chronically for antianxiety or sedative effects be continued perioperatively.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Formulations/alternatives",
"       </strong>",
"      </span>",
"      &mdash; Parenteral forms of benzodiazepines are available, including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      .",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/19/30006?source=see_link\">",
"       Buspirone",
"      </a>",
"      is only available in oral formulation; parenteral benzodiazepines can be substituted if the patient cannot take oral medications and anxiety is a significant problem. Intravenous administration can cause blood pressure lability.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Psychostimulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychostimulant medications, used in the treatment of attention deficit hyperactivity disorder, may increase risk for hypertension and arrhythmias, lower the seizure threshold, and interact with medications that could be needed in the perioperative period (eg, vasopressors). There is a risk of sudden blood pressure increase when halogenated anesthetics are used in conjunction with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    , and, per drug labeling, the stimulant should be withheld on the day of surgery.",
"   </p>",
"   <p>",
"    A case series report of eight patients found no adverse effects when amphetamines were continued on the day of surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/97\">",
"     97",
"    </a>",
"    ]. However, none of the patients required vasopressor support.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Benefit/risk",
"       </strong>",
"      </span>",
"      &mdash; Psychostimulants are not associated with adverse effects when discontinued in the non-abusing patient. Patients generally do not need to be concerned about alertness on the day of surgery.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Continue/discontinue",
"       </strong>",
"      </span>",
"      &mdash; Data are limited but risks are low of temporarily discontinuing psychostimulant medications. We recommend they be withheld on the day of surgery and resumed when the patient is stable.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     CHRONIC OPIOID THERAPY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Benefit/risk",
"       </strong>",
"      </span>",
"      &mdash; Abrupt discontinuation of chronic opioid use may result in withdrawal symptoms including abdominal cramps, nausea, vomiting, diarrhea, insomnia, anxiety, irritability, temperature instability, diaphoresis, and salivation. There is need to avoid precipitating withdrawal symptoms (and an associated hyperadrenergic state including potential CV instability) and hyperalgesia.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Continue/discontinue",
"       </strong>",
"      </span>",
"      &mdash; Patients taking long term opioids for the management of chronic pain need to continue these agents around the time of surgery (",
"      <a class=\"graphic graphic_table graphicRef82352 \" href=\"mobipreview.htm?9/43/9915\">",
"       table 9",
"      </a>",
"      ). Special consideration needs to be given to patients who are chronically maintained on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/53/41816?source=see_link\">",
"       buprenorphine",
"      </a>",
"      for opioid addiction. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29514?source=see_link&amp;anchor=H11#H11\">",
"       \"Treatment of opioid abuse and dependence\", section on 'Use during hospitalization'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Formulations/alternatives",
"       </strong>",
"      </span>",
"      &mdash; For patients unable to take oral medications, rectal, transmucosal, transdermal, and parenteral forms are available. In general, parenteral doses equivalent to oral doses should be used (",
"      <a class=\"graphic graphic_table graphicRef58864 \" href=\"mobipreview.htm?11/31/11760\">",
"       table 10",
"      </a>",
"      ), although higher doses may temporarily be required because of pain related to the surgical procedure. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42778?source=see_link\">",
"       \"Overview of the treatment of chronic pain\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      For patients on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      maintenance for drug dependency or for chronic pain, we suggest restarting their usual methadone dose orally as soon as possible and covering postoperative analgesic requirements with additional opioids as needed via PCA pump. These patients may require high doses, which are usually safe for this population because of tolerance to serious side effects, such as respiratory depression. We suggest consultation with pain physicians. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27546?source=see_link&amp;anchor=H23#H23\">",
"       \"Management of postoperative pain\", section on 'Patients on methadone'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     NEUROLOGIC AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of drugs taken by patients with neurologic disease around the time of surgery are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/9/10394?source=see_link\">",
"     \"Perioperative care of the surgical patient with neurologic disease\"",
"    </a>",
"    .) A brief summary of recommendations is found in a table (",
"    <a class=\"graphic graphic_table graphicRef55167 \" href=\"mobipreview.htm?24/58/25516\">",
"     table 11",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Antiepileptic drugs",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Benefit/risk",
"       </strong>",
"      </span>",
"      &mdash; Major motor seizures that occur during a surgical procedure can increase morbidity and mortality.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Continue/discontinue",
"       </strong>",
"      </span>",
"      &mdash; Antiepileptic drugs generally need to be continued perioperatively in most patients with known seizure disorders. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/9/10394?source=see_link\">",
"       \"Perioperative care of the surgical patient with neurologic disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Formulations/alternatives",
"       </strong>",
"      </span>",
"      &mdash; Options are available for patients who require antiepileptic drugs perioperatively and cannot take oral medications.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       Phenytoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/52/43847?source=see_link\">",
"       levetiracetam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/19/35125?source=see_link\">",
"       lacosamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      are available parenterally. There are no parenteral forms of other antiepileptic drugs. However, many have formulations that allow administration by nasogastric tube. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link\">",
"       \"Pharmacology of antiepileptic drugs\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Antiparkinson agents",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Benefit/risk",
"       </strong>",
"      </span>",
"      &mdash; The effect of anti-Parkinson drugs on dopamine increases the potential for perioperative hemodynamic and arrhythmogenic complications. However, abrupt withdrawal of anti-Parkinson drugs may lead to flares of Parkinson symptoms and the neuroleptic malignant syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/98-100\">",
"       98-100",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20553?source=see_link\">",
"       \"Neuroleptic malignant syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Continue/discontinue",
"       </strong>",
"      </span>",
"      &mdash; It is recommended that dopaminergic drugs be tapered to the lowest possible dose at least two weeks prior to surgery and restarted at this dose as soon as possible following surgery. This reduces the risk of the neuroleptic malignant syndrome with medication withdrawal, while still controlling symptoms.",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/36/36423?source=see_link\">",
"       Carbidopa-levodopa",
"      </a>",
"      has a short duration of action (three to four hours) and can be given the night before surgery. Dopamine agonists have a longer half-life and should be discontinued the evening before surgery to avoid hypotension in the perioperative period. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/9/10394?source=see_link\">",
"       \"Perioperative care of the surgical patient with neurologic disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Formulations/alternatives",
"       </strong>",
"      </span>",
"      &mdash; Parenteral anticholinergic drugs can be used in patients who are unable to take oral medication, but should be used in as low a dose as possible as they may precipitate an acute confusional state, especially in the elderly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     RHEUMATOLOGIC AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perioperative medication management of patients with rheumatic diseases is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/35/15929?source=see_link\">",
"     \"Preoperative evaluation and perioperative management of patients with rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Rheumatoid arthritis drugs",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Benefit/risk",
"       </strong>",
"      </span>",
"      &mdash; Agents used in managing rheumatoid arthritis can be divided into three main categories: NSAIDs, glucocorticoids, and disease modifying antirheumatic drugs (DMARDs). The first two are discussed above. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Nonsteroidal antiinflammatory drugs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      DMARDs include traditional agents such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      , as well as biologic agents such as inhibitors of tumor necrosis factor (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      , certolizumab, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35206?source=see_link\">",
"       golimumab",
"      </a>",
"      ), T cell costimulation (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"       abatacept",
"      </a>",
"      ), interleukins (IL-6 [",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"       tocilizumab",
"      </a>",
"      ] and IL-1 [",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/294?source=see_link\">",
"       anakinra",
"      </a>",
"      ]), and B cell depleting agents (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/101\">",
"       101",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A randomized trial in orthopedic patients found the rate of infection was not increased in patients who continued weekly methotrexate, compared with discontinuing methotrexate two weeks before surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/102\">",
"       102",
"      </a>",
"      ]. Data regarding other DMARDs in the perioperative period are more limited [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/101,103,104\">",
"       101,103,104",
"      </a>",
"      ]. Many DMARDs are renally excreted, and impaired kidney function can lead to accumulation of DMARDs or their metabolites with consequent bone marrow suppression.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Continue/discontinue",
"       </strong>",
"      </span>",
"      &mdash; We recommend that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      be continued in the perioperative period in patients with normal renal function and should be held for two weeks preoperatively in patients with renal impairment.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"       Sulfasalazine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      should be held for a week prior to surgery and resumed after surgery. The long half life of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      argues for discontinuation, if at all, two months before surgery; given the lack of known increased risk associated with this drug, it is reasonable to continue the drug up to surgery.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"       Hydroxychloroquine",
"      </a>",
"      has few potential side effects and can be continued without interruption, if the patient can take oral medications. The biologic DMARDs should be stopped one to several weeks prior to surgery and resumed once the wound is fully closed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Gout therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Benefit/risk",
"       </strong>",
"      </span>",
"      &mdash; Surgery is known to precipitate acute gouty arthropathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/105\">",
"       105",
"      </a>",
"      ]. The optimal management strategy for patients who are maintained on chronic hypouricemic therapy or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      in the perioperative period is unknown.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Continue/discontinue",
"       </strong>",
"      </span>",
"      &mdash; We recommend that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      and the hypouricemic agents",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/18/37157?source=see_link\">",
"       probenecid",
"      </a>",
"      be held on the morning of surgery and resumed when the patient is able to tolerate oral medications (",
"      <a class=\"graphic graphic_table graphicRef82352 \" href=\"mobipreview.htm?9/43/9915\">",
"       table 9",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Formulations/alternatives",
"       </strong>",
"      </span>",
"      &mdash; There is no parenteral substitution for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/18/37157?source=see_link\">",
"       probenecid",
"      </a>",
"      . Parenteral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      is no longer available in the United States; it can cause myelotoxicity, as well as significant skin necrosis if infiltration occurs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/106\">",
"       106",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Should an acute gouty flare occur in a postoperative patient unable to tolerate oral medications, intraarticular steroids, or systemic steroids can be used. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/24/17800?source=see_link\">",
"       \"Treatment of acute gout\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h1\">",
"     MEDICATIONS FOR BENIGN PROSTATIC HYPERTROPHY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Benefit/risk",
"       </strong>",
"      </span>",
"      &mdash; Some patients treated with alpha-1-antagonists (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/15/36085?source=see_link\">",
"       terazosin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/59/8119?source=see_link\">",
"       doxazosin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/28/39365?source=see_link\">",
"       tamsulosin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/55/26485?source=see_link\">",
"       alfuzosin",
"      </a>",
"      ) have developed intraoperative floppy iris syndrome (IFIS), a condition involving intractable intraoperative iris prolapse with cataract surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/107-109\">",
"       107-109",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Continue/discontinue",
"       </strong>",
"      </span>",
"      &mdash; Patients should be asked about use of alpha-1-antagonists during the preoperative evaluation. It is not known if discontinuing alpha-1-antagonists reduces the risk of IFIS; clinical impression is that the drug effect is long-lasting (weeks, months, or years), and most eye surgeons do not insist that these agents be discontinued. Various operative regimens can reduce the occurrence of IFIS. It is important to make sure the surgeon is aware if the patient was receiving such a medication. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/19/2362?source=see_link\">",
"       \"Cataract in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h1\">",
"     HERBAL MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herbal medications, used frequently, may have effects that could be deleterious in the perioperative period, including clotting abnormalities and interactions with anesthetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/110\">",
"     110",
"    </a>",
"    ]. Clinicians should specifically inquire about herbal medication use in presurgical patients, as patients often do not readily disclose use.",
"   </p>",
"   <p>",
"    A review that examined eight commonly used herbal remedies found the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/45/40666/abstract/111\">",
"     111",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ephedra (ma huang) may increase the risk of heart attack and stroke and should be discontinued at least 24 hours prior to surgery.",
"     </li>",
"     <li>",
"      Garlic may increase bleeding risk and should be discontinued at least seven days prior to surgery.",
"     </li>",
"     <li>",
"      Ginkgo may increase bleeding risk and should be discontinued at least 36 hours prior to surgery.",
"     </li>",
"     <li>",
"      Ginseng lowers blood sugar and may increase bleeding risk and should be discontinued at least seven days prior to surgery.",
"     </li>",
"     <li>",
"      Kava may increase the sedative effect of anesthetics and should be discontinued at least 24 hours prior to surgery. An association between kava use and fatal hepatotoxicity has been reported. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/2/25642?source=see_link\">",
"       \"Hepatotoxicity due to herbal medications and dietary supplements\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      St. John's wort may diminish the effects of several drugs by induction of cytochrome p450 enzymes and should be discontinued at least five days prior to surgery.",
"     </li>",
"     <li>",
"      Valerian may increase the sedative effect of anesthetics and is associated with benzodiazepine-like withdrawal. There are no data on preoperative discontinuation. Ideally it is tapered weeks before surgery; if not, withdrawal is treated with benzodiazepines.",
"     </li>",
"     <li>",
"      Echinacea is associated with allergic reactions and immune stimulation. There are no data on preoperative discontinuation.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Risk/Benefit",
"      </span>",
"      - There is no evidence that herbal medications improve surgical outcomes, and there are theoretic reasons that these agents may increase perioperative morbidity.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Continue/discontinue",
"      </span>",
"      - For simplicity and because the purity and nature of some herbal medications is unclear, we recommend stopping herbal agents at least one week before surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h1\">",
"     ANTIRETROVIRAL AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The perioperative management of patients taking antiretroviral agents is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/29/42456?source=see_link\">",
"     \"Surgical issues in HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;General recommendations for the management of several medications are found in the following tables:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiovascular agents (",
"      <a class=\"graphic graphic_table graphicRef62659 \" href=\"mobipreview.htm?42/50/43820\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Gastrointestinal and pulmonary agents (",
"      <a class=\"graphic graphic_table graphicRef56778 \" href=\"mobipreview.htm?8/30/8684\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Endocrine agents (",
"      <a class=\"graphic graphic_table graphicRef77781 \" href=\"mobipreview.htm?24/4/24652\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Agents affecting hemostasis (",
"      <a class=\"graphic graphic_table graphicRef68515 \" href=\"mobipreview.htm?1/10/1196\">",
"       table 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Psychotropic agents (",
"      <a class=\"graphic graphic_table graphicRef66948 \" href=\"mobipreview.htm?8/34/8749\">",
"       table 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Opioids (",
"      <a class=\"graphic graphic_table graphicRef82352 \" href=\"mobipreview.htm?9/43/9915\">",
"       table 9",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Neurologic agents (",
"      <a class=\"graphic graphic_table graphicRef55167 \" href=\"mobipreview.htm?24/58/25516\">",
"       table 11",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Rheumatologic agents (",
"      <a class=\"graphic graphic_table graphicRef61808 \" href=\"mobipreview.htm?26/27/27068\">",
"       table 12",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/1\">",
"      Kennedy JM, van Rij AM, Spears GF, et al. Polypharmacy in a general surgical unit and consequences of drug withdrawal. Br J Clin Pharmacol 2000; 49:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/2\">",
"      Kroenke K, Gooby-Toedt D, Jackson JL. Chronic medications in the perioperative period. South Med J 1998; 91:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/3\">",
"      Spell NO 3rd. Stopping and restarting medications in the perioperative period. Med Clin North Am 2001; 85:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/4\">",
"      Smith MS, Muir H, Hall R. Perioperative management of drug therapy, clinical considerations. Drugs 1996; 51:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/5\">",
"      Clay BJ, Halasyamani L, Stucky ER, et al. Results of a medication reconciliation survey from the 2006 Society of Hospital Medicine national meeting. J Hosp Med 2008; 3:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/6\">",
"      Pass SE, Simpson RW. Discontinuation and reinstitution of medications during the perioperative period. Am J Health Syst Pharm 2004; 61:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/7\">",
"      Shammash JB, Trost JC, Gold JM, et al. Perioperative beta-blocker withdrawal and mortality in vascular surgical patients. Am Heart J 2001; 141:148.",
"     </a>",
"    </li>",
"    <li>",
"     Hoffman BB. Therapy of hypertension. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th ed, Brunton LB, Lazo JS, Parker KL (Eds), McGraw-Hill, New York 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/9\">",
"      Berggren, H, Ekroth, R, Herlitz, J, et al. Myocardial protective effect of maintained beta-blockade in aorto-coronary bypass surgery. Scandinavian J Thoracic Cardiovascular Surg 1902; 17:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/10\">",
"      Pont&eacute;n J, Biber B, Henriksson BA, et al. beta-Receptor blockade and neurolept anaesthesia. Withdrawal vs continuation of long-term therapy in gall-bladder and carotid artery surgery. Acta Anaesthesiol Scand 1982; 26:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/11\">",
"      St&uuml;hmeier KD, Mainzer B, Cierpka J, et al. Small, oral dose of clonidine reduces the incidence of intraoperative myocardial ischemia in patients having vascular surgery. Anesthesiology 1996; 85:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/12\">",
"      Oliver MF, Goldman L, Julian DG, Holme I. Effect of mivazerol on perioperative cardiac complications during non-cardiac surgery in patients with coronary heart disease: the European Mivazerol Trial (EMIT). Anesthesiology 1999; 91:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/13\">",
"      Wallace AW, Galindez D, Salahieh A, et al. Effect of clonidine on cardiovascular morbidity and mortality after noncardiac surgery. Anesthesiology 2004; 101:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/14\">",
"      Lilja M, Jounela AJ, Juustila H. Withdrawal syndromes and the cessation of antihypertensive therapy. Arch Intern Med 1982; 142:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/15\">",
"      Hart GR, Anderson RJ. Withdrawal syndromes and the cessation of antihypertensive therapy. Arch Intern Med 1981; 141:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/16\">",
"      Bruce DL, Croley TF, Lee JS. Preoperative clonidine withdrawal syndrome. Anesthesiology 1979; 51:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/17\">",
"      Metz S, Klein C, Morton N. Rebound hypertension after discontinuation of transdermal clonidine therapy. Am J Med 1987; 82:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/18\">",
"      Bertrand M, Godet G, Meersschaert K, et al. Should the angiotensin II antagonists be discontinued before surgery? Anesth Analg 2001; 92:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/19\">",
"      Hayashi Y, Maze M. Alpha 2 adrenoceptor agonists and anaesthesia. Br J Anaesth 1993; 71:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/20\">",
"      Qu&iacute;ntin L, Cicala R, Kent M, Thomsen B. Effect of clonidine on myocardial ischaemia: a double-blind pilot trial. Can J Anaesth 1993; 40:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/21\">",
"      Houston MC. Abrupt cessation of treatment in hypertension: consideration of clinical features, mechanisms, prevention and management of the discontinuation syndrome. Am Heart J 1981; 102:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/22\">",
"      Ram CV, Holland OB, Fairchild C, Gomez-Sanchez CE. Withdrawal syndrome following cessation of guanabenz therapy. J Clin Pharmacol 1979; 19:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/23\">",
"      Colson P, M&eacute;dioni P, Saussine M, et al. Hemodynamic effect of calcium channel blockade during anesthesia for coronary artery surgery. J Cardiothorac Vasc Anesth 1992; 6:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/24\">",
"      Wijeysundera DN, Beattie WS. Calcium channel blockers for reducing cardiac morbidity after noncardiac surgery: a meta-analysis. Anesth Analg 2003; 97:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/25\">",
"      Reves JG, Kissin I, Lell WA, Tosone S. Calcium entry blockers: uses and implications for anesthesiologists. Anesthesiology 1982; 57:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/26\">",
"      Engelman RM, Hadji-Rousou I, Breyer RH, et al. Rebound vasospasm after coronary revascularization in association with calcium antagonist withdrawal. Ann Thorac Surg 1984; 37:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/27\">",
"      Kizer JR, Kimmel SE. Epidemiologic review of the calcium channel blocker drugs. An up-to-date perspective on the proposed hazards. Arch Intern Med 2001; 161:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/28\">",
"      Legault C, Furberg CD, Wagenknecht LE, et al. Nimodipine neuroprotection in cardiac valve replacement: report of an early terminated trial. Stroke 1996; 27:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/29\">",
"      Wagenknecht LE, Furberg CD, Hammon JW, et al. Surgical bleeding: unexpected effect of a calcium antagonist. BMJ 1995; 310:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/30\">",
"      Zuccal&aacute; G, Pahor M, Landi F, et al. Use of calcium antagonists and need for perioperative transfusion in older patients with hip fracture: observational study. BMJ 1997; 314:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/31\">",
"      Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. Ad Hoc Subcommittee of the Liaison Committee of the World Health Organisation and the International Society of Hypertension. J Hypertens 1997; 15:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/32\">",
"      Grodecki-DeFranco P, Steinhubl S, Taylor P, et al. Calcium antagonist use and perioperative bleeding complications: an analysis of 5,157 patients. Circulation 1996; 94(suppl):I.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/33\">",
"      Finegan BA, Hussain MD, Tam YK. Pharmacokinetics of diltiazem in patients undergoing coronary artery bypass grafting. Ther Drug Monit 1992; 14:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/34\">",
"      Rosenman DJ, McDonald FS, Ebbert JO, et al. Clinical consequences of withholding versus administering renin-angiotensin-aldosterone system antagonists in the preoperative period. J Hosp Med 2008; 3:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/35\">",
"      Coriat P, Richer C, Douraki T, et al. Influence of chronic angiotensin-converting enzyme inhibition on anesthetic induction. Anesthesiology 1994; 81:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/36\">",
"      Pigott DW, Nagle C, Allman K, et al. Effect of omitting regular ACE inhibitor medication before cardiac surgery on haemodynamic variables and vasoactive drug requirements. Br J Anaesth 1999; 83:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/37\">",
"      Brabant SM, Bertrand M, Eyraud D, et al. The hemodynamic effects of anesthetic induction in vascular surgical patients chronically treated with angiotensin II receptor antagonists. Anesth Analg 1999; 89:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/38\">",
"      Comfere T, Sprung J, Kumar MM, et al. Angiotensin system inhibitors in a general surgical population. Anesth Analg 2005; 100:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/39\">",
"      Benedetto U, Melina G, Capuano F, et al. Preoperative angiotensin-converting enzyme inhibitors protect myocardium from ischemia during coronary artery bypass graft surgery. J Cardiovasc Med (Hagerstown) 2008; 9:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/40\">",
"      Benedetto U, Sciarretta S, Roscitano A, et al. Preoperative Angiotensin-converting enzyme inhibitors and acute kidney injury after coronary artery bypass grafting. Ann Thorac Surg 2008; 86:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/41\">",
"      Arora P, Rajagopalam S, Ranjan R, et al. Preoperative use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers is associated with increased risk for acute kidney injury after cardiovascular surgery. Clin J Am Soc Nephrol 2008; 3:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/42\">",
"      Hirsch IA, Tomlinson DL, Slogoff S, Keats AS. The overstated risk of preoperative hypokalemia. Anesth Analg 1988; 67:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/43\">",
"      Nally BR, Dunbar SB, Zellinger M, Davis A. Supraventricular tachycardia after coronary artery bypass grafting surgery and fluid and electrolyte variables. Heart Lung 1996; 25:31.",
"     </a>",
"    </li>",
"    <li>",
"     Roizen MF. etic implications of concurrent diseases. In: Anesthesia, Miller RD (Ed), Churchill Livingstone, Philadelphia 2000. p.903.",
"    </li>",
"    <li>",
"     Farmer JA, Gotto AM. Dyslipidemia and other risk factors for coronary artery disease. In: A Textbook of Cardiovascular Medicine, Braunwald E (Ed), W.B. Saunders, Philadelphia 1997. p.1126.",
"    </li>",
"    <li>",
"     Physicians Desk Reference, Medical Economics Company, Montvale, NJ 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/47\">",
"      Hamilton-Craig I. Statin-associated myopathy. Med J Aust 2001; 175:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/48\">",
"      Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001; 35:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/49\">",
"      Schouten O, Boersma E, Hoeks SE, et al. Fluvastatin and perioperative events in patients undergoing vascular surgery. N Engl J Med 2009; 361:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/50\">",
"      Dunkelgrun M, Boersma E, Schouten O, et al. Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing noncardiovascular surgery: a randomized controlled trial (DECREASE-IV). Ann Surg 2009; 249:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/51\">",
"      Blanco M, Nombela F, Castellanos M, et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 2007; 69:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/52\">",
"      Nishina K, Mikawa K, Takao Y, et al. A comparison of rabeprazole, lansoprazole, and ranitidine for improving preoperative gastric fluid property in adults undergoing elective surgery. Anesth Analg 2000; 90:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/53\">",
"      Cruickshank RH, Morrison DA, Bamber PA, Nimmo WS. Effect of i.v. omeprazole on the pH and volume of gastric contents before surgery. Br J Anaesth 1989; 63:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/54\">",
"      Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 1998; 158:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/55\">",
"      Williams RG, Yardley MP. Oral contraceptive therapy and the surgical management of ENT patients: a review of current clinical practice. Clin Otolaryngol Allied Sci 1990; 15:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/56\">",
"      Vandenbroucke JP, Rosing J, Bloemenkamp KW, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 344:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/57\">",
"      Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000; 132:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/58\">",
"      Miller J, Chan BK, Nelson HD. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 136:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/59\">",
"      Hurbanek JG, Jaffer AK, Morra N, et al. Postmenopausal hormone replacement and venous thromboembolism following hip and knee arthroplasty. Thromb Haemost 2004; 92:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/60\">",
"      Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999; 281:2189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/61\">",
"      Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/62\">",
"      Malden N, Beltes C, Lopes V. Dental extractions and bisphosphonates: the assessment, consent and management, a proposed algorithm. Br Dent J 2009; 206:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/63\">",
"      Connelly CS, Panush RS. Should nonsteroidal anti-inflammatory drugs be stopped before elective surgery? Arch Intern Med 1991; 151:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/64\">",
"      Sethi GK, Copeland JG, Goldman S, et al. Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting. Department of Veterans Affairs Cooperative Study on Antiplatelet Therapy. J Am Coll Cardiol 1990; 15:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/65\">",
"      Bashein G, Nessly ML, Rice AL, et al. Preoperative aspirin therapy and reoperation for bleeding after coronary artery bypass surgery. Arch Intern Med 1991; 151:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/66\">",
"      Scher KS. Unplanned reoperation for bleeding. Am Surg 1996; 62:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/67\">",
"      Watson CJ, Deane AM, Doyle PT, Bullock KN. Identifiable factors in post-prostatectomy haemorrhage: the role of aspirin. Br J Urol 1990; 66:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/68\">",
"      Taggart DP, Siddiqui A, Wheatley DJ. Low-dose preoperative aspirin therapy, postoperative blood loss, and transfusion requirements. Ann Thorac Surg 1990; 50:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/69\">",
"      Mangano DT, Multicenter Study of Perioperative Ischemia Research Group. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002; 347:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/70\">",
"      Dacey LJ, Munoz JJ, Johnson ER, et al. Effect of preoperative aspirin use on mortality in coronary artery bypass grafting patients. Ann Thorac Surg 2000; 70:1986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/71\">",
"      Neilipovitz DT, Bryson GL, Nichol G. The effect of perioperative aspirin therapy in peripheral vascular surgery: a decision analysis. Anesth Analg 2001; 93:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/72\">",
"      Ferrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol 2005; 45:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/73\">",
"      Sibon I, Orgogozo JM. Antiplatelet drug discontinuation is a risk factor for ischemic stroke. Neurology 2004; 62:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/74\">",
"      Oscarsson A, Gupta A, Fredrikson M, et al. To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. Br J Anaesth 2010; 104:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/75\">",
"      Gerstein NS, Schulman PM, Gerstein WH, et al. Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome. Ann Surg 2012; 255:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/76\">",
"      Katz J, Feldman MA, Bass EB, et al. Risks and benefits of anticoagulant and antiplatelet medication use before cataract surgery. Ophthalmology 2003; 110:1784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/77\">",
"      Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000; 355:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/78\">",
"      Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:454S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/79\">",
"      Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e326S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/80\">",
"      Peterson P, Hayes TE, Arkin CF, et al. The preoperative bleeding time test lacks clinical benefit: College of American Pathologists' and American Society of Clinical Pathologists' position article. Arch Surg 1998; 133:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/81\">",
"      Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:299S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/82\">",
"      Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs : the relationships among dose, effectiveness, and side effects. Chest 2001; 119:39S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/83\">",
"      Stone DH, Goodney PP, Schanzer A, et al. Clopidogrel is not associated with major bleeding complications during peripheral arterial surgery. J Vasc Surg 2011; 54:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/84\">",
"      Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/85\">",
"      Beattie WS, Warriner CB, Etches R, et al. The addition of continuous intravenous infusion of ketorolac to a patient-controlled analgetic morphine regime reduced postoperative myocardial ischemia in patients undergoing elective total hip or knee arthroplasty. Anesth Analg 1997; 84:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/86\">",
"      Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:299S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/87\">",
"      Van Hecken A, Schwartz JI, Depr&eacute; M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000; 40:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/88\">",
"      Nunn B, Chamberlain PD. Effect of nabumetone (BRL 14777), a new anti-inflammatory drug, on human platelet reactivity ex vivo: comparison with naproxen. J Pharm Pharmacol 1982; 34:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/89\">",
"      Goldenberg NA, Jacobson L, Manco-Johnson MJ. Brief communication: duration of platelet dysfunction after a 7-day course of Ibuprofen. Ann Intern Med 2005; 142:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/90\">",
"      Borthwick E, Ferguson A. Perioperative acute kidney injury: risk factors, recognition, management, and outcomes. BMJ 2010; 341:c3365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/91\">",
"      Huyse FJ, Touw DJ, van Schijndel RS, et al. Psychotropic drugs and the perioperative period: a proposal for a guideline in elective surgery. Psychosomatics 2006; 47:8.",
"     </a>",
"    </li>",
"    <li>",
"     Depaulo JR, Barker LR. Affective disorders. In: Principles of Ambulatory Medicine, Barker LR, Burton JR, Zieve PD (Eds), Williams and Wilkins, Baltimore 1995. p.166.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/93\">",
"      Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine (Baltimore) 2000; 79:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/94\">",
"      Stack CG, Rogers P, Linter SP. Monoamine oxidase inhibitors and anaesthesia. A review. Br J Anaesth 1988; 60:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/95\">",
"      Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/96\">",
"      Larsen KA, Kelly SE, Stern TA, et al. Administration of olanzapine to prevent postoperative delirium in elderly joint-replacement patients: a randomized, controlled trial. Psychosomatics 2010; 51:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/97\">",
"      Fischer SP, Schmiesing CA, Guta CG, Brock-Utne JG. General anesthesia and chronic amphetamine use: should the drug be stopped preoperatively? Anesth Analg 2006; 103:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/98\">",
"      Friedman JH, Feinberg SS, Feldman RG. A neuroleptic malignantlike syndrome due to levodopa therapy withdrawal. JAMA 1985; 254:2792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/99\">",
"      Gordon PH, Frucht SJ. Neuroleptic malignant syndrome in advanced Parkinson's disease. Mov Disord 2001; 16:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/100\">",
"      Ueda M, Hamamoto M, Nagayama H, et al. Susceptibility to neuroleptic malignant syndrome in Parkinson's disease. Neurology 1999; 52:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/101\">",
"      Mushtaq S, Goodman SM, Scanzello CR. Perioperative management of biologic agents used in treatment of rheumatoid arthritis. Am J Ther 2011; 18:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/102\">",
"      Grennan DM, Gray J, Loudon J, Fear S. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis 2001; 60:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/103\">",
"      Rosandich PA, Kelley JT 3rd, Conn DL. Perioperative management of patients with rheumatoid arthritis in the era of biologic response modifiers. Curr Opin Rheumatol 2004; 16:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/104\">",
"      Pieringer H, Stuby U, Biesenbach G. Patients with rheumatoid arthritis undergoing surgery: how should we deal with antirheumatic treatment? Semin Arthritis Rheum 2007; 36:278.",
"     </a>",
"    </li>",
"    <li>",
"     Kelly WN, Fox IH, Palelleo TD. Gout and related disorders of purine metabolism. In: Textbook of Rheumatology, WB Saunders, Philadelphia 1989. p.1395.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/106\">",
"      Wallace SL, Singer JZ. Review: systemic toxicity associated with the intravenous administration of colchicine--guidelines for use. J Rheumatol 1988; 15:495.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/medwatch/safety/2005/safety05.htm#Flomax (Accessed on February 22, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/108\">",
"      Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg 2005; 31:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/109\">",
"      Schwinn DA, Afshari NA. Alpha1-adrenergic antagonists and floppy iris syndrome: tip of the iceberg? Ophthalmology 2005; 112:2059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/110\">",
"      Kaye AD, Clarke RC, Sabar R, et al. Herbal medicines: current trends in anesthesiology practice--a hospital survey. J Clin Anesth 2000; 12:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/45/40666/abstract/111\">",
"      Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA 2001; 286:208.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4814 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-F706DDF602-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_45_40666=[""].join("\n");
var outline_f39_45_40666=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H48\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRINCIPLES OF MEDICATION MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CARDIOVASCULAR MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Alpha 2 agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ACE inhibitors and angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Diuretics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Non-statin hypolipidemic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Statins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      GASTROINTESTINAL AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26237687\">",
"      H2 blockers and proton pump inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PULMONARY AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Inhaled beta agonists and anticholinergics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Theophylline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Leukotriene inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ENDOCRINE AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Diabetic medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Oral contraceptives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Selective estrogen receptor modulators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Drugs used for thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Drugs used for osteoporosis/osteopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      MEDICATIONS AFFECTING HEMOSTASIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Aspirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Other antiplatelet agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Warfarin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27162260\">",
"      Dabigatran",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1744185635\">",
"      MEDICATIONS AFFECTING RENAL FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      PSYCHOTROPIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Tricyclic antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Serotonin reuptake inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Monoamine oxidase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Mood stabilizing agents (lithium and valproate)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Antipsychotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Antianxiety agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Psychostimulants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      CHRONIC OPIOID THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      NEUROLOGIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Antiparkinson agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      RHEUMATOLOGIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Rheumatoid arthritis drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Gout therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      MEDICATIONS FOR BENIGN PROSTATIC HYPERTROPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      HERBAL MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      ANTIRETROVIRAL AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/4814\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/4814|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/50/43820\" title=\"table 1\">",
"      Periop cardiovascular agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/30/8684\" title=\"table 2\">",
"      Periop GI pulmonary agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/4/24652\" title=\"table 3\">",
"      Periop endocrine agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/34/39468\" title=\"table 4\">",
"      Surgical risk groups",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/10/1196\" title=\"table 5\">",
"      Periop hemostasis agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/34/8749\" title=\"table 6\">",
"      Periop psychotropics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/55/19324\" title=\"table 7\">",
"      Monoamine oxidase inhibitor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/39/27259\" title=\"table 8\">",
"      MAOI drugs and foods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/43/9915\" title=\"table 9\">",
"      Periop chronic pain medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/31/11760\" title=\"table 10\">",
"      Select opioids chronic pain and equianalgesic doses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/58/25516\" title=\"table 11\">",
"      Periop neurologic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/27/27068\" title=\"table 12\">",
"      Periop rheumatologic agents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/1/30746?source=related_link\">",
"      Agents affecting the 5-lipoxygenase pathway in the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/34/24104?source=related_link\">",
"      Aminoglycosides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/44/7881?source=related_link\">",
"      Anticoagulant, antiplatelet, and fibrinolytic (thrombolytic) therapy in patients at high risk for ocular hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10634?source=related_link\">",
"      Antiplatelet therapy after coronary artery stenting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2618?source=related_link\">",
"      Antiplatelet therapy for secondary prevention of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31017?source=related_link\">",
"      Aspiration pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/2/26663?source=related_link\">",
"      Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43065?source=related_link\">",
"      Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27802?source=related_link\">",
"      Bipolar disorder in adults: Maintenance treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38026?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/19/2362?source=related_link\">",
"      Cataract in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/18/36137?source=related_link\">",
"      Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/24/7562?source=related_link\">",
"      First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/2/25642?source=related_link\">",
"      Hepatotoxicity due to herbal medications and dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/29/42453?source=related_link\">",
"      Lithium and the thyroid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3704?source=related_link\">",
"      Major side effects of beta blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/50/35626?source=related_link\">",
"      Management of anticoagulation before and after elective surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29402?source=related_link\">",
"      Management of cardiac risk for noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27546?source=related_link\">",
"      Management of postoperative pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/32?source=related_link\">",
"      Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/26/40360?source=related_link\">",
"      Medical therapy to prevent complications after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20553?source=related_link\">",
"      Neuroleptic malignant syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/4/24648?source=related_link\">",
"      Nonselective NSAIDs: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/2/4137?source=related_link\">",
"      Nonthyroid surgery in the patient with thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41735?source=related_link\">",
"      Overview of the principles of medical consultation and perioperative medicine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42778?source=related_link\">",
"      Overview of the treatment of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/9/10394?source=related_link\">",
"      Perioperative care of the surgical patient with neurologic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/0/18440?source=related_link\">",
"      Perioperative heart failure in noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/63/29688?source=related_link\">",
"      Perioperative management of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/17/33046?source=related_link\">",
"      Perioperative management of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/10/42154?source=related_link\">",
"      Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/43/32439?source=related_link\">",
"      Preoperative assessment of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/35/15929?source=related_link\">",
"      Preoperative evaluation and perioperative management of patients with rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/42/35498?source=related_link\">",
"      Prevention of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/32999?source=related_link\">",
"      Renal toxicity of lithium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/33/32281?source=related_link\">",
"      Secondary prevention for specific causes of ischemic stroke and transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44246?source=related_link\">",
"      Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/32/41481?source=related_link\">",
"      Selective estrogen receptor modulators for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16376?source=related_link\">",
"      Serotonin syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33802?source=related_link\">",
"      Statin myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/51/13113?source=related_link\">",
"      Strategies to reduce postoperative pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/21/18776?source=related_link\">",
"      Stress ulcer prophylaxis in the intensive care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/29/42456?source=related_link\">",
"      Surgical issues in HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17384?source=related_link\">",
"      The surgical patient taking glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/24/17800?source=related_link\">",
"      Treatment of acute gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29514?source=related_link\">",
"      Treatment of opioid abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/56/31626?source=related_link\">",
"      Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/20/36169?source=related_link\">",
"      Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/50/1827?source=related_link\">",
"      Withdrawal syndromes with antihypertensive therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_45_40667="Aldosterone on Na K excretion";
var content_f39_45_40667=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F79401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F79401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Aldosterone regulation of sodium and potassium excretion",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Clinical stage",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Aldosterone secretion",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Proximal or loop reabsorption",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Distal Na+ delivery",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        &Delta;Urinary excretion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Na+",
"       </td>",
"       <td class=\"subtitle2\">",
"        K+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Na+ depletion",
"       </td>",
"       <td>",
"        Incr",
"       </td>",
"       <td>",
"        Incr",
"       </td>",
"       <td>",
"        Decr",
"       </td>",
"       <td>",
"        Decr",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Na+ load",
"       </td>",
"       <td>",
"        Decr",
"       </td>",
"       <td>",
"        Decr",
"       </td>",
"       <td>",
"        Incr",
"       </td>",
"       <td>",
"        Incr",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        K+ load",
"       </td>",
"       <td>",
"        Incr",
"       </td>",
"       <td>",
"        Decr",
"       </td>",
"       <td>",
"        Incr",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Incr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        K+ depletion",
"       </td>",
"       <td>",
"        Decr",
"       </td>",
"       <td>",
"        Incr",
"       </td>",
"       <td>",
"        Decr",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Decr",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Interrelationships between aldosterone and the regulation of sodium and potassium balance. The modulating effect of changes in distal sodium delivery allows sodium and potassium excretion to be regulated independently by aldosterone.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_45_40667=[""].join("\n");
var outline_f39_45_40667=null;
var title_f39_45_40668="CHADS2 score and thromboembolic risk with and without warfarin";
var content_f39_45_40668=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61615&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61615&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    CHADS2 score, thromboembolic risk, and effect of warfarin anticoagulation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Clinical parameter",
"       </td>",
"       <td class=\"subtitle1\">",
"        Points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        <strong>",
"         C",
"        </strong>",
"        ongestive heart failure (any history)",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        <strong>",
"         H",
"        </strong>",
"        ypertension (prior history)",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        <strong>",
"         A",
"        </strong>",
"        ge &ge;75 years",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        <strong>",
"         D",
"        </strong>",
"        iabetes mellitus",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"3\">",
"        <strong>",
"         S",
"        </strong>",
"        econdary prevention in patients with a prior ischemic stroke or a transient ischemic attack; most experts also include patients with a systemic embolic event",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        CHADS2 score",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Events per 100 person-years*",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        NNT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Warfarin",
"       </td>",
"       <td class=\"subtitle2\">",
"        No warfarin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        0.49",
"       </td>",
"       <td>",
"        417",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0.72",
"       </td>",
"       <td>",
"        1.52",
"       </td>",
"       <td>",
"        125",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1.27",
"       </td>",
"       <td>",
"        2.50",
"       </td>",
"       <td>",
"        81",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2.20",
"       </td>",
"       <td>",
"        5.27",
"       </td>",
"       <td>",
"        33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        2.35",
"       </td>",
"       <td>",
"        6.02",
"       </td>",
"       <td>",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5 or 6",
"       </td>",
"       <td>",
"        4.60",
"       </td>",
"       <td>",
"        6.88",
"       </td>",
"       <td>",
"        44",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NNT: number needed to treat to prevent one stroke per year with warfarin.",
"     <br/>",
"     * The CHADS2 score estimates the risk of stroke, which is defined as focal neurologic signs or symptoms that persist for more than 24 hours and that cannot be explained by hemorrhage, trauma, or other factors, or peripheral embolization, which is much less common. Transient ischemic attacks are not included. All differences between warfarin and no warfarin groups are statistically significant except for a trend with a CHADS2 score of 0. Patients are considered to be at low risk with a score of 0, at intermediate risk with a score of 1 or 2, and at high risk with a score &ge;3. One exception is that most experts would consider patients with a prior ischemic stroke, transient ischemic attack, or systemic embolic event to be at high risk even if they had no other risk factors and therefore a score of 2. However, the great majority of these patients have some other risk factor and a score of at least 3.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Go AS, Hylek EM, Chang Y, et al. JAMA 2003; 290:2685; and CHADS2 score from Gage BF, Waterman AD, Shannon W. JAMA 2001; 285:2864.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_45_40668=[""].join("\n");
var outline_f39_45_40668=null;
var title_f39_45_40669="Cheatle slit in ileum";
var content_f39_45_40669=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F53083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F53083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cheatle slit in ileum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 280px; height: 210px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_45_40669=[""].join("\n");
var outline_f39_45_40669=null;
var title_f39_45_40670="Large CBD stones ERCP";
var content_f39_45_40670=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Common bile duct stones",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 265px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic retrograde cholangiopancreatographic study in a patient with obstructive jaundice shows multiple stones (arrows) in a dilated common bile duct.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James B McGee, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_45_40670=[""].join("\n");
var outline_f39_45_40670=null;
var title_f39_45_40671="Nissen fundoplication PI";
var content_f39_45_40671=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F72609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F72609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Nissen fundoplication",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Original artwork by JP Gray, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_45_40671=[""].join("\n");
var outline_f39_45_40671=null;
